POLO-like kinase 4 (PLK4) inhibitor, pharmaceutical composition, preparation method and application thereof
By providing a PLK4 inhibitor compound, the problem of poor treatment for cancer overexpression of TRIM37 in the prior art is solved, and effective treatment of specific cancers is achieved by inhibiting PLK4 activity and inducing cell death.
Patent Information
- Application Number
- CN202380028190.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-02-23
- Filing Date
- 2023-02-23
- Publication Date
- 2024-11-12
AI Technical Summary
Existing PLK4 inhibitors are difficult to effectively inhibit cancer caused by overexpression of TRIM37, especially in cellular environments where the function of substances around the centriole is impaired, and traditional treatment methods have the problem of limited therapeutic effects.
A compound is provided with the properties of a PLK4 inhibitor, induces cell death by contacting cells, especially in cancer cells with overexpressing TRIM37 and administered in the form of a pharmaceutical composition to enhance therapeutic effect.
Effectively inhibit PLK4 activity, especially in cancer cells with overexpression of TRIM37, it improves the therapeutic effect on cancer, and is particularly suitable for uterine cancer, ovarian cancer, breast cancer and other types of TRIM37 amplification.
Smart Images

Figure CN118946560A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to compounds and pharmaceutical compositions, their preparation and their use in treating diseases or conditions, such as cancer, particularly those diseases or conditions that are sensitive to inhibition of polo-like kinase-4. Background Art
[0002] Protein kinases are a large group of intracellular transmembrane signaling proteins in eukaryotic cells. These enzymes are responsible for transferring the terminal (gamma) phosphate from ATP to specific amino acid residues of target proteins. Phosphorylation of specific amino acid residues in target proteins can modulate their activity, leading to dramatic changes in cellular signaling and metabolism. Protein kinases can be found in cell membranes, cytosol, organelles, and structures such as centrioles and are responsible for mediating a variety of cellular functions, including metabolism, cell growth, differentiation, cell signaling, regulation of immune responses, and cell death. Therefore, inhibitors of a selected kinase or family of kinases are expected to be useful in the treatment of cancer and other diseases or disorders.
[0003] Centrioles template the assembly of microtubules and recruit pericentriolar material to form centrosomes. Centriole duplication is strictly controlled, and normal mitotic cells have exactly two centrosomes. Excess centrosomes are common in cancer and have been considered to contribute to tumorigenesis. Polo-like kinase 4 (PLK4) is a major player in centriole biogenesis. Depletion or inhibition of its kinase activity prevents the formation of centrioles, while overexpression leads to the formation of multiple centrioles. By assembling microtubules with pericentriolar material, cells can survive without centrioles. Importantly, the loss of both centrioles and pericentriolar material greatly impairs cell viability. Therefore, tumor cells with low levels of pericentriolar material are sensitive to inhibition of PLK4 activity. Selected genetic factors (such as overexpression of TRIM37) that inhibit the level of pericentriolar material and make tumor cells sensitive to PLK4 inhibition have been identified. Therefore, it is expected that PLK4 inhibitors generally have anti-cancer properties and have anti-cancer properties in specific cases of similar cellular environments where TRIM37 amplifies or causes impaired pericentriolar function. Summary of the invention
[0004] In one aspect, the present invention provides a compound of formula (I):
[0005]
[0006] or a pharmaceutically acceptable salt thereof,
[0007] in
[0008] n is 0, 1, 2, 3 or 4;
[0009] m is 0, 1 or 2;
[0010] L is an optionally substituted C 2-9 Heterocyclic group, optionally substituted C 2-9 Heteroaryl, optionally substituted C 6-10 Aryl or optionally substituted C 3-8 Cycloalkyl, wherein L is further optionally replaced by n occurrences of R 3 replace;
[0011] R 1a is hydrogen, halogen, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Alkoxy, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl, or nitrile;
[0012] R 1b is hydrogen; or
[0013] R 1a and R 1b together with the atoms to which they are attached, are 3-5 membered cycloalkyl, cycloalkenyl, cycloalkynyl, heterocycloalkyl, aryl or heteroaryl;
[0014] A is O or S, R 2A and R 2B None; or A is N, R 2A does not exist, and R 2B is hydrogen, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 6-10 Aryl C 1-6 Alkyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 6-10 Aryl, optionally substituted C 2-9 Heterocyclic group, optionally substituted C 1-9 Heteroaryl, optionally substituted C 1-9 Heteroaryl C 1-6 Alkyl, or optionally substituted C 1-6 Alkylsulfonyl, or R 2B and L together with the atoms to which they are attached combine to form an optionally substituted C 2-9 Heterocyclic or optionally substituted C 2-9 heteroaryl; or A is C, and R 2A and R 2B are each independently hydrogen, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6Heteroalkyl, optionally substituted C 6-10 Aryl C 1-6 Alkyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 6-10 Aryl, optionally substituted C 2-9 Heterocyclic group, optionally substituted C 1-9 Heteroaryl, optionally substituted C 1-9 Heteroaryl C 1-6 Alkyl, or optionally substituted C 1-6 Alkylsulfonyl;
[0015] Each R 3 are independently halogen, cyano, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 6-10 Aryl C 1-6 Alkyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 3-8 Cycloalkenyl, optionally substituted C 6-10 Aryl, optionally substituted C 2-9 Heterocyclic group, optionally substituted C 1-9 Heteroaryl, optionally substituted C 1-9 Heteroaryl C 1-6 Alkyl, -S(O) m R 3A 、-N(R 3B )2OR 3B ;
[0016] R 3A is an optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 6-10 Aryl, optionally substituted C 2-9 Heterocyclic group, optionally substituted C 1-9 Heteroaryl, -OR 3B or -N(R 3B )2
[0017] Each R 3B are independently hydrogen, optionally substituted C 1-6 Alkyl, optionally substituted C 6-10 Aryl C 1-6 Alkyl, optionally substituted C3-8 Cycloalkyl, optionally substituted C 6-10 Aryl, optionally substituted C 2-9 Heterocyclic group, optionally substituted C 1-9 Heteroaryl, optionally substituted C 1-9 Heteroaryl C 1-6 Alkyl, or optionally substituted C 1-6 Alkylsulfonyl; or two R 3B The groups together with the atoms to which they are attached combine to form an optionally substituted C 2-9 Heterocyclic group;
[0018] X is N, R 4 does not exist; or X is C, and R 4 is hydrogen, halogen, cyano, optionally substituted amino, optionally substituted acyl, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 3-8 Cycloalkenyl, optionally substituted C 6-10 Aryl, optionally substituted C 2-9 Heterocyclic group, or optionally substituted C 1-9 heteroaryl;
[0019] R 5 is an optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 3-8 Cycloalkenyl, optionally substituted C 6-10 Aryl, optionally substituted C 2-9 Heterocyclic group, optionally substituted C 1-9 Heteroaryl, -CONH2 or -ZR 5A ;
[0020] Z is an optionally substituted amino group, an optionally substituted C 2-9 Heterocyclylene, optionally substituted C 2-9 Heteroarylene, optionally substituted C 6-10 Arylene, or optionally substituted C 3-8 Cycloalkylene;
[0021] R 5A is hydrogen, halogen, cyano, optionally substituted C1-6 Alkylsulfonyl, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 3-8 Cycloalkenyl, optionally substituted C 6-10 Aryl, optionally substituted C 2-9 heterocyclic group, or optionally substituted C 1-9 heteroaryl;
[0022] R 6 is hydrogen, halogen, cyano, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl or -OR 6A ;and
[0023] R 6A is hydrogen, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, or optionally substituted C 3-8 Cycloalkyl.
[0024] In some embodiments, the compound has Formula (II):
[0025]
[0026] or a pharmaceutically acceptable salt thereof.
[0027] In some embodiments, the compound has formula (III):
[0028]
[0029] or a pharmaceutically acceptable salt thereof.
[0030] In some embodiments, the compound has formula (II-A):
[0031]
[0032] or a pharmaceutically acceptable salt thereof.
[0033] In some embodiments, the compound has formula (III-A):
[0034]
[0035] or a pharmaceutically acceptable salt thereof.
[0036] In some embodiments, the compound has formula (II-B):
[0037]
[0038] or a pharmaceutically acceptable salt thereof.
[0039] In some embodiments, the compound has formula (III-B):
[0040]
[0041] or a pharmaceutically acceptable salt thereof.
[0042] In some embodiments, R 2A and R 2B In some embodiments, R 2A and R 2B One of which is an optionally substituted C 1-6 In some embodiments, R 2A and R 2B One of which is an optionally substituted C 1-6 Heteroalkyl.
[0043] In some embodiments, R 2B for:
[0044]
[0045] In some embodiments, the compound has formula (II-C):
[0046]
[0047] or a pharmaceutically acceptable salt thereof.
[0048] In some embodiments, the compound has formula (III-C):
[0049]
[0050] or a pharmaceutically acceptable salt thereof.
[0051] In some embodiments, the compound has formula (II-D):
[0052]
[0053]
[0054] In some embodiments, the compound has formula (III-D):
[0055]
[0056] or a pharmaceutically acceptable salt thereof.
[0057] In some embodiments, R 1a and R 1b is independently optionally substituted C 1-6 Alkyl, halogen, optionally substituted C 1-6 alkoxy, optionally substituted alkynyl, or optionally substituted C 3-6 In some embodiments, R 1a and R 1b R is independently -CH3-Cl, -OMe, -CH2OMe, -CN, -CF2H, -CF3, -CHF2, cyclopropyl or cyclobutyl. 1a and R 1b Together with the atoms to which they are attached, R is cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclyl, or heteroaryl. 1a and R 1b Together with the atoms they are attached to are:
[0058]
[0059] In some embodiments, L is optionally substituted C 6-10 In some embodiments, the optionally substituted C 6-10 Aryl is optionally substituted phenyl.
[0060] In some embodiments, L is optionally substituted C 2-9 In some embodiments, L is an optionally substituted C5 heteroaryl. In more specific embodiments, the optionally substituted C5 heteroaryl contains one N. In some embodiments, -L-(R 3 ) n for:
[0061]
[0062] In some embodiments, at least one R 3 In some embodiments, at least one R 3 is F. In some embodiments, at least one R 3 In some embodiments, at least one R 3 is Br. In some embodiments, at least one R 3 -S(O) m R 3AIn some embodiments, m is 1. In some embodiments, m is 2. In some embodiments, wherein R 3A is an optionally substituted C 1-6 In some embodiments, R 3A is -CH3. In some embodiments, R 3A is an optionally substituted C 3-8 In some embodiments, R 3A is an optionally substituted cyclopropyl. 3 is an optionally substituted C 2-9 In some embodiments, at least one R 3 -N(R 3B )2. In some embodiments, at least one R 3 For-OR 3B .
[0063] In some embodiments, -L-(R 3 ) n for:
[0064]
[0065]
[0066] In some embodiments, -L-(R 3 ) n for:
[0067]
[0068] In some embodiments, -L-(R 3 ) n for:
[0069] In some embodiments, -L-(R 3 ) n for:
[0070]
[0071] In some embodiments, -L-(R 3 ) n for:
[0072]
[0073] In some embodiments, -L-(R 3 ) n for:
[0074]
[0075] In some embodiments, -L-(R 3 ) n for:
[0076]
[0077] In some embodiments, R 4 In some embodiments, R 4 is F. In some embodiments, R 4 In some embodiments, R 4 In some embodiments, R 4 is an optionally substituted amino group. 4 is -NH2 or -N(CH3)2. In some embodiments, R 4 In some embodiments, R 4 It is -CH3.
[0078] In some embodiments, R 5 is an optionally substituted C 1-9 In some embodiments, R 5 is an optionally substituted C3-C4 heteroaryl or an optionally substituted C4 heterocycle.
[0079] In some embodiments, the optionally substituted C3-C4 heteroaryl or optionally substituted C4 heterocycle contains 1 to 2 N atoms. 5 for:
[0080]
[0081]
[0082]
[0083]
[0084] In some embodiments, R 5 for
[0085]
[0086] In some embodiments, the optionally substituted C3 heteroaryl contains 1 N atom and 1 S atom or 1 O atom. 5 for:
[0087]
[0088] In some embodiments, R5 For-ZR 5A In some embodiments, Z is optionally substituted amino, and R 5A for In some embodiments, Z is optionally substituted C 2-9 Heteroarylene.
[0089] In some embodiments, R 5 is an optionally substituted C 2-9 In some embodiments, R 5 for:
[0090]
[0091]
[0092] In some embodiments, R 5 for:
[0093]
[0094] In some embodiments, R 5A for:
[0095]
[0096] In some embodiments, R 5 for:
[0097]
[0098] In some embodiments, R 6 is an optionally substituted C 1-6 In some embodiments, R 6 for:
[0099]
[0100] In some embodiments, R 6 For-OR 6A In some embodiments, R 6A is -CH3. In some embodiments, R 6 is an optionally substituted C 3-8 In some embodiments, R 6 is an optionally substituted cyclopropyl. 6 for:
[0101]
[0102] In some embodiments, the compound has Formula (IV):
[0103]
[0104] In some embodiments, the compound has Formula (V):
[0105]
[0106] In some embodiments, the compound is selected from the group consisting of Compounds 1 to 365, including pharmaceutically acceptable salts thereof.
[0107] In another aspect, the present invention provides a pharmaceutical composition as described herein or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient. In some embodiments, the composition is isotopically enriched with deuterium.
[0108] In another aspect, the present invention relates to a method of inhibiting PLK4 expression in a cell, the method comprising contacting the cell with any compound described herein or a pharmaceutically acceptable salt thereof. In some embodiments, the cell overexpresses TRIM37. In some embodiments, the cell is in a subject.
[0109] On the other hand, the present invention provides a method for treating a subject in need thereof, the method comprising administering to the subject a compound described herein or a pharmaceutically acceptable salt thereof. In some embodiments, the subject suffers from a disease or disorder with symptoms of cell hyperproliferation and needs treatment. In some embodiments, the disease is cancer. In some embodiments, the cancer is a cancer that overexpresses TRIM37.
[0110] In another aspect, the present invention provides a method of treating cancer in a subject, the method comprising administering to the subject a therapeutically effective amount of a compound described herein or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of any compound described herein comprising a pharmaceutically acceptable excipient, wherein the cancer has been previously identified as a cancer that overexpresses TRIM37.
[0111] In some embodiments, the cancer overexpressing TRIM37 is uterine cancer, ovarian cancer, breast cancer, gastric cancer, esophageal cancer, lung cancer, or endometrial cancer.
[0112] In another aspect, the present invention provides a method of inducing cell death in a cancer cell that overexpresses TRIM37, the method comprising contacting the cell with an effective amount of a PLK4 inhibitor. In some embodiments, the PLK4 inhibitor is a compound described herein or a pharmaceutically acceptable salt thereof.
[0113] In some embodiments, the cell is in a subject.
[0114] abbreviation
[0115] Abbreviations and terms commonly used in the fields of organic chemistry, medicinal chemistry, pharmacology, and medicine are used herein and are familiar to practitioners in these fields. Representative abbreviations and definitions are provided below:
[0116] Ac is acetyl [CH3C(O)-];
[0117] ACN is acetonitrile;
[0118] Ac2O is acetic anhydride;
[0119] AcOH is acetic acid;
[0120] APC is antigen presenting cell;
[0121] Ar is an aryl group;
[0122] aq. is water-based;
[0123] 9-BBN is 9-borabicyclo[3.3.1]nonane;
[0124] BINAP is (2,2'-bis(diphenylphosphino)-1,1'-binaphthyl);
[0125] Bn is benzyl;
[0126] Boc is tert-butyloxycarbonyl;
[0127] n-BuLi is n-butyllithium;
[0128] Br2 is bromine;
[0129] CDI is carbonyldiimidazole;
[0130] cmpd is the compound;
[0131] conc. for concentrated;
[0132] DCM is dichloromethane;
[0133] DIAD is diisopropyl azodicarboxylate;
[0134] DIBAL is diisobutylaluminum hydride;
[0135] DIPEA is diisopropylethylamine;
[0136] DMA is dimethylacetamide;
[0137] DMAP is 4-dimethylaminopyridine;
[0138] DME is dimethoxyethane;
[0139] DMF is N,N-dimethylformamide;
[0140] DMSO is dimethyl sulfoxide;
[0141] dppf is 1,1'-bis(diphenylphosphino)ferrocene;
[0142] DTBPf is 1,1'-bis(di-tert-butylphosphino)ferrocene;
[0143] EDAC (or EDC) is 1-ethyl-3-[3-(dimethylamino)propyl]-carbodiimide HCl;
[0144] ESI is electrospray ionization mass spectrometry;
[0145] Et2O is ether;
[0146] Et3N is triethylamine;
[0147] Et is ethyl;
[0148] EtOAc is ethyl acetate;
[0149] EtOH is ethanol;
[0150] (+ESI) is electrospray ionization in positive ion mode;
[0151] 3-F-Ph is 3-fluorophenyl,
[0152] h is hour;
[0153] hrs is hours;
[0154] HATU is 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate;
[0155] HCl is hydrochloric acid;
[0156] Het is heteroaryl;
[0157] Hex is hexane;
[0158] HOBt is 1-hydroxybenzotriazole;
[0159] HPLC is high performance liquid chromatography;
[0160] IPA or iPrOH is isopropyl alcohol;
[0161] IPAc is isopropyl acetate;
[0162] I2 is iodine;
[0163] LCMS is HPLC with mass spectrometry detection;
[0164] LiHMDS is lithium bis(trimethylsilyl)amide;
[0165] LG is a leaving group;
[0166] M is mole;
[0167] mCPBA is meta-chloroperbenzoic acid;
[0168] mmol is millimole;
[0169] Me is a methyl group;
[0170] MeI is methyl iodide;
[0171] MeCN is acetonitrile;
[0172] MeMgBr is methylmagnesium bromide;
[0173] MeMgCl is methylmagnesium chloride;
[0174] MeOH is methanol;
[0175] min is minutes;
[0176] MOM is methoxymethyl;
[0177] Ms is methylsulfonyl;
[0178] MS is mass spectrometry;
[0179] MTBE is methyl tert-butyl ether;
[0180] MW is microwave;
[0181] N is equivalent;
[0182] NaBH(OAc)3 is sodium triacetoxyborohydride
[0183] NaH is sodium hydride;
[0184] NaHMDS is sodium bis(trimethylsilyl)amide;
[0185] NaOAc is sodium acetate;
[0186] NaOtBu is sodium tert-butoxide;
[0187] NBS is N-bromosuccinimide;
[0188] NCS is N-chlorosuccinimide;
[0189] NIS is N-iodosuccinimide;
[0190] NMO is N-methylmorpholine N-oxide;
[0191] NMP is N-methylpyrrolidone;
[0192] NMR is nuclear magnetic resonance spectroscopy;
[0193] PdCl2(dppf) is [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II);
[0194] PdCl2(dppf).CH2Cl2 is [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complexed with dichloromethane;
[0195] Pd2(dba)3 is tris(dibenzylideneacetone)dipalladium;
[0196] PdCl2(PPh3)2 is dichlorobis(triphenylphosphine)palladium;
[0197] Pd-PEPPSI TM -SIPr is (1,3-bis(2,6-diisopropylphenyl)imidazolylidene)(3-chloropyridyl)dichloropalladium(II);
[0198] PE is petroleum ether;
[0199] PG represents a protecting group;
[0200] Ph is phenyl;
[0201] PhMe is toluene;
[0202] PIV-Cl is pivaloyl chloride, trimethylacetyl chloride;
[0203] PPh3 is triphenylphosphine;
[0204] PMB is p-methoxybenzyl;
[0205] The reagent alcohol was a mixture of 90% ethanol, 5% isopropanol, and 5% methanol;
[0206] rt or RT is room temperature;
[0207] RBF is a round bottom flask;
[0208] Ruphos is 2-dicyclohexylphosphino-2',6'-diisopropoxybiphenyl;
[0209] RuPhos Pd G1 is chloro-(2-dicyclohexylphosphino-2',6'-diisopropoxy-1,1'-biphenyl)[2-(2-aminoethyl)phenyl]palladium(II);
[0210] sat. is saturated;
[0211] SEM is [2-(trimethylsilyl)ethoxy]methyl;
[0212] SFC is supercritical fluid chromatography;
[0213] S N Ar is a nucleophilic aromatic substitution;
[0214] TBAB is tetrabutylammonium bromide;
[0215] TBAF is tetrabutylammonium fluoride;
[0216] TBS is tert-butyldimethylsilyl;
[0217] tBu is tert-butyl;
[0218] Tf is trifluoromethanesulfonyl;
[0219] TFA is trifluoroacetic acid;
[0220] THF is tetrahydrofuran;
[0221] THP is tetrahydropyran;
[0222] TLC is thin layer chromatography;
[0223] TMAD is tetramethylazodicarbonamide;
[0224] TMS is trimethylsilyl;
[0225] TPAP is tetrapropylammonium perruthenate;
[0226] Ts is p-toluenesulfonyl;
[0227] UPLC is ultra-performance liquid chromatography;
[0228] UPLC-MS is UPLC with mass spectrometry detection;
[0229] Xantphos is 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene;
[0230] XPhosPdG2 is chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II).
[0231] XPhosPdG3 is (2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]methanesulfonate palladium(II)
[0232] definition
[0233] As used herein, the term "abnormal" means different from normal. When used to describe an activity, abnormal refers to an activity that is higher or lower than the average of a normal control or a normal disease-free control sample. Abnormal activity can refer to an amount of activity that causes a disease, wherein restoring the abnormal activity to a normal or non-disease-related amount (e.g., by administering a compound or using a method described herein) results in a reduction in the disease or one or more disease symptoms.
[0234] As used herein, the term "acyl" refers to the group -C(=O)-R, wherein R is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl or heterocyclyl. Acyl groups may be optionally substituted as described herein for each individual R group.
[0235] As used herein, the term "adenocarcinoma" refers to a malignant tumor arising from a layer of glandular cells formed in an organ in an organism. Non-limiting examples of adenocarcinomas include non-small cell lung cancer, prostate cancer, pancreatic cancer, esophageal cancer, and colorectal cancer.
[0236] As used herein, the term "alkanoyl" means hydrogen or alkyl attached to a parent molecular group via a carbonyl group, and is exemplified by formyl (i.e., formaldehyde group), acetyl, propionyl, butyryl, and isobutyryl. Unsubstituted alkanoyl contains 1 to 7 carbons. Alkanoyl can be unsubstituted or substituted as described herein for alkyl (e.g., optionally substituted C1-7 alkanoyl). The suffix "-acyl" can be added to another group defined herein, such as aryl, cycloalkyl, and heterocyclyl, to define "aroyl", "cycloalkanoyl", and "(heterocyclyl) acyl". These groups represent carbonyls substituted by aryl, cycloalkyl, or heterocyclyl, respectively. Each of "aroyl", "cycloalkanoyl", and "(heterocyclyl) acyl" can be optionally substituted as defined herein for "aryl", "cycloalkyl", or "heterocyclyl".
[0237] As used herein, the term "alkenyl" refers to a non-cyclic monovalent straight or branched hydrocarbon group containing one, two or three carbon-carbon double bonds. Non-limiting examples of alkenyl include vinyl, prop-1-enyl, prop-2-enyl, 1-methylvinyl, but-1-enyl, but-2-enyl, but-3-enyl, 1-methylprop-1-enyl, 2-methylprop-1-enyl and 1-methylprop-2-enyl. Alkenyl can be optionally substituted as defined herein for alkyl.
[0238] As used herein, the term "alkenylene" refers to a divalent alkenyl group. Optionally substituted alkenylene is an optionally substituted alkenylene as described herein for alkenyl.
[0239] As used herein, the term "alkoxy" refers to a chemical substituent of the formula -OR, wherein R is C 1-6Alkyl, unless otherwise indicated. In some embodiments, alkyl may be further substituted as defined herein. The term "alkoxy" may be combined with other terms defined herein, such as aryl, cycloalkyl or heterocyclyl, to define "arylalkoxy", "cycloalkylalkoxy" and "(heterocyclyl)alkoxy" groups. These groups represent alkoxy groups substituted with aryl, cycloalkyl or heterocyclyl, respectively. Each of "arylalkoxy", "cycloalkylalkoxy" and "(heterocyclyl)alkoxy" may be optionally substituted as defined herein for each individual moiety.
[0240] As used herein, the term "alkoxyalkyl" refers to a chemical substituent of the formula -LOR, wherein L is C 1-6 Alkylene, R is C 1-6 Optionally substituted alkoxyalkyl is an optionally substituted alkoxyalkyl as described herein for alkyl.
[0241] As used herein, the term "alkyl" refers to a non-cyclic straight or branched chain saturated hydrocarbon group having from 1 to 12 carbons when unsubstituted, unless otherwise specified. In certain preferred embodiments, the unsubstituted alkyl group has from 1 to 6 carbons. Alkyl is exemplified by methyl; ethyl; n- and isopropyl; n-, sec-, iso- and tert-butyl; neopentyl, etc., and may be optionally substituted, as valence permits, with one, two, three, or (in the case of an alkyl group having two or more carbons) four or more substituents independently selected from the group consisting of: amino; alkoxy; aryl; aryloxy; azido; cycloalkyl; cycloalkoxy; cycloalkenyl; cycloalkynyl; halo; heterocyclyl; (heterocyclyl)oxy; heteroaryl; hydroxy; nitro; thiol; silyl; cyano; alkylsulfonyl; alkylsulfinyl; alkylthio; =O; =S; -C(O)R or -S02R, where R is amino; and =NR', where R' is H, alkyl, aryl or heterocyclyl. Each substituent may itself be unsubstituted or substituted, as valence permits, with unsubstituted substituents as defined herein for each respective group.
[0242] As used herein, the term "alkylene" refers to a divalent alkyl group. Optionally substituted alkylene is an optionally substituted alkylene as described herein for an alkyl group.
[0243] As used herein, the term "alkylamino" refers to a group having the formula -N(R N1 )2 or -NHR N1 A group in which R N1 is an alkyl group as defined herein. The alkyl portion of the alkylamino group may be optionally substituted as defined for an alkyl group. Each optional substituent on a substituted alkylamino group may itself be unsubstituted or substituted (where valence permits) with an unsubstituted substituent as defined herein for each individual group.
[0244] As used herein, the term "alkylthio" denotes a group of the formula -S-(alkyl). Alkylthio may be optionally substituted as defined for alkyl.
[0245] As used herein, the term "alkylsulfinyl" denotes a group of the formula -S(O)-(alkyl). An alkylsulfinyl group may be optionally substituted as defined for an alkyl group.
[0246] As used herein, the term "alkylsulfonyl" denotes a group of formula -S(O)2-(alkyl). Alkylsulfonyl may be optionally substituted as defined for alkyl.
[0247] As used herein, the term "alkynyl" refers to a monovalent straight or branched hydrocarbon group having two to six carbon atoms containing at least one carbon-carbon triple bond, and is exemplified by ethynyl, 1-propynyl, etc. Alkynyl groups can be unsubstituted or substituted as defined for alkyl groups (e.g., optionally substituted alkynyl groups).
[0248] As used herein, the term "alkynylene" refers to a divalent alkynyl group. Optionally substituted alkynylene is an optionally substituted alkynylene as described herein for an alkynyl group.
[0249] As used herein, the term "amino" refers to -N(R N1 )2, wherein if the amino group is unsubstituted, the two R N1 are all H; or if the amino group is substituted, each R N1 are independently H, -OH, -NO2, -N(R N2 2. -SO2OR N2 、-SO2R N2 、-SOR N2 、-C(O)OR N2 , N-protecting group, alkyl, alkenyl, alkynyl, alkoxy, aryl, arylalkyl, aryloxy, cycloalkyl, cycloalkenyl, heteroalkyl or heterocyclyl, provided that at least one R N1 is not H, and each R N2 is independently H, alkyl or aryl. Each substituent itself may be unsubstituted or substituted with an unsubstituted substituent as defined herein for each individual group. In some embodiments, the amino group is an unsubstituted amino group (i.e., -NH2) or a substituted amino group (e.g., -NHR N1 ), where R N1 Independently -OH, SO2OR N2 、-SO2R N2 、-SOR N2 、-COOR N2 , optionally substituted alkyl, or optionally substituted aryl, and each R N2In some embodiments, the amino group is -NHR. N1 , where R N1 is an optionally substituted alkyl group.
[0250] As used herein, the term "aryl" refers to a monocyclic, bicyclic or polycyclic carbocyclic ring system having one or two aromatic rings. The aryl group may include 6 to 10 carbon atoms. All atoms in an unsubstituted carbocyclic aryl group are carbon atoms. Non-limiting examples of carbocyclic aryl groups include phenyl, naphthyl, 1,2-dihydronaphthyl, 1,2,3,4-tetrahydronaphthyl, fluorenyl, dihydroindenyl, indenyl, etc. The aryl group may be unsubstituted or substituted by one, two, three, four or five substituents independently selected from the group consisting of: alkyl; alkenyl; alkynyl; alkoxy; alkylsulfinyl; alkylthio; alkylsulfonyl; amino; aryl; aryloxy; azido; cycloalkyl; cycloalkyloxy; cycloalkenyl; cycloalkynyl; halo; heteroalkyl; heterocyclyl; (heterocyclyl)oxy; hydroxyl; nitro; thiol; silyl; -(CH2) n -C(O)OR A ; -C(O)R; and -SO2R, wherein R is amino or alkyl, R A is H or alkyl, and n is 0 or 1. Each substituent may itself be unsubstituted or substituted with an unsubstituted substituent as defined herein for each respective group.
[0251] As used herein, the term "arylalkyl" refers to an alkyl group substituted with an aryl group. The aryl and alkyl portions may be optionally substituted as described herein as a single group.
[0252] As used herein, the term "arylene" refers to a divalent aromatic group. Optionally substituted arylene is an optionally substituted arylene group as described herein for an aryl group.
[0253] As used herein, the term "aryloxy" refers to a chemical substituent of the formula -OR, wherein R is an aryl group, unless otherwise indicated. In an optionally substituted aryloxy group, the aryl group is optionally substituted as described herein for an aryl group.
[0254] As used herein, the term "azido" refers to a -N3 group.
[0255] As used herein, the term "cancer" refers to all types of cancers, neoplasms, or malignancies found in mammals, such as humans.
[0256] As used herein, the term "carbocycle" refers to an optionally substituted C3-16 monocyclic, bicyclic or tricyclic structure in which the carbon atoms form a ring that may be aromatic or non-aromatic. Carbocyclic structures include cycloalkyl, cycloalkenyl, cycloalkynyl and certain aryl groups.
[0257] As used herein, the term "carbonyl" refers to a -C(O)- group.
[0258] As used herein, the term "cancer" refers to a malignant new growth formed by epithelial cells that tends to infiltrate surrounding tissues and give rise to metastases.
[0259] As used herein, the term "cyano" refers to a -CN group.
[0260] As used herein, the term "cycloalkenyl" refers to a non-aromatic carbocyclic group (e.g., C 3-10 Cycloalkenyl) unless otherwise indicated. The limiting examples of cycloalkenyl include cycloprop-1-alkenyl, cycloprop-2-alkenyl, cyclobut-1-alkenyl, cyclobut-1-alkenyl, cyclobut-2-alkenyl, cyclopent-1-alkenyl, cyclopent-2-alkenyl, cyclopent-3-alkenyl, norbornene-1-base, norbornene-2-base, norbornene-5-base and norbornene-7-base. Cycloalkenyl can be unsubstituted or substituted as described for cycloalkyl (for example, optionally substituted cycloalkenyl).
[0261] As used herein, the term "cycloalkenylalkyl" refers to an alkyl group substituted by a cycloalkenyl group, each as defined herein. The cycloalkenyl and alkyl portions may be substituted as defined herein as separate groups.
[0262] As used herein, the term "cycloalkenylene" refers to a divalent cycloalkenyl group. Optionally substituted cycloalkenylene is an optionally substituted cycloalkenylene as described herein for cycloalkyl.
[0263] As used herein, the term "cycloalkoxy" refers to a chemical substituent of the formula -OR, wherein R is a cycloalkyl, unless otherwise indicated. In some embodiments, the cycloalkyl group may be further substituted as defined herein.
[0264] As used herein, the term "cycloalkyl" refers to a cyclic alkyl group having three to ten carbon atoms (e.g., C 3-C10Cycloalkyl) unless otherwise indicated. Cycloalkyl may be monocyclic or bicyclic. Bicyclic cycloalkyl may be a bicyclic [pq0] alkyl type, wherein p and q are each independently 1, 2, 3, 4, 5, 6 or 7, provided that the sum of p and q is 2, 3, 4, 5, 6, 7 or 8. Alternatively, bicyclic cycloalkyl may include a bridged cycloalkyl structure, such as a bicyclic [pqr] alkyl, wherein r is 1, 2 or 3, p and q are each independently 1, 2, 3, 4, 5 or 6, provided that the sum of p, q and r is 3, 4, 5, 6, 7 or 8. Cycloalkyl may be a spirocyclic group, such as a spiro [pq] alkyl, wherein p and q are each independently 2, 3, 4, 5, 6 or 7, provided that the sum of p and q is 4, 5, 6, 7, 8 or 9. Non-limiting examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, 1-bicyclo[2.2.1.]heptyl, 2-bicyclo[2.2.1.]heptyl, 5-bicyclo[2.2.1.]heptyl, 7-bicyclo[2.2.1.]heptyl, and decahydronaphthyl. The cycloalkyl group may be unsubstituted or substituted (e.g., optionally substituted cycloalkyl) with one, two, three, four, or five substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkylsulfinyl, alkylthio, alkylsulfonyl, amino, aryl, aryloxy, azido, cycloalkyl, cycloalkoxy, cycloalkenyl, cycloalkynyl, halo, heteroalkyl, heterocyclyl, (heterocyclyl)oxy, heteroaryl, hydroxy, nitro, thiol, silyl, cyano, =O, =S, -S02R, wherein R is optionally substituted amino, =NR', wherein R' is H, alkyl, aryl, or heterocyclyl, and -CON(R) A )2, where each R A are independently H or alkyl, or two R A Together with the atoms to which they are attached, they form a heterocyclyl. Each substituent may itself be unsubstituted or substituted with an unsubstituted substituent as defined herein for each respective group.
[0265] As used herein, the term "cycloalkylalkyl" refers to an alkyl group substituted by a cycloalkyl group, each as defined herein. The cycloalkyl and alkyl portions may be optionally substituted as described herein as a single group.
[0266] As used herein, the term "cycloalkylene" refers to a divalent cycloalkyl group. Optionally substituted cycloalkylene is an optionally substituted cycloalkylene as described herein for cycloalkyl.
[0267] As used herein, the term "cycloalkynyl" refers to a monovalent carbocyclic group having one or two carbon-carbon triple bonds and having eight to twelve carbons, unless otherwise indicated. The cycloalkynyl group may include a trans-ring bond or bridge. Non-limiting examples of cycloalkynyl groups include cyclooctynyl, cyclononynyl, cyclodecynyl and cyclodecadiynyl. The cycloalkynyl group may be unsubstituted or substituted (e.g., optionally substituted cycloalkynyl) as defined for cycloalkyl.
[0268] "Disease" or "disorder" refers to a state of being or health in a patient or subject that can be treated with the compounds or methods provided herein.
[0269] As used herein, the term "halo" refers to a halogen selected from bromine, chlorine, iodine and fluorine.
[0270] As used herein, the term "heteroalkyl" refers to an alkyl, alkenyl, or alkynyl group that is interrupted once by one or two heteroatoms; interrupted twice by one or two heteroatoms, each time independently; interrupted three times by one or two heteroatoms, each time independently; or interrupted four times by one or two heteroatoms, each time independently. Each heteroatom is independently O, N, or S. In some embodiments, the heteroatom is O or N. Heteroalkyl groups do not include two consecutive oxygen or sulfur atoms. Heteroalkyl groups may be unsubstituted or substituted (e.g., optionally substituted heteroalkyl groups). When a heteroalkyl group is substituted and a substituent is bonded to a heteroatom, the substituent is selected based on the nature and valence of the heteroatom. Thus, where valence permits, the substituent bonded to the heteroatom is selected from the group consisting of: =O, -N(R N2 2. -SO2OR N3 、-SO2R N2 、-SOR N3 、-COOR N3 , N-protecting group, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclic group or cyano group, wherein each R N2 are independently H, alkyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl or heterocyclyl, and each R N3 alkyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl or heterocyclic radical. Each of these substituents may itself be unsubstituted or substituted with an unsubstituted substituent defined herein for each individual group. When heteroalkyl is substituted and the substituent is bonded to carbon, the substituent is selected from those described for the alkyl, provided that the substituent is not Cl, Br or I on the carbon atom bonded to the heteroatom. It should be understood that the carbon atom is located at the end of the heteroalkyl.
[0271] As used herein, the term "heteroarylalkyl" refers to an alkyl group substituted with a heteroaryl group, each as defined herein. The heteroaryl and alkyl portions may be optionally substituted as described herein as separate groups.
[0272] As used herein, the term "heteroarylene" refers to a divalent heteroaryl group. An optionally substituted heteroarylene group is an optionally substituted heteroarylene group as described herein for a heteroaryl group.
[0273] As used herein, the term "heteroaryloxy" refers to the structure -OR, wherein R is heteroaryl. The heteroaryloxy group may be optionally substituted as defined for heterocyclyl.
[0274] As used herein, unless otherwise indicated, the term "heterocyclyl" refers to a monocyclic, bicyclic, tricyclic or tetracyclic ring system with 3, 4, 5, 6, 7 or 8-membered fused rings, bridged rings and / or spirocyclic rings, containing one, two, three or four heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur. In some embodiments, unless otherwise indicated, the term "heterocyclyl" is a monocyclic, bicyclic, tricyclic or tetracyclic ring system with 5, 6, 7 or 8-membered fused rings or bridged rings, containing one, two, three or four heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur. The heterocyclic group may be aromatic or non-aromatic. Non-aromatic 5-membered heterocyclic groups have zero or one double bond, non-aromatic 6-membered and 7-membered heterocyclic groups have zero to two double bonds, and non-aromatic 8-membered heterocyclic groups have zero to two double bonds and / or zero or one carbon-carbon triple bond. Unless otherwise indicated, the heterocyclic group includes 1 to 16 carbon atoms. Certain heterocyclyl groups may include up to 9 carbon atoms. Non-aromatic heterocyclyl groups include pyrrolinyl, pyrrolidinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolinyl, piperidinyl, homopiperidinyl, piperazinyl, pyridazinyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiomorpholinyl, tetrahydrothiazolyl, isotetrahydrothiazolyl, tetrahydrothiazolyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, dihydrothienyl, dihydroindolyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, pyranyl, dihydropyranyl, dithiazolyl, and the like. If the heterocyclic ring system has at least one aromatic resonance structure or at least one aromatic tautomer, the structure is an aromatic heterocyclyl (i.e., heteroaryl). Non-limiting examples of heteroaryl groups include benzimidazolyl, benzofuranyl, benzothiazolyl, benzothiophenyl, benzoxazolyl, furanyl, imidazolyl, indolyl, isoindazolyl, isoquinolyl, isothiazolyl, isothiazolyl, isoxazolyl, oxadiazolyl, oxazolyl, purinyl, pyrrolyl, pyridinyl, pyrazinyl, pyrimidinyl, quinazolinyl, quinolinyl, thiadiazolyl (e.g., 1,3,4-thiadiazole), thiazolyl, thienyl, triazolyl, tetrazolyl, etc. The term "heterocyclyl" also refers to heterocyclic compounds having a bridged polycyclic structure in which one or more carbon and / or heteroatoms bridge two non-adjacent members of a monocyclic ring, such as quinuclidine, tropane, or diaza-bicyclo[2.2.2]octane. The term "heterocyclyl" includes bicyclic, tricyclic and tetracyclic groups, wherein any of the above heterocyclic rings are fused to one, two or three carbocyclic rings, such as an aryl ring, a cyclohexane ring, a cyclohexene ring, a cyclopentane ring, a cyclopentene ring or another monocyclic heterocycle. Examples of fused heterocyclyls include 1,2,3,5,8,8a-hexahydroindolizine; 2,3-dihydrobenzofuran; 2,3-dihydroindole; and 2,3-dihydrobenzothiophene.The heterocyclyl group may be unsubstituted or substituted with one, two, three, four or five substituents independently selected from the group consisting of: alkyl; alkenyl; alkynyl; alkoxy; alkylsulfinyl; alkylthio; alkylsulfonyl; amino; aryl; aryloxy; azido; cycloalkyl; cycloalkyloxy; cycloalkenyl; cycloalkynyl; halo; heteroalkyl; heterocyclyl; (heterocyclyl)oxy; hydroxy; nitro; thiol; silyl; cyano; -C(O)R; -S02R, wherein R is amino or alkyl; =O; =S; =NR', wherein R' is H, alkyl, aryl or heterocyclyl. Each substituent itself may be unsubstituted or substituted with an unsubstituted substituent as defined herein for each respective group.
[0275] As used herein, the term "heterocyclylalkyl" refers to an alkyl group substituted with a heterocyclyl group, each as defined herein. The heterocyclyl and alkyl portions may be optionally substituted as described herein as separate groups.
[0276] As used herein, the term "heterocyclylene" refers to a divalent heterocyclyl group. Optionally substituted heterocyclylene is an optionally substituted heterocyclylene as described herein for heterocyclyl.
[0277] As used herein, the term "(heterocyclyl)oxy" refers to a chemical substituent of the formula -OR, wherein R is heterocyclyl, unless otherwise stated. The (heterocyclyl)oxy group may be optionally substituted as described for heterocyclyl.
[0278]
[0043] The terms "hydroxyl" and "hydroxy" as used interchangeably herein refer to an -OH group.
[0279] As used herein, the term "isotopically enriched" refers to a pharmaceutical agent having an isotopic content of an isotope at a predetermined position within the molecule that is at least 100 times higher than the natural abundance of the isotope. For example, a composition isotopically enriched in deuterium includes an agent having an abundance of deuterium at least 100 times greater than the natural abundance of deuterium at at least one hydrogen atom position. Preferably, the isotopic enrichment of deuterium is at least 1000 times greater than the natural abundance of deuterium. More preferably, the isotopic enrichment of deuterium is at least 4000 times greater than the natural abundance of deuterium (e.g., at least 4750 times greater, e.g., up to 5000 times greater).
[0280] As used herein, the term "leukemia" refers generally to progressive malignant diseases of the blood-forming organs, usually characterized by abnormal proliferation and development of white blood cells and their precursors in the blood and bone marrow. The clinical classification of leukemia is usually based on (1) acute or chronic disease duration and characteristics; (2) the type of cells involved: myeloid cells (myelocytes), lymphoid cells (lymphoblasts), or monocytes; (3) leukemic or non-leukemic (subleukemic) blood The increase or absence of an increase in the number of abnormal cells.
[0281] As used herein, the term "lymphoma" refers to cancers arising from cells of immune origin.
[0282] As used herein, the term "melanoma" shall be deemed to mean a tumor arising from the melanocytic system of the skin and other organs.
[0283] As used herein, the term "nitro" refers to a -NO2 group.
[0284] As used herein, the term "oxo" refers to a divalent oxygen atom (eg, the structure of oxo can be shown as =0).
[0285] As used herein, the term "Ph" means a phenyl group.
[0286] As used herein, the term "pharmaceutical composition" means a composition containing a compound described herein, formulated with a pharmaceutically acceptable excipient, and approved by a governmental regulatory agency for manufacture or sale as part of a therapeutic regimen for treating a disease in a mammal. The pharmaceutical composition can be formulated, for example, in unit dosage form (e.g., tablets, capsules, caplets, caplets, or syrups) for oral administration; for topical administration (e.g., in the form of a cream, gel, lotion, or ointment); for intravenous administration (e.g., in the form of a sterile solution that does not contain particulate emboli and is in a solvent system suitable for intravenous use); or in any other formulation described herein.
[0287] As used interchangeably herein, "pharmaceutically acceptable excipients" or "pharmaceutically acceptable carriers" refer to any ingredients other than the compounds described herein that are non-toxic and non-inflammatory in patients (e.g., vehicles capable of suspending or dissolving active compounds). Excipients may include, for example, anti-adherents, antioxidants, binders, coatings, compression aids, disintegrants, dyes (colorants), softeners, emulsifiers, fillers (diluents), film formers or coatings, flavoring agents, fragrances, glidants (flow enhancers), lubricants, preservatives, printing inks, adsorbents, suspending or dispersing agents, sweeteners, or water of hydration. Exemplary excipients include, but are not limited to, butylated hydroxytoluene (BHT), calcium carbonate, calcium phosphate (dicalcium phosphate), calcium stearate, croscarmellose, cross-linked polyvinyl pyrrolidone, citric acid, cross-linked povidone, cysteine, ethylcellulose, gelatin, hydroxypropyl cellulose, hydroxypropyl methylcellulose, lactose, magnesium stearate, maltitol, mannitol, methionine, methylcellulose, methylparaben, microcrystalline cellulose, polyethylene glycol, polyvinyl pyrrolidone, povidone, pregelatinized starch, propylparaben, retinyl palmitate, shellac, silicon dioxide, sodium carboxymethylcellulose, sodium citrate, sodium starch glycolate, sorbitol, starch (corn), stearic acid, stearic acid, sucrose, talc, titanium dioxide, vitamin A, vitamin E, vitamin C, and xylitol.
[0288] As used herein, the term "pharmaceutically acceptable salt" means salts that are suitable for contact with human and animal tissues without excessive toxicity, irritation, allergic response, etc., and are commensurate with a reasonable benefit / risk ratio within the scope of reasonable medical judgment. Pharmaceutically acceptable salts are well known in the art. For example, pharmaceutically acceptable salts are described in: Berge et al., J. Pharmaceutical Sciences 66: 1-19, 1977 and Pharmaceutical Salts: Properties, Selection, and Use, (P. H. Stahl and C. G. Wermuth, eds.), Wiley-VCH, 2008. Salts can be prepared in situ during the final isolation and purification of the compounds described herein, or prepared separately by reacting a free base group with a suitable organic acid. Representative acid addition salts include acetate, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptonate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrobromide, hydrochloride, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, toluenesulfonate, undecanoate, valerate, and the like. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like; as well as non-toxic ammonium, quaternary ammonium, and amine cations, including but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, and the like.
[0289] As used herein, the term "PLK4" refers to polo-like kinase 4, also known as serine / threonine protein kinase PLK4 (gene name PLK4).
[0290] As used herein, the term "PLK4 inhibitor" refers to a compound that, upon contact with the enzyme PLK4 (whether in vitro, in cell culture or in an animal), reduces PLK4 activity such that the measured PLK4 IC 50 For certain PLK4 inhibitors, the PLK4 IC 50It may be 100 nM or less (e.g., 10 nM or less, or 3 nM or less) and may be as low as 100 pM or 10 pM. Preferably, PLK IC 50 1 nM to 1 μM (eg, 1 nM to 750 nM, 1 nM to 500 nM, or 1 nM to 250 nM). Even more preferably, PLK4 IC 50 Less than 20 nm (eg, 1 nM to 20 nM).
[0291] As used herein, the term "premalignant" or "precancerous" refers to a condition that is non-malignant but has the potential to become malignant.
[0292] As used herein, the term "protecting group" means a group intended to protect a hydroxyl, amino or carbonyl group from participating in one or more undesirable reactions during a chemical synthesis. As used herein, the term "O-protecting group" means a group intended to protect a hydroxyl or carbonyl group from participating in one or more undesirable reactions during a chemical synthesis. As used herein, the term "N-protecting group" means a group intended to protect a nitrogen-containing (e.g., amino, amide, heterocyclic NH or hydrazine) group from participating in one or more undesirable reactions during a chemical synthesis. Commonly used O-protecting groups and N-protecting groups are disclosed in Greene, "Protective Groups in Organic Synthesis", 3rd edition (John Wiley & Sons, New York, 1999), which is incorporated herein by reference. Exemplary O-protecting groups and N-protecting groups include alkanoyl, aroyl or carbamoyl groups, such as formyl, acetyl, propionyl, pivaloyl, tert-butylacetyl, 2-chloroacetyl, 2-bromoacetyl, trifluoroacetyl, trichloroacetyl, phthaloyl, o-nitrophenoxyacetyl, α-chlorobutyryl, benzoyl, 4-chlorobenzoyl, 4-bromobenzoyl, tert-butyldimethylsilyl, triisopropylsiloxymethyl, 4,4′-dimethoxytrityl, isobutyryl, phenoxyacetyl, 4-isopropylphenoxyacetyl, dimethylformamidinyl and 4-nitrobenzoyl.
[0293] Exemplary O-protecting groups for protecting carbonyl-containing groups include, but are not limited to, acetal, acylal, 1,3-dithiane, 1,3-dioxane, 1,3-dioxolane, and 1,3-dithiolane.
[0294] Other O-protecting groups include, but are not limited to, substituted alkyl, aryl, and aryl-alkyl ethers (e.g., trityl; methylthiomethyl; methoxymethyl; benzyloxymethyl; silyloxymethyl; 2,2,2,-trichloroethoxymethyl; tetrahydropyranyl; tetrahydrofuranyl; ethoxyethyl; 1-[2-(trimethylsilyl)ethoxy]ethyl; 2-trimethylsilylethyl; tert-butyl ether; p-chlorophenyl, p-methoxyphenyl, p-nitrophenyl, benzyl, p-methoxybenzyl, and nitrobenzyl); Silyl ethers (e.g., trimethylsilyl; triethylsilyl; triisopropylsilyl; dimethylisopropylsilyl; tert-butyldimethylsilyl; tert-butyldiphenylsilyl; tribenzylsilyl; triphenylsilyl; and diphenylmethylsilyl); carbonates (e.g., methyl, methoxymethyl, 9-fluorenylmethyl; ethyl; 2,2,2-trichloroethyl; 2-(trimethylsilyl)ethyl; vinyl, allyl, nitrophenyl; benzyl; methoxybenzyl; 3,4-dimethoxybenzyl; and nitrobenzyl).
[0295] Other N-protecting groups include, but are not limited to, chiral auxiliary agents such as protected or unprotected D-amino acids, L-amino acids, or D,L-amino acids, such as alanine, leucine, phenylalanine, etc.; sulfonyl-containing groups, such as benzenesulfonyl, p-toluenesulfonyl, etc.; carbamate-forming groups, such as benzyloxycarbonyl, p-chlorobenzyloxycarbonyl, p-methoxybenzyloxycarbonyl, p-nitrobenzyloxycarbonyl, 2-nitrobenzyloxycarbonyl, p-bromobenzyloxycarbonyl, 3,4-dimethoxybenzyloxycarbonyl, 3,5-dimethoxybenzyloxycarbonyl, 2,4-dimethoxybenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 2-nitro-4,5-dimethoxybenzyloxycarbonyl, 3,4,5-trimethoxybenzyloxycarbonyl, 1-( ] carbonyl, tert-butyloxycarbonyl, diisopropylmethoxycarbonyl, isopropyloxycarbonyl, ethoxycarbonyl, methoxycarbonyl, allyloxycarbonyl, 2,2,2,-trichloroethoxycarbonyl, phenoxycarbonyl, 4-nitrophenoxycarbonyl, fluorenyl-9-methoxycarbonyl, cyclopentyloxycarbonyl, adamantyloxycarbonyl, cyclohexyloxycarbonyl, phenylthiocarbonyl and the like; aryl-alkyl groups such as benzyl, p-methoxybenzyl, 2,4-dimethoxybenzyl, triphenylmethyl, benzyloxymethyl and the like; silylalkyl acetal groups such as [2-(trimethylsilyl)ethoxy]methyl; and silyl groups such as trimethylsilyl and the like. Useful N-protecting groups are formyl, acetyl, benzoyl, valeryl, tert-butylacetyl, alanyl, phenylsulfonyl, benzyl, dimethoxybenzyl, [2-(trimethylsilyl)ethoxy]methyl (SEM), tetrahydrofuranyl (THP), tert-butyloxycarbonyl (Boc) and benzyloxycarbonyl (Cbz).
[0296] The term "tautomer" refers to structural isomers that are easily interconvertible, usually by relocation of a proton. Tautomers are different chemical species that can be identified by different spectral features, but cannot usually be separated individually. Non-limiting examples of tautomers include keto-enols, enamines-imines, amides-imidic acids, nitroso-oximes, enones-alkynols, and amino acid-ammonium carboxylates.
[0297] The term "sarcoma" generally refers to tumors formed from material resembling embryonic connective tissue and usually composed of tightly packed cells embedded in a fibrous or homogeneous material.
[0298] As used herein, the term "subject" refers to a human or non-human animal (e.g., a mammal) having a disease or disorder or at risk of a disease or disorder, as determined by a qualified professional (e.g., a physician or nurse practitioner) with or without laboratory tests known or unknown in the art on a sample from the subject. Preferably, the subject is a human. Non-limiting examples of diseases and disorders include diseases with symptoms of cellular hyperproliferation, such as cancer.
[0299] As used herein, "treatment" or "treating" refers to the medical management of a subject for the purpose of alleviating, ameliorating, stabilizing, preventing or curing a disease or disorder. The term includes active treatment (treatment aimed at improving a disease or disorder); causal treatment (treatment aimed at the cause of the relevant disease or disorder); palliative treatment (treatment aimed at relieving the symptoms of a disease or disorder); preventive treatment (treatment aimed at minimizing or partially or completely inhibiting the development of the relevant disease or disorder); and supportive treatment (treatment used to supplement another therapy).
[0300] The term "TRIM37" refers to protein tripartite motif containing 37 and its gene. DETAILED DESCRIPTION
[0301] In general, the present invention provides compounds, pharmaceutical compositions containing the compounds, methods for preparing the compounds, and methods of use. The compounds of the present invention may be PLK4 inhibitors. These compounds can be used to inhibit PLK4 in cells, such as cells in a subject (e.g., cells that overexpress TRIM37 or have altered centrosome or centriole function or number). The subject may need treatment for a disease or disorder, such as a disease or disorder with symptoms of cell hyperproliferation, such as cancer. The PLK4 inhibitory activity of the compounds disclosed herein can be used to treat subjects in need of treatment for cancer.
[0302] The Polo-like kinase (PLK) family of serine / threonine kinases is characterized by the presence of a Polo box domain and plays a key role in the regulation of mitosis. Of the five members described to date, PLK1, PLK2, PLK3, PLK4, and PLK5, PLK1 is the most studied member, and multiple PLK1 inhibitors have been described. PLK4 is structurally the most unique member of the family. Unlike PLK1, PLK2, and PLK3, PLK4 has only one Polo box and one active site with high homology to the Aurora kinases. PLK4 has a limited tissue distribution and is only present in proliferative tissues. PLK4 is localized to the centrosome and is a key regulator of centriole duplication. Dysregulation of PLK4 leads to a loss of centrosome data integrity and causes chromosomal instability. PLK4 has been shown to be upregulated in breast cancer, particularly in the basal-like subtype, and high PLK4 levels are associated with poor patient outcomes. Consistent with its critical role in centriole biogenesis, it has been shown that genetic inhibition of PLK4 activity or loss of PLK4 leads to centriole loss.
[0303] PLK4 inhibitors may be particularly useful for treating tumors harboring TRIM37 amplification using synthetic lethal therapeutic strategies. The TRIM37 locus is located at the border of 17q22 and 17q23, a chromosomal region that is amplified in many cancers, most notably in approximately 50%-60% of neuroblastomas and approximately 10% of breast cancers. TRIM37 is a ubiquitin E3 ligase that plays an important role in regulating the cellular expression of pericentriolar material. Overexpression of TRIM37 leads to enhanced degradation of pericentriolar material. Successful microtubule nucleation is essential for cell division and survival. Cells can survive in the absence of centrosomes by relying on pericentriolar material. In situations where the abundance of pericentriolar material is suppressed, such as by overexpression of TRIM37, cells cannot survive after PLK4 inhibition due to the inability to adequately form microtubules.
[0304] The compound of the present invention may be, for example, a compound of formula (I):
[0305]
[0306] or a pharmaceutically acceptable salt thereof,
[0307] in
[0308] n is 0, 1, 2, 3 or 4;
[0309] m is 0, 1 or 2;
[0310] L is an optionally substituted C 2-9 Heterocyclic group, optionally substituted C 2-9 Heteroaryl, optionally substituted C 6-10Aryl, or optionally substituted C 3-8 Cycloalkyl, wherein L is further optionally replaced by n occurrences of R 3 replace;
[0311] R 1 is hydrogen, halogen, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, or optionally substituted C 3-8 Cycloalkyl;
[0312] A is O or S, R 2A and R 2B None; or A is N, R 2A does not exist, and R 2B is hydrogen, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 6-10 Aryl C 1-6 Alkyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 6-10 Aryl, optionally substituted C 2-9 Heterocyclic group, optionally substituted C 1-9 Heteroaryl, optionally substituted C 1-9 Heteroaryl C 1-6 Alkyl, or optionally substituted C 1-6 Alkylsulfonyl, or R 2B and L together with the atoms to which they are attached combine to form an optionally substituted C 2-9 Heterocyclic or optionally substituted C 2-9 heteroaryl; or A is C, and R 2A and R 2B are each independently hydrogen, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 6-10 Aryl C 1-6 Alkyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 6-10 Aryl, optionally substituted C 2-9 Heterocyclic group, optionally substituted C 1-9 Heteroaryl, optionally substituted C 1-9 Heteroaryl C 1-6 Alkyl, or optionally substituted C 1-6 Alkylsulfonyl;
[0313] Each R 3are independently halogen, cyano, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 6-10 Aryl C 1-6 Alkyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 3-8 Cycloalkenyl, optionally substituted C 6-10 Aryl, optionally substituted C 2-9 Heterocyclic group, optionally substituted C 1-9 Heteroaryl, optionally substituted C 1-9 Heteroaryl C 1-6 Alkyl, -S(O) m R 3A 、-N(R 3B )2OR 3B ;
[0314] R 3A is an optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 6-10 Aryl, optionally substituted C 2-9 Heterocyclic group, optionally substituted C 1-9 Heteroaryl, -OR 3B or -N(R 3B )2.
[0315] Each R 3B are independently hydrogen, optionally substituted C 1-6 Alkyl, optionally substituted C 6-10 Aryl C 1-6 Alkyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 6-10 Aryl, optionally substituted C 2-9 Heterocyclic group, optionally substituted C 1-9 Heteroaryl, optionally substituted C 1-9 Heteroaryl C 1-6 Alkyl, or optionally substituted C 1-6 Alkylsulfonyl; or two R 3B The groups together with the atoms to which they are attached combine to form an optionally substituted C 2-9 Heterocyclic group;
[0316] X is N, R4 does not exist; or X is C, and R 4 is hydrogen, halogen, cyano, optionally substituted amino, optionally substituted acyl, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 3-8 Cycloalkenyl, optionally substituted C 6-10 Aryl, optionally substituted C 2-9 heterocyclic group, or optionally substituted C 1-9 heteroaryl;
[0317] R 5 is an optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 3-8 Cycloalkenyl, optionally substituted C 6-10 Aryl, optionally substituted C 2-9 Heterocyclic group, optionally substituted C 1-9 Heteroaryl or -ZR 5A ;
[0318] Z is an optionally substituted C 2-9 Heterocyclylene, optionally substituted C 2-9 Heteroarylene, optionally substituted C 6-10 Arylene, or optionally substituted C 3-8 Cycloalkylene;
[0319] R 5A is hydrogen, halogen, cyano, optionally substituted C 1-6 Alkylsulfonyl, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 3-8 Cycloalkenyl, optionally substituted C 6-10 Aryl, optionally substituted C 2-9 heterocyclic group, or optionally substituted C 1-9 heteroaryl;
[0320] R 6is hydrogen, halogen, cyano, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl or -OR 6A ;and
[0321] R 6A is hydrogen, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, or optionally substituted C 3-8 Cycloalkyl.
[0322] The compounds of the present invention may be exemplified by the compounds listed in the following Table 1 or pharmaceutically acceptable salts thereof.
[0323] Table 1
[0324]
[0325]
[0326]
[0327]
[0328]
[0329]
[0330]
[0331]
[0332]
[0333]
[0334]
[0335]
[0336]
[0337]
[0338]
[0339]
[0340]
[0341]
[0342]
[0343]
[0344]
[0345]
[0346]
[0347]
[0348]
[0349] The present invention includes (where possible) individual diastereomers, enantiomers, epimers and atropisomers of the compounds disclosed herein, as well as mixtures of diastereomers and / or enantiomers thereof, including racemic mixtures. Although the specific stereochemistry disclosed herein is preferred, other stereoisomers, including diastereomers, enantiomers, epimers, atropisomers and mixtures thereof may also be used to treat PLK4-mediated diseases. Inactive or less active diastereomers and enantiomers may be used, for example, in scientific studies related to receptors and activation mechanisms.
[0350] It is understood that certain molecules can exist in multiple tautomeric forms. The present invention includes all tautomers, even though only one tautomer may be indicated in an example.
[0351] The present invention also includes pharmaceutically acceptable salts of the compounds, and pharmaceutical compositions comprising the compounds and a pharmaceutically acceptable carrier. These compounds are particularly useful, for example, in certain types of cancer, and once cancer develops in a patient, can be used to slow the progression of the cancer.
[0352] The compounds disclosed herein can be used in pharmaceutical compositions comprising (a) a compound or a pharmaceutically acceptable salt thereof and (b) a pharmaceutically acceptable carrier. The compounds can be used in pharmaceutical compositions comprising one or more other active pharmaceutical ingredients. The compounds can also be used in pharmaceutical compositions in which the compounds disclosed herein or a pharmaceutically acceptable salt thereof is the sole active ingredient.
[0353] Optical isomers-diastereomers-geometric isomers-tautomers
[0354] The compounds disclosed herein may contain, for example, one or more stereocenters and may exist as racemates, racemic mixtures, single enantiomers, individual diastereomers, and mixtures of diastereomers and / or enantiomers. The present invention includes all of these isomeric forms of the compounds disclosed herein. It is intended that all possible stereoisomers (e.g., enantiomers and / or diastereomers) in the case of mixtures as well as pure compounds or partially purified compounds are included within the scope of the present invention (i.e., all possible combinations of stereogenic centers as pure compounds or mixtures).
[0355] Some of the compounds described herein may contain a bond that is rotationally hindered, so that two different rotamers or atropisomers can be separated and found to have different biological activities, which may be advantageous. All possible atropisomers are intended to be included within the scope of the present invention.
[0356] Some of the compounds described herein may contain olefinic double bonds, and unless specified otherwise, are intended to include both E and Z geometric isomers.
[0357] Some of the compounds described herein may exist with different points of hydrogen attachment, known as tautomers. An example is a keto and its enol form, known as keto-enol tautomers. The present invention encompasses individual tautomers and mixtures thereof.
[0358] Compounds disclosed herein having one or more asymmetric centers can be separated into diastereomers, enantiomers, etc. by methods known in the art.
[0359] Alternatively, enantiomers and other compounds having chiral centers can be synthesized by stereospecific synthesis using optically pure starting materials and / or reagents of known configuration.
[0360] Metabolites-Prodrugs
[0361] The present invention includes metabolites with therapeutic activity, wherein the metabolites themselves fall within the scope of the claims. The present invention also includes prodrugs, which are compounds that are converted to the claimed compounds when or after administration to a patient. In some cases, the chemical structures claimed in this application may themselves be prodrugs.
[0362] Isotopically enriched derivatives
[0363] The present invention includes molecules that have been isotopically enriched at one or more positions within the molecule. Thus, deuterium-enriched compounds fall within the scope of the claims.
[0364] Methods for preparing the compounds of the present invention
[0365] The compounds of the invention can be prepared using reactions and techniques known in the art as well as those described herein. One skilled in the art will appreciate that the methods for preparing the compounds of the invention described herein are non-limiting and that steps within the methods can be interchanged without affecting the structure of the final product.
[0366] Method A
[0367] Type I compounds, wherein A is O or S or AR 2B NH and XR 4 N can be prepared in five steps as described in Scheme A. SnAr reaction between a suitably protected aminopyrazole IV and a substituted 4,6-dichloro-2-(methylthio)pyrimidine V under basic conditions yields aminopyrazolopyrimidine type VI. Oxidation of methylthiol VI followed by reaction with a suitable boronic acid (R 5 -B(OH)2) or stannane (R 5 -SnBu3) undergoes Suzuki or Stille coupling to provide the advanced intermediate methylsulfone pyrimidine VIII. 3 ) n -L-NH2), phenol ((R 3 ) n -L-OH) or thiophenol ((R 3 ) n -L-SH) followed by removal of the protecting group PG 1 , which can ultimately provide type I tetrasubstituted pyrimidines.
[0368] Plan A
[0369]
[0370] Method B
[0371] Type I compounds, in which AR 2B NR 2B And XR 4 N can be prepared in 7 steps as described in Scheme B. The introduction of a protecting group (e.g., SEM, PMB, etc.) of the aminopyrazolopyrimidine type VI described in Method A followed by oxidation of the methylthiol can generate the diprotected amino-pyrazolopyrimidine XI. 5 -B(OH)2) or stannane (R 5 -SnBu3) undergoes Suzuki or Stille coupling to provide the higher intermediate methylsulfone pyrimidine XII. SnAr-type addition of appropriately substituted anilines ((R 3 ) n -L-NH2) to XII, followed by alkylation of the aniline to give intermediate XIV. Removal of the protecting group PG 1 and PG 2, which can ultimately provide the type I tetrasubstituted pyrimidine exemplified in Scheme B.
[0372] Plan B
[0373]
[0374] Method C
[0375] Type I compounds, wherein A is O or S or AR 2B NR 2B , X is C and R 4 is H and can be prepared in 6 steps as described in Scheme C. A suitable substituted boronic acid (R 5 Suzuki coupling between -B(OH)2) and 4-bromo-6-chloro-2-fluoropyridin-3-ol produces regioselective pyridines of type XV. The phenol moiety is then converted to the corresponding triflate XVI, followed by a second Suzuki coupling to provide pyridines of type XVII. SnAr-type addition of amino-pyrazole IV to fluoro-chloropyridine XVII regioselectively affords chloro-pyridines XVIII. Appropriately substituted anilines ((R 3 ) n -L-NH2), phenol ((R 3 ) n -L-OH) or thiophenol ((R 3 ) n -L-SH) undergoes a second SnAr-type reaction on chloro-pyridine XVIII, followed by PG 1 Deprotection can ultimately provide the tetrasubstituted pyridines of Type I as exemplified in Scheme C.
[0376] Plan C
[0377]
[0378] Method D
[0379] Type I compounds, where R 6 is OMe, A is O or S or AR 2B NR 2B , X is C and R 4 is not H and can be prepared in 6 steps as described in Scheme D. Bromination of commercially available phenols of type XX followed by methylation of the phenol moiety can provide intermediate dibromo-chloropyridines of type XXII. Buchwald-Hartwig amination of XXI with amino-pyrazole IV followed by reaction with a suitably substituted boronic acid (R 5 -B(OH)2) can provide chloro-pyridines of type XXIV. Appropriately substituted anilines ((R 3 ) n -L-NH2), phenol ((R3 ) n -L-OH) or thiophenol ((R 3 ) n -L-SH) on chloro-pyridine XXIV in a SnAr-type reaction followed by PG 1 Deprotection can ultimately provide the tetrasubstituted pyridines of Type I as exemplified in Scheme D.
[0380] Plan D
[0381]
[0382] Method E
[0383] Type I compounds, wherein A is O or S or AR 2B NR 2B , and XR 4 =N can alternatively be prepared by previously described method B, as depicted in Scheme E in 5 steps, starting with the addition of amino-pyrazole IV to trichloropyrimidine XXVI via a SnAr type reaction. Protection of the amino group is followed by an appropriately substituted aniline ((R 3 ) n -L-NHR 2B )、phenol((R 3 ) n -L-OH) or thiophenol ((R 3 ) n -L-SH) can generate intermediate XXIX. 5 -B(OH)2) undergoes a Suzuki coupling to provide the previously described type XIV tetrasubstituted pyrimidines. 1 and PG 2 Deprotection can ultimately provide the desired Type I pyrimidine as exemplified in Scheme E.
[0384] Plan E
[0385]
[0386] Method F
[0387] Type I compounds, in which AR 2B NR 2B , XR 4 N and R 5 The core pyrimidine is linked via a CN bond and can be prepared in four steps from the common intermediate XI as depicted in Scheme F. First, a suitably substituted aniline ((R 3 ) n-L-NH2) to generate XXX-type pyrimidine. The resulting aniline is then substituted to provide XXXI, followed by the introduction of R by Buchwald-Hartwig amination. 5 Produces type XIV pyrimidines. Then PG 1 and PG 2 Deprotection can ultimately provide the desired type I pyrimidine, where R 5 It is linked to the core pyrimidine via a carbon-nitrogen bond.
[0388] Plan F
[0389]
[0390] Method G
[0391] Type I compounds, in which AR 2B NR 2B , XR 4 N and R 5 Linked to the core pyrimidine via a CN or CC bond, it can be prepared in 5 steps from the common intermediate X in analogy to method B but in an alternative reaction sequence as depicted in Scheme G. Thiomethylpyrimidine XXXII is first subjected to Buchwald-Hartwig amination, Suzuki or Stille coupling prior to the oxidation step to afford XII. The remaining three steps from XII to the final compound of type I are described in method B.
[0392] Plan G
[0393]
[0394] Method H
[0395] Type I compounds, in which AR 2B NR 2B , XR 4 N and R 5 Linked to the core pyrimidine via a CC bond, it can be prepared in 2 steps from the previously described intermediate XXXI as depicted in Scheme G. 5 The chloro-pyrimidine XXXI is introduced by Suzuki or Stille coupling to generate XXXIII-type pyrimidines. 1 and PG 2 Deprotection can ultimately provide the desired type I pyrimidine, where R 5 It is linked to the core pyrimidine via a carbon-carbon bond.
[0396] Scheme H
[0397]
[0398] Method I
[0399] Type I compounds, in which AR 2B CR 2B , XR 4 N and R 5 The core pyrimidine can be prepared in two steps from the previously described intermediate XII via a C-C bond. SnAr-type addition of arylacetate or arylacetonitrile to intermediate XII under alkaline conditions can provide pyrimidines of type XXXIV. Subsequent decarboxylation and PG 1 and PG 2 Deprotection can ultimately provide the desired type I pyrimidine, where R 2B For intermediates of type XXXIV, where R 2B For nitrile, directly to PG 1 and PG 2 Deprotection can ultimately provide the desired type I pyrimidine, where R 2B is nitrile and A is carbon.
[0400] Scheme I
[0401]
[0402] Treatment
[0403] The compounds of the invention may be used to treat diseases or conditions that are dependent on PLK4 activity (eg, cancers that overexpress TRIM37).
[0404] The disease or disorder may have symptoms of cell hyperproliferation. For example, the disease or disorder may be cancer (eg, a cancer that overexpresses TRIM37).
[0405] Cancers with a high incidence of overexpressing TRIM37 include, for example, uterine cancer, ovarian cancer, breast cancer, gastric cancer, esophageal cancer, lung cancer, and endometrial cancer.
[0406] The compounds of the present invention can be administered by a route selected from the group consisting of oral, sublingual, buccal, transdermal, intradermal, intramuscular, parenteral, intravenous, intraarterial, intracranial, subcutaneous, intraorbital, intraventricular, intraspinal, intraperitoneal, intranasal, inhalation, intratumoral and topical administration.
[0407] Pharmaceutical composition
[0408] The compounds used in the methods described herein are preferably formulated into pharmaceutical compositions in a biocompatible form suitable for in vivo administration for administration to human subjects. Pharmaceutical compositions typically include a compound as described herein and a pharmaceutically acceptable excipient. Certain pharmaceutical compositions may include one or more additional pharmaceutically active agents as described herein.
[0409] The compounds described herein may also be used in their free base form, in their salt, zwitterion, solvate form, or as their prodrugs or pharmaceutical compositions. All forms are within the scope of the present invention. The compounds, their salts, zwitterions, solvates, prodrugs or pharmaceutical compositions may be administered to patients in a variety of forms, depending on the selected route of administration, as will be appreciated by those skilled in the art. The compounds used in the methods described herein and the corresponding formulated pharmaceutical compositions may be administered, for example, by oral, parenteral, buccal, sublingual, nasal, rectal, patch, pump or transdermal administration. Parenteral administration includes intravenous, intraperitoneal, subcutaneous, intramuscular, transepithelial, nasal, intrapulmonary, intrathecal, rectal and topical modes of administration. Parenteral administration may be performed by continuous infusion over a selected time period.
[0410] For human use, the compounds of the invention may be administered alone or mixed with a pharmaceutical carrier selected according to the intended route of administration and standard pharmaceutical practice. Thus, the pharmaceutical compositions used according to the invention may be formulated in a conventional manner using one or more physiologically acceptable carriers comprising excipients and adjuvants that facilitate processing of the compounds of the invention into pharmaceutically usable preparations.
[0411] The present invention also includes pharmaceutical compositions that may contain one or more pharmaceutically acceptable carriers. In preparing the pharmaceutical compositions of the present invention, the active ingredient is typically mixed with an excipient, diluted with an excipient, or encapsulated in a carrier in the form of, for example, a capsule, a sachet, paper, or other container. When an excipient is used as a diluent, it can be a solid, semisolid, or liquid material (e.g., normal saline) as a vehicle, carrier, or medium for the active ingredient. Thus, the composition can be in the form of tablets, powders, lozenges, capsules, cachets, elixirs, suspensions, emulsions, solutions, syrups, and soft and hard gelatin capsules. As is known in the art, the type of diluent can vary depending on the intended route of administration. The resulting composition may include additional agents, such as preservatives.
[0412] Excipients or carriers are selected according to the mode of administration and route. Suitable pharmaceutical carriers and medical necessities for pharmaceutical preparations are described in the well-known references in the art Remington: The Science and Practice of Pharmacy, the 21st edition, Gennaro compiled, Lippincott Williams & Wilkins (2005) and USP / NF (United States Pharmacopoeia and National Formulary). Examples of suitable excipients are lactose, dextrose, sucrose, sorbitol, mannitol, starch, gum arabic, calcium phosphate, alginate, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinyl pyrrolidone, cellulose, water, syrup and methylcellulose. Preparations may additionally include: lubricants, such as talc, magnesium stearate and mineral oil; wetting agents; emulsifiers and suspensions; preservatives, such as methyl benzoate and propyl hydroxybenzoate; sweeteners; and flavoring agents. Other exemplary excipients are described in Handbook of Pharmaceutical Excipients, 6th edition, Rowe et al., eds., Pharmaceutical Press (2009).
[0413] These pharmaceutical compositions can be manufactured in a conventional manner, for example, by conventional mixing, dissolving, granulating, making dragees, grinding, emulsifying, encapsulating, embedding or lyophilizing processes. Methods for preparing preparations well known in the art can be found in, for example, Remington: The Science and Practice of Pharmacy, 21st edition, Gennaro, Lippincott Williams & Wilkins (2005) and Encyclopedia of Pharmaceutical Technology, J. Swarbrick and JC Boylan, 1988-1999, Marcel Dekker, New York. Appropriate preparations depend on the selected route of administration. The preparation and preparation of such compositions are well known to those skilled in the art of pharmaceutical preparations. When preparing the preparation, the active compound can be ground to provide a suitable particle size and then combined with other ingredients. If the active compound is substantially insoluble, it can be ground to a particle size of less than 200 meshes. If the active compound is substantially water-soluble, the particle size can be adjusted by grinding to provide a substantially uniform distribution in the preparation, for example, about 40 meshes.
[0414] dose
[0415] The dosage of the compound used in the methods described herein, or a pharmaceutically acceptable salt or prodrug thereof, or a pharmaceutical composition may vary according to many factors, such as the following: the pharmacodynamic properties of the compound; the mode of administration; the age, health and weight of the recipient; the nature and extent of the symptoms; the frequency of treatment and the type of concurrent treatment (if any); and the clearance rate of the compound in the animal to be treated. A person skilled in the art can determine a suitable dose based on the above factors. The compounds used in the methods described herein may be initially administered at a suitable dose, which may be adjusted as necessary, depending on the clinical response. In general, a suitable daily dose of a compound of the invention will be the amount of the compound at the lowest dose that is effective in producing a therapeutic effect. Such an effective dose generally depends on the above factors.
[0416] The compounds of the present invention can be applied to patients in a single dose or multiple doses. When multiple doses are applied, these doses can be spaced apart from each other for example by 1-24 hours, 1-7 days, 1-4 weeks or 1-12 months. The compound can be applied according to a schedule, or the compound can be applied without a predetermined schedule. The active compound can be applied, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 times a day, once every 2, 3, 4, 5 or 6 days, 1, 2, 3, 4, 5, 6 or 7 times a week, 1, 2, 3, 4, 5 or 6 times a month, or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 times a year. It should be understood that for any particular subject, a specific dosage regimen should be adjusted over time according to the subject's needs and the professional judgment of the person administering or supervising the administration of the composition.
[0417] Although the attending physician will ultimately determine the appropriate amount and dosage regimen, the effective amount of the compounds of the present invention may be, for example, the total daily dose of any compound described herein, for example, between 0.05 mg and 3000 mg. Alternatively, the dosage may be calculated using the patient's weight. The dosage range may include, for example, between 10-1000 mg (e.g., 50-800 mg). In some embodiments, 50 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 450 mg, 500 mg, 550 mg, 600 mg, 650 mg, 700 mg, 750 mg, 800 mg, 850 mg, 900 mg, 950 mg, or 1000 mg of the compound is administered.
[0418] In the method of the present invention, the time period of applying multiple dosage compounds of the present invention to the patient can vary. For example, in some embodiments, the dosage of the compounds of the present invention is applied to the patient in 1-7 days, 1-12 weeks or 1-3 months. In some embodiments, the compound is applied to the patient in a time period of, for example, 4-11 months or 1-30 years. In some embodiments, the compound is applied to the patient at the onset of symptoms. In any of these embodiments, the amount of the compound applied can change during the application period. When the compound is applied every day, application can be performed, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 times a day.
[0419] preparation
[0420] Compounds identified as being able to treat any of the conditions described herein can be administered to a patient or animal in a unit dosage form together with a pharmaceutically acceptable diluent, carrier or excipient using any of the methods described herein. Compounds for the therapy can be produced and isolated by any standard techniques known to those skilled in the art of pharmaceutical chemistry. Conventional pharmaceutical practice can be used to provide suitable formulations or compositions to administer the identified compounds to patients suffering from a disease or illness. Administration can begin before the patient develops symptoms.
[0421] Exemplary routes of administration of the compounds (e.g., compounds of the invention) or pharmaceutical compositions thereof used in the present invention include oral, sublingual, buccal, transdermal, intradermal, intramuscular, parenteral, intravenous, intraarterial, intracranial, subcutaneous, intraorbital, intraventricular, intraspinal, intraperitoneal, intranasal, inhalation, and topical administration. Ideally, the compounds are administered with a pharmaceutically acceptable carrier. Pharmaceutical formulations of the compounds described herein formulated for the treatment of the conditions described herein are also part of the present invention.
[0422] Preparations for oral administration
[0423] Pharmaceutical compositions contemplated by the present invention include those formulated for oral administration ("oral dosage forms"). Oral dosage forms may be in the form of, for example, tablets, capsules, liquid solutions or suspensions, powders, or liquid or solid crystals, which contain the active ingredient in a mixture with a non-toxic pharmaceutically acceptable excipient. Excipients can be, for example, inert diluents or fillers (e.g., sucrose, sorbitol, sugar, mannitol, microcrystalline cellulose, starch (including potato starch), calcium carbonate, sodium chloride, lactose, calcium phosphate, calcium sulfate or sodium phosphate); granulating and disintegrants (e.g., cellulose derivatives, including microcrystalline cellulose, starch (including potato starch), cross-linked sodium carboxymethyl cellulose, alginates or alginic acid); binders (e.g., sucrose, glucose, sorbitol, gum arabic, alginic acid, sodium alginate, gelatin, starch, pregelatinized starch, microcrystalline cellulose, magnesium aluminum silicate, sodium carboxymethyl cellulose, methylcellulose, hydroxypropyl methylcellulose, ethylcellulose, polyvinyl pyrrolidone or polyethylene glycol); and lubricants, glidants and anti-adherents (e.g., magnesium stearate, zinc stearate, stearic acid, silicon dioxide, hydrogenated vegetable oils or talc). Other pharmaceutically acceptable excipients may be colorants, flavoring agents, plasticizers, wetting agents, buffers and the like.
[0424] Formulations for oral administration may also be made into chewable tablets; hard gelatin capsules in which the active ingredient is mixed with an inert solid diluent (e.g., potato starch, lactose, microcrystalline cellulose, calcium carbonate, calcium phosphate or kaolin); or soft gelatin capsules in which the active ingredient is mixed with water or an oil medium (e.g., peanut oil, liquid paraffin or olive oil). Powders, granules and pills can be prepared using the ingredients mentioned above under tablets and capsules in a conventional manner using, for example, a mixer, a fluidized bed apparatus or a spray drying device.
[0425] Controlled release compositions for oral use can be configured to release active bulk drugs by controlling the dissolution and / or diffusion of active drug substances. Any of a variety of strategies can be used to obtain a curve of controlled release and target plasma concentration versus time. In one example, controlled release is obtained by suitably selecting various formulation parameters and ingredients, including, for example, various types of controlled release compositions and coatings. Examples include single or multiple unit tablets or capsule compositions, oil solutions, suspensions, emulsions, microcapsules, microspheres, nanoparticles, patches, and liposomes. In some embodiments, the composition includes a biodegradable, pH and / or temperature-sensitive polymer coating.
[0426] The tablet, capsule, pill or granule preparation of the compound can be coated with a suitable coating, or the compound can be incorporated into a suitable matrix to achieve dissolution or diffusion controlled release. The controlled release coating can include one or more coating materials mentioned above and / or such as shellac, beeswax, sugar wax, castor wax, carnauba wax, stearyl alcohol, glyceryl monostearate, glyceryl distearate, glyceryl palmitostearate, ethylcellulose, acrylic resin, dl-polylactic acid, cellulose acetate butyrate, polyvinyl chloride, polyvinyl acetate, vinyl pyrrolidone, polyethylene, polymethacrylate, methyl methacrylate, 2-hydroxymethylacrylate, methacrylate hydrogel, 1,3-butylene glycol, ethylene glycol methacrylate and / or polyethylene glycol. In a controlled release matrix preparation, the matrix material can also include such as hydrated methylcellulose, carnauba wax and stearyl alcohol, carbomer 934, silicone, tristearin, methyl acrylate-methyl methacrylate, polyvinyl chloride, polyethylene and / or halogenated fluorocarbons.
[0427] Liquid forms in which the compounds and compositions of the invention may be incorporated for oral administration include aqueous solutions, suitably flavored syrups, aqueous or oily suspensions and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles.
[0428] Preparations for parenteral administration
[0429] The compounds described herein for the methods of the present invention can be administered in the form of pharmaceutically acceptable parenteral (e.g., intravenous or intramuscular) preparations as described herein. Pharmaceutical preparations can also be administered parenterally (intravenously, intramuscularly, subcutaneously, etc.) in dosage forms or preparations containing conventional, non-toxic pharmaceutically acceptable carriers and adjuvants. Specifically, preparations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions, which may contain antioxidants, buffers, antibacterial agents, and solutes that make the preparations isotonic with the blood of the intended recipient; aqueous and non-aqueous sterile suspensions, which may contain suspending agents and thickening agents. For example, in order to prepare such a composition, the compounds of the present invention can be dissolved or suspended in a liquid vehicle that is acceptable to the parenteral. Acceptable vehicles and solvents that can be used are water; water adjusted to a suitable pH by adding an appropriate amount of hydrochloric acid, sodium hydroxide or a suitable buffer; 1,3-butanediol; Ringer's solution and isotonic sodium chloride solution. Aqueous formulations may also contain one or more preservatives, such as methylparaben, ethylparaben, or n-propylparaben.Additional information on parenteral formulations may be found, for example, in the United States Pharmacopeia-National Formulary (USP-NF), which is incorporated herein by reference.
[0430] The parenteral formulation may be any of the five general types of formulations identified by the USP-NF as suitable for parenteral administration:
[0431] (1) Pharmaceutical injections: liquid preparations of bulk drugs (e.g., the compounds of the present invention) or their solutions;
[0432] (2) Injectable drugs: APIs (e.g., compounds of the present invention) as dry solids, which will be combined with suitable sterile vehicles for parenteral administration as pharmaceutical injections;
[0433] (3) Pharmaceutical injection emulsions: liquid preparations of the API (e.g., the compounds of the present invention) dissolved or dispersed in a suitable emulsion medium;
[0434] (4) Pharmaceutical injection suspension: a liquid preparation of a drug substance (e.g., a compound of the present invention) suspended in a suitable liquid medium; and
[0435] (5) Injectable pharmaceutical suspensions: The drug substance (eg, the compound of the present invention) as a dry solid will be combined with a suitable sterile vehicle for parenteral administration as an injectable pharmaceutical suspension.
[0436] Preparations for parenteral administration include solutions of compounds appropriately mixed with surfactants such as hydroxypropylcellulose prepared in water. Dispersions can also be prepared in glycerol, liquid polyethylene glycol, DMSO and mixtures thereof containing or not containing alcohol and in oil. Under normal storage and use conditions, these preparations may contain preservatives to prevent microbial growth. Conventional procedures and ingredients for selecting and preparing suitable preparations are described in, for example, Remington: The Science and Practice of Pharmacy, 21st edition, Gennaro, Lippincott Williams & Wilkins (2005) and The United States Pharmacopeia: The National Formulary (USP 36NF31) (published in 2013).
[0437] Preparations for parenteral administration may, for example, include excipients, sterile water or saline, polyalkylene glycols such as polyethylene glycol, vegetable oils or hydrogenated naphthalene. Biocompatible, biodegradable lactide polymers, lactide / glycolide copolymers or polyoxyethylene-polyoxypropylene copolymers may be used to control the release of the compound. Other potentially useful compound parenteral delivery systems include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems and liposomes. Preparations for inhalation may include excipients such as lactose, or may be aqueous solutions comprising, for example, polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, or may be oily solutions for use in the form of nasal drops or as a gel.
[0438] Parenteral formulations can be formulated for rapid release of the compound or for sustained / extended release. Exemplary formulations for parenteral release of the compound include: aqueous solutions, powders for reconstitution, cosolvent solutions, oil / water emulsions, suspensions, oil-based solutions, liposomes, microspheres, and polymer gels.
[0439] combination
[0440] The compounds of the invention may be administered to a subject in combination with one or more of the following additional agents, for example:
[0441] (a) cytotoxic agents;
[0442] (b) antimetabolites;
[0443] (c) alkylating agents;
[0444] (d) anthracyclines;
[0445] (e) antibiotics;
[0446] (f) antimitotic agents;
[0447] (g) Hormone therapy;
[0448] (h) signal transduction inhibitors;
[0449] (i) gene expression regulators;
[0450] (j) apoptosis inducers;
[0451] (k) angiogenesis inhibitors;
[0452] (l) immunotherapeutic agents;
[0453] (m) DNA damage repair inhibitors;
[0454] or
[0455] Its combination.
[0456] The cytotoxic agent can be, for example, actinomycin-D, alemtuzumab, alitretinoin, allopurinol, hexamethylmelamine, amifostine, amphotericin, amsacrine, arsenic trioxide, asparaginase, azacitidine, azathioprine, Bacille Calmette-Guérin (BCG), bendamustine, bexarotene, bevacizumab, bleomycin, bortezomib, busulfan, capecitabine, carboplatin, carfilzomib, carmustine, cetuximab, cisplatin, chlorambucil, cladribine, clofarabine, colchicine, cristaspase , cyclophosphamide, cyclosporine, cytarabine, cytochalasin B, dacarbazine, dactinomycin, darbepoetin alfa, dasatinib, daunorubicin, 1-dehydrotestosterone, denileukin, dexamethasone, dexrazoxane, dihydroxyanthraquinone dione, disulfiram, docetaxel, doxorubicin, emedin, epirubicin, erlotinib, epigallocatechin gallate, epoetin alfa, estramustine, ethidium bromide, etoposide, everolimus, filgrastim, finasalate, floxuridine, fludarabine, 5-fluorouracil (5-FU), fulvestrant, ganciclovir, geldanamycin, gemcitabine, glycopenicillin steroids, gramicidin D, histrelin acetate, hydroxyurea, ibritumomab tiuxetan, idarubicin, ifosfamide, imatinib, irinotecan, interferon, interferon α-2a, interferon α-2b, ixabepilone, lactate dehydrogenase A (LDH-A), lenalidomide, letrozole, folinic acid, levamisole, lidocaine, lomustine, nitrogen mustard, melphalan, 6-mercaptopurine, mesna, methotrexate, methoxsalen, chlorpheniramine, metronidazole, mithramycin, mitomycin-C, mitoxantrone, nandrolone, nelarabine, nilotinib, nofetumomab, oprepa oprelvekin, oxaliplatin, paclitaxel, pemetrexed, pentostatin, palifermin, pamidronate, pegademase, pegaspargase, pegfilgrastim, pemetrexed disodium, plicamycin, porfimer sodium, procaine, procarbazine, propranolol, puromycin, quinacrine, radicicol, radioisotopes, raltitrexed, rapamycin, rasburicase, salinosporamide A A), sargramostim, sunitinib, temozolomide, teniposide, tetracaine, 6-thioguanine, thiotepa, topotecan, toremifene, trastuzumab, treosulfan, tretinoin, valrubicin, vinblastine, vincristine, vindesine, vinorelbine, zoledronate, or a combination thereof.
[0457] The antimetabolite can be, for example, methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarboxazid, cladribine, pemetrexed, gemcitabine, capecitabine, hydroxyurea, mercaptopurine, fludarabine, pralatrexate, clofarabine, cytarabine, decitabine, floxuridine, nelarabine, trimetrexate, thioguanine, pentostatin, or a combination thereof.
[0458] The alkylating agent can be, for example, nitrogen mustard, thiotepa, chlorambucil, melphalan, carmustine (BSNU), lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, cis-dichlorodiamine platinum (II) (DDP) cisplatin, altretamine, cyclophosphamide, ifosfamide, hexamethylmelamine, altretamine, procarbazine, dacarbazine, temozolomide, streptozocin, carboplatin, cisplatin, oxaliplatin, umustine, bendamustine, trabectedin, semustine, or a combination thereof.
[0459] The anthracycline can be, for example, daunorubicin, doxorubicin, aclarubicin, adriamycin, amrubicin, anamycin, carrubicin, epirubicin, idarubicin, mitoxantrone, valrubicin, or a combination thereof.
[0460] The antibiotic can be, for example, dactinomycin, bleomycin, mithramycin, anthramycin (AMC), ampicillin, baminecillin, carbenicillin, cloxacillin, dicloxacillin, flucloxacillin, mezlocillin, nafcillin, oxacillin, piperacillin, pivampicillin, pivmecillin, ticarcillin, aztreonam, imipenem, doripenem, ertapenem, meropenem, cephalosporin, clarithromycin, dirithromycin, roxithromycin, telithromycin, lincomycin, pristinamycin, quinupristin, amikacin, gentamicin, kanamycin, neomycin, netilmicin, paromomycin, tobramycin, streptomycin, sulfamethoxazole, sulfamethoxazole , sulfisoxazole, demeclocycline, minocycline, oxytetracycline, tetracycline, penicillin, amoxicillin, cephalexin, erythromycin, clarithromycin, azithromycin, ciprofloxacin, levofloxacin, ofloxacin, doxycycline, clindamycin, metronidazole, tigecycline, chloramphenicol, metronidazole, metronidazole, nitrofurantoin, vancomycin, teicoplanin, telavanxin, linezolid, cycloserine, rifamycin, polymyxin B, bacitracin, puromycin, capreomycin, quinolinone, daunorubicin, doxorubicin, 4'-deoxydoxorubicin, epirubicin, idarubicin, plicamycin, mitomycin-c, mitoxantrone, or a combination thereof.
[0461] The antimitotic agent can be, for example, vincristine, vinblastine, vinorelbine, docetaxel, estramustine, ixabepilone, paclitaxel, maytansinoid, dolastatin, scintillansin, or a combination thereof.
[0462] The signal transduction inhibitor can be, for example, imatinib, trastuzumab, erlotinib, sorafenib, sunitinib, temsirolimus, vemurafenib, lapatinib, bortezomib, cetuximab, panitumumab, matuzumab, gefitinib, STI 571, rapamycin, flavopiridol, imatinib mesylate, vatanib, semaxinib, motesanib, axitinib, afatinib, bosutinib, crizotinib, cabozantinib, dasatinib, entrectinib, pazopanib, lapatinib, vandetanib, or a combination thereof.
[0463] Gene expression regulators can be, for example, siRNA, shRNA, antisense oligonucleotides, HDAC inhibitors, or combinations thereof. HDAC inhibitors can be, for example, trichostatin A, trapoxin B, valproic acid, vorinostat, belinostat, LAQ824, panobinostat, entinostat, tacedinaline, mocetionstat, givinostat, resminostat, abexinostat, quisinostat, rocilinostat, practinostat, CHR-3996, butyric acid, phenylbutyric acid, 4SC202, romidepsin, sirtinol, cambinol, EX-527, nicotinamide, or combinations thereof. The antisense oligonucleotide may be, for example, custirsen, apatorsen, AZD9150, trabadersen, EZN-2968, LErafAON-ETU, or a combination thereof. The siRNA may be, for example, ALN-VSP, CALAA-01, Atu-027, SPC2996, or a combination thereof.
[0464] Hormone therapy can be, for example, a luteinizing hormone-releasing hormone (LHRH) antagonist. Hormone therapy can be, for example, firmagon, leuprolide, goserelin, buserelin, flutamide, bicalutamide, ketoconazole, aminoglutethimide, prednisone, hydroxyprogesterone caproate, medroxyprogesterone acetate, megestrol acetate, diethylstilbestrol, ethinyl estradiol, tamoxifen, testosterone propionate, flumethyltestosterone, flutamide, raloxifene, droloxifene, idoxifene, 4-hydroxytamoxifen, troxifene, ketoxifen (keoxifene), LY117018, onapristone, toremifene citrate, megestrol acetate, exemestane, fadrozole, vorozole, letrozole, anastrozole, nilutamide, tripterelin, histrelin, abiraterone, medroxyprogesterone acetate, diethylstilbestrol, premarin, flumethoxetine, tretinoin, fenretinide, troxacitabine or a combination thereof.
[0465] The apoptosis inducing agent may be, for example, recombinant human TNF-related apoptosis-inducing ligand (TRAIL), camptothecin, bortezomib, etoposide, tamoxifen, or a combination thereof.
[0466] The angiogenesis inhibitor can be, for example, sorafenib, sunitinib, pazopanib, everolimus, or a combination thereof.
[0467] Immunotherapeutic agents may be, for example, monoclonal antibodies, cancer vaccines (e.g., dendritic cell (DC) vaccines), oncolytic viruses, cytokines, adoptive T cell therapy, Bacillus Calmette-Guerin (BCG), GM-CSF, thalidomide, lenalidomide, pomalidomide, imiquimod, or a combination thereof. Monoclonal antibodies may be, for example, anti-CTLA4, anti-PD1, anti-PD-L1, anti-LAG3, anti-KIR, or a combination thereof. The monoclonal antibody can be, for example, alemtuzumab, trastuzumab, ibritumomab tiuxetan, brentuximab vedotin, trastuzumab, ado-trastuzumab emtansine, blinatumomab, bevacizumab, cetuximab, pertuzumab, panitumumab, ramucirumab, obinutuzumab, ofatumumab, rituximab, pertuzumab, tositumomab, gemtuzumab ozogamicin, tositumomab, or a combination thereof. The cancer vaccine can be, for example, Sipuleucel-T, BioVaxID, NeuVax, DCVax, SuVaxM, hsp110 chaperone complex vaccine, CDX-1401, MIS416, CDX-110, GVAX Pancreas, HyperAcute TM Pancreas, GTOP-99 or Imprime The oncolytic virus may be, for example, talimogene laherparepvec. The cytokine may be, for example, IL-2, IFNα, or a combination thereof. The adoptive T cell therapy may be, for example, tisagenlecleucel, axicabtagene ciloleucel, or a combination thereof.
[0468] DNA damage repair inhibitors may be, for example, PARP inhibitors, cell checkpoint kinase inhibitors, or combinations thereof. PARP inhibitors may be, for example, olaparib, rucaparib, veliparib (ABT-888), niraparib (ZL-2306), iniparib (BSI-201), talazoparib (BMN 673), 2X-121, CEP-9722, KU-0059436 (AZD2281), PF-01367338, or combinations thereof. Cell checkpoint kinase inhibitors may be, for example, MK-1775 or AZD1775, AZD7762, LY2606368, PF-0477736, AZD0156, GDC-0575, ARRY-575, CCT245737, PNT-737, or combinations thereof.
[0469] Example
[0470] The following examples are intended to illustrate the present invention. They are not intended to limit the present invention in any way.
[0471] If not otherwise described in the examples below, reactions were typically carried out at room temperature (rt or RT) under nitrogen atmosphere using anhydrous solvents (Sure / Seal TM ) by TLC or by using UPLC HSS C18 2.1x30 mm column eluted with a gradient (1.86 min) of acetonitrile (15% to 98%) in water (both containing 0.1% formic acid) on a Waters Acquity-H Reactions were monitored by injecting small aliquots on a Class system. Unless otherwise stated, all products were analyzed by preparative HPLC on a Teledyne Isco Combi Using Phenomenex on the EZ Prep System 5μmNX-C18 150 x 21.2 mm column (at 40 mL / min in 12 minutes (<100 mg or multiple injections <100 mg)) or HP C18 Rf gold column (>100 mg) was purified by eluting with an appropriate gradient of acetonitrile in water (both containing 0.1% formic acid). The gradient was based on the The fractions containing the desired compound were pooled and finally lyophilized. Use the appropriate size on the Rf system Rf silica gel column was used for silica gel chromatography purification. UPLC BEH C18 2.1x50 mm column eluted with a gradient (7 min) of acetonitrile (2% to 98%) in water (all containing 0.1% formic acid) on a Waters Acquity-H The purity of the final compound was assessed by injecting a small aliquot on the Class system.
[0472] Example 1. Preparation of compounds
[0473] Intermediates
[0474] The intermediates exemplified in Table 2 were used to prepare the compounds described herein.
[0475] Table 2
[0476]
[0477]
[0478] Intermediate 1 / 5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-amine
[0479]
[0480] Step 1 / 5-Methyl-3-nitro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole
[0481] To 5-methyl-3-nitro-1H-pyrazole (50.0 g, 393 mmol) in toluene (1.0 L) was added TFA (6.0 mL, 78.7 mmol) and 3,4-dihydro-2H-pyran 3,4-dihydro-2H-pyran (39.5 mL, 433 mmol) in one portion. The reaction mixture was heated to 90 ° C. The reaction mixture was cooled to rt and then poured onto 10% KHCO3 (1.0 L). The phases were separated and the aqueous phase was back extracted twice with EtOAc (2x 200 mL). The combined organic phases were washed with brine (200 mL). Activated carbon (7.5 g, 15% w) was added and the suspension was stirred for 15 minutes, then anhydrous Na2SO4 (50 g) was added and the suspension was stirred for 30 minutes. The resulting suspension was filtered through The combined organic phases were concentrated in vacuo to provide 5-methyl-3-nitro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole (88.04 g, 89% pure, 95% corrected yield). 1H NMR (400MHz, CDCL3) δppm1.46-1.72(m,3H),1.79-1.89(m,1H),1.98-2.08(m,1H),2.21(s,3H),2. 28-2.45(m,1H),3.40-3.72(m,3H),3.96-4.08(m,1H),5.03(dd,J=10.3,2.4Hz,1H),5.42(s,1H).
[0482] Step 2 / Intermediate 1
[0483] 5-Methyl-3-nitro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole (78.7 g, 373 mmol) was suspended in methanol (1.25 L) and the suspension was then loaded into a 2 gallon Parr pressure reactor. 10% palladium on carbon (wet carrier) (7.9 g, 10% w) was added and the reactor was then purged three times with 30 PSI nitrogen and three times with 20 PSI hydrogen. The hydrogen pressure was set to 35 PSI and the reaction was stirred at rt for 90 minutes. The reactor and filter were rinsed with methanol (2 x 500 mL) and the solvent was then concentrated to dryness to give 71.9 g of the crude desired compound as a brown oil. The crude product was reabsorbed on silica gel (80 g) and then purified by silica gel chromatography, eluting with a gradient of MeOH (0-4%) in DCM. Pure fractions were pooled and concentrated to dryness to afford Intermediate 1 as an amber oil (57.7 g, 97% pure by HPLC at 215 nm, 86% corrected yield). 1 H NMR (400MHz, CDCl3) δppm 1.46-1.72(m,3H),1.79-1.89(m,1H),1.98-2.08(m,1H),2.21(s,3H),2.28-2.45(m, 1H), 3.40-3.72 (m, 3H), 3.96-4.08 (m, 1H), 5.03 (dd, J = 10.3, 2.4Hz, 1H), 5.42 (s, 1H).
[0484] Intermediate 2 / N,1-bis(4-methoxybenzyl)-5-methyl-1H-pyrazol-3-amine
[0485]
[0486] Step 1 / 1-(4-methoxybenzyl)-5-methyl-3-nitro-1H-pyrazole
[0487] A mixture of 5-methyl-3-nitro-1H-pyrazole (19.2 g, 151 mmol), 1-(chloromethyl)-4-methoxy-benzene (21.6 mL, 159 mmol), K2CO3 (41.8 g, 302 mmol) in MeCN (200 mL) was heated at 80 ° C for 3 hours. The reaction mixture was filtered and the filtrate was concentrated in vacuo. The resulting yellow solid was dissolved in DCM and purified by silica gel chromatography, eluting with EtOAc (0-40%) in hexanes. The relevant fractions were combined and evaporated to give 1-[(4-methoxyphenyl)methyl]-5-methyl-3-nitro-pyrazole (23.0 g, 62% yield).
[0488] Step 2 / 1-(4-methoxybenzyl)-5-methyl-1H-pyrazol-3-amine
[0489] To 1-(4-methoxybenzyl)-5-methyl-3-nitro-1H-pyrazole (21.5 g, 87.1 mmol) in MeOH (550 mL) was added zinc (56.9 g, 871 mmol) and NH4HCO2 (54.9 g, 871 mmol) at 0° C. The reaction mixture was stirred for 30 minutes, filtered through celite, and evaporated in vacuo to provide 1-(4-methoxybenzyl)-5-methyl-1H-pyrazol-3-amine (15.57 g, 82% yield), which was used in the next step without further purification.
[0490] Step 3 / Intermediate 2
[0491] A mixture of 1-(4-methoxybenzyl)-5-methyl-1H-pyrazole-3-amine (11.67 g, 53.71 mmol) and 4-methoxybenzaldehyde (6.53 mL, 53.7 mmol) in DCM (200 mL) was stirred at rt for 30 minutes. NaBH(OAc)3 (12.52 g, 59.08 mmol) was added and the reaction mixture was stirred at rt for 2 hours. The reaction mixture was quenched with saturated aqueous NaHCO3 and extracted with DCM. The organic layer was evaporated in vacuo and purified by silica gel chromatography, eluting with EtOAc. The relevant fractions were combined to give Intermediate 2 (12.57 g, 69% yield) as a white solid. UPLC-MS (+ESI) m / z=338.3 (M+H) +
[0492] Intermediate 3 / 4,6-dichloro-5-methoxy-2-(methylthio)pyrimidine
[0493]
[0494] Intermediate 3 was prepared according to the procedure described in WO2016 / 166604A1
[0495] Intermediate 4 / 4,6-dichloro-5-cyclopropyl-2-(methylthio)pyrimidine
[0496]
[0497] Step 1 / 5-Cyclopropyl-2-(methylthio)pyrimidine-4,6(1H,5H)-dione
[0498] A mixture of 1,3-diethyl 2-cyclopropylmalonate (111 g, 80% pure, 435 mmol), thiourea (40.0 g, 526 mmol) in MeOH (420 mL) was stirred for 10 minutes, then a solution of NaOMe in MeOH (25% w / w, 108 g, 500 mmol) was added. The final mixture was heated to 50 °C and maintained for 16 hours. The mixture was cooled to rt and MeI (74.0 g, 522 mmol) was added. The final mixture was stirred at rt for 22 hours, then quenched with water (500 mL) and acidified to pH about 1 by adding concentrated HCl solution (10 mL). The mixture was concentrated under reduced pressure to remove most of the methanol. The suspension was cooled to 20 °C and filtered with filter paper on a Buchner funnel. The filter cake was rinsed with water (2 x 100 mL). The solid was dried under vacuum for 3 hours to provide 5-cyclopropyl-2-(methylthio)pyrimidine-4,6(1H,5H)-dione as a white powder (80.0 g, 80% yield, 86% pure by w / w quantitative NMR), which was used in the next step without further purification. UPLC-MS (+ESI) m / z = 199.1 (M+H) +
[0499] Step 2 / Intermediate 4
[0500] POCl3 (60 mL, 644 mmol) was added to 5-cyclopropyl-2-(methylthio)pyrimidine-4,6(1H,5H)-dione (76.5 g, 332 mmol) in MeCN (300 mL) and N,N-dimethylformamide (38 mL), diluted with MeCN (100 mL), and added gradually over 35 minutes. The final mixture was heated to 70 ° C and maintained for 3 hours, and then heated at 20 ° C for 16 hours. The resulting reaction mixture was cooled in a water bath and then quenched by adding water (750 mL) within 20 minutes. The resulting solid was filtered with filter paper on a Buchner funnel and rinsed with water (2 x 200 mL). After suction to remove most of the water, the filter cake was dried under vacuum at 50 ° C for 45 hours to provide intermediate 4 (77.0 g, 89% yield, 89.0% purity by HPLC at 215 nm) as a yellow solid. UPLC-MS (+ESI) m / z = 235.0 (M+H) +
[0501] Intermediate 5 / 6-Chloro-5-methoxy-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-2-(methylsulfonyl)pyrimidin-4-amine
[0502]
[0503] Step 1 / 6-Chloro-5-methoxy-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-2-(methylthio)pyrimidin-4-amine
[0504] At rt and N2 atmosphere, NaHMDS (159.9mL, 159.9mmol) solution was added to a solution of intermediate 1 (9.66g, 53.3mmol) in THF (320mL) within 30 minutes. Intermediate 3 (12.00g, 53.31mmol) was then added and the reaction mixture was stirred at 80°C for 3 hours, when UPLC-MS showed that the original material was completely consumed. The mixture was cooled to rt and then poured into 500mL saturated NaHCO3 aqueous solution. The resulting mixture was extracted with EtOAc (3x). The combined organic matter was washed with brine, dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel chromatography eluting with EtOAc in Hep (0-80%) to provide 6-chloro-5-methoxy-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-2-(methylthio)pyrimidin-4-amine (10.0 g, 51% yield) as a light yellow solid. UPLC-MS (+ESI) m / z = 370.0 (M+H) + . 1 H NMR(400MHz,DMSO-d6)δppm 1.44-1.56(m,2H),1.58-1.74(m,1H),1.83(dd,J=13.0,2.2Hz,1H),1.98(d,J=13.0Hz,1H),2.21-2.28(m,1H),2.30(s,3H), 2.45(s,3H),3.58-3.68(m,1H),3.74(s,3H),3.90(d,J=11.5Hz,1H),5.32(dd,J=9.8,2.2Hz,1H),6.46(s,1H),9.78(s,1H).
[0505] Step 2 / Intermediate 5
[0506] Hydrogen peroxide 35% (w / w) in water (12.0 mL, 124 mmol) was added to a mixture of 6-chloro-5-methoxy-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-2-(methylthio)pyrimidin-4-amine (6.54 g, 17.7 mmol), tetrabutylammonium hydrogen sulfate (960.0 mg, 2.83 mmol) and sodium tungstate dihydrate (583 mg, 1.77 mmol) in EtOAc (106 mL) and THF (106 mL). The mixture was heated at 50°C for 2 hours. The reaction mixture was then cooled to 0°C, diluted with EtOAc and washed with 10% NaHSO3 (260 mL). The layers were separated and the aqueous layer was back extracted with EtOAc (2x). The combined organic layers were washed with brine, dried over MgSO 4 , filtered and concentrated to give crude intermediate 5 as a light orange solid (7.10 g, 88% purity by HPLC at 254 nm). UPLC-MS (+ESI) m / z=402.0 (M+H) +1 H NMR(400MHz,DMSO-d6)δppm 1.45-1.57(m,2H),1.59-1.75(m,1H),1.85(dd,J=13.0,2.4Hz,1H),1.94-2.03(m,1H),2.21-2.30(m,1H),2.32(s,3H),3.31-3.32(m, 3H), 3.64(td,J=11.0,3.4Hz,1H),3.87(s,3H),3.90(dd,J=11.2,1.7Hz,1H),5.35(dd,J=10.0,2.4Hz,1H),6.55(s,1H),10.50(s,1H).
[0507] Intermediate 6 / 6-Chloro-5-methoxy-N-(4-methoxybenzyl)-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-2-(methylsulfonyl)pyrimidin-4-amine
[0508]
[0509] Under nitrogen atmosphere, 4-methoxybenzyl chloride (5.18 mL, 35.1 mmol) was added to a mixture of intermediate 5 (7.05 g, 17.6 mmol) and K2CO3 (7.28 g, 52.6 mmol) in MeCN (35 mL). The mixture was stirred at 80 °C for 18 hours, then cooled to rt and diluted with water. The mixture was extracted with EtOAc (3x), and the combined organic layers were dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel column chromatography eluting with Hep / EtOAc (0-100%) to provide intermediate 6 (5.90 g, 65%) as a white solid. UPLC-MS (+ESI) m / z=522.0 (M+H) +1 H NMR(400MHz,DMSO-d6)δppm 1.46-1.56(m,2H),1.57-1.70(m,1H),1.80(dd,J=13.3,2.8Hz,1H),1.90- 2.00(m,1H),2.08-2.21(m,1H),2.28(s,3H),3.28(s,3H),3.32(s,3H),3. 56-3.65(m,1H),3.70(s,3H),3.78-3.87(m,1H),5.03(s,2H),5.38(dd,J= 9.0, 2.2Hz, 1H), 6.01 (s, 1H), 6.83 (d, J = 8.6Hz, 2H), 7.31 (d, J = 8.6Hz, 2H).
[0510] Intermediate 7 / 6-Chloro-5-cyclopropyl-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-2-(methylsulfonyl)pyrimidin-4-amine
[0511]
[0512] Step 1 / 6-Chloro-5-cyclopropyl-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-2-(methylthio)pyrimidin-4-amine
[0513] To a solution of intermediate 1 (10.9 g, 46.4 mmol) dissolved in THF (270 mL) was added NaHMDS (104 mL, 104 mmol, 1 M in THF) followed by intermediate 4 (8, 40 g, 46.4 mmol, corrected purity: 89%). The resulting solution was heated to reflux for 30 minutes, cooled to rt and concentrated to dryness. The residue was dissolved in EtOAc (500 mL) and washed with water (250 mL). The aqueous phase was back extracted twice with EtOAc (2 x 100 mL) and the collected organic phases were then washed with water (100 mL), brine (100 mL), dried over Na2SO4 and filtered. At this stage, the crude material from a previous test on 1.12 g of intermediate 4 was added to the batch. The combined organic phases were partially evaporated to 80 mL and Hep (190 mL) was added to crystallize the product. The solids were collected by filtration and the filter cake was washed with heptane (100 mL). The solids were dried at 45-50° C. under vacuum until constant weight was observed to provide 6-chloro-5-cyclopropyl-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-2-(methylthio)pyrimidin-4-amine (14.06 g, 73% corrected yield) as an off-white solid. 1 H NMR (400MHz, CDCL3) δppm 0.73 (d, J=4.2Hz, 2H), 1.18 (dd, J=7.9, 1.6Hz, 2H), 1.42-1.81 (m, 5H), 1.89 (br d,J=12.2Hz,1H),2.04-2.18(m,1H),2.36(s,4H),2.55(s,3H),3.57-3.75(m,1H),4.11(br d, J=11.5Hz, 1H), 5.19 (dd, J=10.4, 2.3Hz, 1H), 6.67 (s, 1H), 7.84 (s, 1H).
[0514] Step 2 / Intermediate 7
[0515] 6-Chloro-5-cyclopropyl-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-2-(methylthio)pyrimidin-4-amine (450 mg, 1.2 mmol) was dissolved in MeOH (10 mL) and water (5 mL). Oxone (398 mg, 2.4 mmol) was added at rt. The resulting mixture was stirred for 16 hours. The resulting mixture was poured into water and then extracted with EtOAc (3x). The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by Prep-TLC (DCM / MeOH=15:1) to provide intermediate 7 (165 mg, yield 34%) as a white solid. UPLC-MS (+ESI) m / z=412.0 (M+H) +
[0516] Intermediate 8 / 6-chloro-5-cyclopropyl-N-(4-methoxybenzyl)-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-2-(methylsulfonyl)pyrimidin-4-amine
[0517]
[0518] Step 1 / 6-Chloro-5-cyclopropyl-N-(4-methoxybenzyl)-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-2-(methylthio)pyrimidin-4-amine
[0519] 6-Chloro-5-cyclopropyl-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-2-(methylthio)pyrimidine (see Intermediate 7, Step 1) (14.0 g, 36.9 mmol) and K2CO3 (10.2 g, 73.7 mmol) were suspended in N,N-dimethylacetamide (140 mL) and 4-methoxybenzyl chloride (6.93 g, 44.2 mmol) was added in one portion. The suspension was heated to 90° C. and maintained for 9 hours. The reaction mixture was cooled to rt and poured onto a mixture of EtOAc (100 mL) and water (700 mL). The phases were separated and the aqueous phase was back-extracted twice with EtOAc (2×100 mL). The pooled organic phases were washed successively with water (2×100 mL) and brine (100 mL), dried over Na2SO4, filtered, and concentrated to dryness. The crude product is suspended in diisopropyl ether (100mL) and is heated to reflux and keeps 30 minutes. The gained slurries are slowly cooled to rt, then heptane (150mL) is added. Solid is collected by filtration, washed with a mixture of 15% diisopropyl ether in heptane (50mL). Solid is dried under vacuum at 45 ℃-50 ℃, until constant weight is observed, to provide 6-chloro-5-cyclopropyl-N-(4-methoxybenzyl)-N-(5-methyl-1-(tetrahydro-2H-pyrans-2-yl)-1H-pyrazole-3-yl)-2-(methylthio)pyrimidine-4-amine (14.72g, yield 80%). 1 H NMR(400MHz,CDCl3)δppm 0.34(br d,J=5.4Hz,2H),0.53(td,J=8.4,4.9Hz,1H),0.58-0.68(m,1H),1.02-1.12(m,1H),1.51-1.77(m,5H),1.7 9-1.91(m,1H),2.04-2.17(m,1H),2.24-2.39(m,4H),2.44(s,3H),3.57-3.68(m,1H),3.78(s,3H),4.00(br d,J=11.5Hz,1H),5.05-5.14(m,1H),5.18(dd,J=9.5,2.4Hz,1H),5.21-5.29(m,1H),5.70(s,1H),6.81(d,J=8.8Hz,2H),7.34(d,J=8.6Hz,2H).
[0520] Step 2 / Intermediate 8
[0521] To a solution of 6-chloro-5-cyclopropyl-N-(4-methoxybenzyl)-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-2-(methylthio)pyrimidin-4-amine (11.71 g, 23.42 mmol) in EtOAc (210 mL) and THF (210 mL) were added tetrabutylammonium hydrogen sulfate (1.27 g, 3.75 mmol), sodium tungstate dihydrate (772 mg, 3.35 mmol) and 35% hydrogen peroxide in water (15.9 g, 164 mmol) in sequence. The resulting solution was heated to 50° C. for 4.5 hours. The resulting reaction mixture was cooled to 5° C.-10° C. and poured onto 10% NaHSO 3 (0.8 L). The phases were separated and the aqueous phase was back extracted twice with ethyl acetate (2×100 mL). The organic phase collected is washed with water (100mL), brine (100mL) successively, through Na2SO4 drying, filtered, and concentrated to almost dryness.Add heptane (100mL) and be concentrated to dryness, to obtain 12.5g crude product of light yellow solid.Solid is suspended in diisopropyl ether (70mL) and is heated to reflux and keeps for 45 minutes.Stop heating and stir slurries at rt for 0.5 hour.Add heptane (70mL), then collect solid by filtration.Filter cake is washed with heptane (35mL), finally dried under vacuum at 45 ℃-50 ℃, to provide intermediate 8 (11.85g, yield 94%) of off-white solid. 1 H NMR (400MHz, CDCl3) δppm 0.31-0.43(m,2H),0.62(td,J=8.5,4.5Hz,1H),0.65-0.75(m,1H),1.14(tt,J=8.4,5.8Hz,1H),1.53-1.77(m,3H),1.85(br dd,J=13.1,2.6Hz,1H),2.03-2.16(m,1H),2.32(s,4H),3.20(s,3H),3.59-3.69(m,1H),3.77(s,3H),4.02(br d,J=11.2Hz,1H),5.05-5.13(m,1H),5.16-5.27(m,2H),5.79(s,1H),6.81(d,J=8.8Hz,2H),7.39(d,J=8.8Hz,2H).
[0522] Intermediate 9 / 6-Chloro-5-cyclopropyl-N-(4-methoxybenzyl)-N-(1-(4-methoxybenzyl)-5-methyl-1H-pyrazol-3-yl)-2-(methylsulfonyl)pyrimidin-4-amine
[0523]
[0524] Step 1 / 6-chloro-5-cyclopropyl-N-(4-methoxybenzyl)-N-(1-(4-methoxybenzyl)-5-methyl-1H-pyrazol-3-yl)-2-(methylthio)pyrimidin-4-amine
[0525] NaHMDS (1 M, 6.41 mL, 6.41 mmol) was added to a solution of intermediate 2 (2.16 g, 6.41 mmol) in THF (10 mL) and stirred at rt for 10 minutes. Intermediate 4 (1.37 g, 5.83 mmol) was then added and the resulting mixture was stirred at 80 °C for 30 minutes. The reaction mixture was concentrated in vacuo and the residue was purified by silica gel chromatography eluting with EtOAc (70%) in Hep. The relevant fractions were combined to provide 6-chloro-5-cyclopropyl-N-(4-methoxybenzyl)-N-(1-(4-methoxybenzyl)-5-methyl-1H-pyrazol-3-yl)-2-(methylthio)pyrimidin-4-amine (1.47 g, 47% yield). UPLC-MS (+ESI) m / z=536.2 (M+H) +
[0526] Step 2 / Intermediate 9
[0527] To 6-chloro-5-cyclopropyl-N-(4-methoxybenzyl)-N-(1-(4-methoxybenzyl)-5-methyl-1H-pyrazol-3-yl)-2-(methylthio)pyrimidin-4-amine (1.47 g, 2.74 mmol) in DCM (10 mL) at 0°C was added mCPBA (946 mg, 5.48 mmol). The reaction was warmed to rt for 1 hour. An additional 950 mg of mCPBA was added to complete the reaction. The reaction mixture was concentrated in vacuo and the residue was purified by silica gel chromatography eluting with EtOAc in Hep (70%-100%). The relevant fractions were combined to give intermediate 9 (1.13 g, 73% yield). UPLC-MS (+ESI) m / z=568.2 (M+H) +
[0528] Intermediate 10 / 6-Chloro-5-methoxy-N-(4-methoxybenzyl)-N-(1-(4-methoxybenzyl)-5-methyl-1H-pyrazol-3-yl)-2-(methylsulfonyl)pyrimidin-4-amine
[0529]
[0530] Step 1 / 6-Chloro-5-methoxy-N-(4-methoxybenzyl)-N-(1-(4-methoxybenzyl)-5-methyl-1H-pyrazol-3-yl)-2-(methylthio)pyrimidin-4-amine
[0531] NaHMDS (9.18 mL, 9.18 mmol, 1 M) was added to a solution of intermediate 2 (3.1 g, 9.19 mmol) in THF (20 mL) and stirred at rt for 10 minutes. The resulting mixture was added dropwise to intermediate 3 (2.07 g, 9.18 mmol) in THF (20 mL) at rt via a syringe. The reaction mixture was evaporated in vacuo and purified by silica gel chromatography eluting with EtOAc (70%) in hexane. The relevant fractions were combined to give 6-chloro-5-methoxy-N-(4-methoxybenzyl)-N-(1-(4-methoxybenzyl)-5-methyl-1H-pyrazol-3-yl)-2-(methylthio)pyrimidin-4-amine (1.82 g, 38% yield). UPLC-MS (+ESI) m / z=526.2 (M+H) +
[0532] Step 2 / Intermediate 10
[0533] To 6-chloro-5-methoxy-N-(4-methoxybenzyl)-N-(1-(4-methoxybenzyl)-5-methyl-1H-pyrazol-3-yl)-2-(methylthio)pyrimidin-4-amine (1.82 g, 3.46 mmol) in DCM (10 mL) at 0°C was added mCPBA (1.19 g, 6.92 mmol). The reaction was warmed to rt, stirred for 4 hours and placed in the refrigerator overnight. The reaction mixture was concentrated in vacuo and the residue was purified by silica gel chromatography eluting with EtOAc in Hex (50%-100%). The relevant fractions were combined and concentrated to give intermediate 10 (1.14 g, 59% yield). UPLC-MS (+ESI) m / z=558.2 (M+H) + .
[0534] Intermediate 11 / 2,4,6-trichloro-5-cyclopropylpyrimidine
[0535]
[0536] Step 1 / 5-Cyclopropylpyrimidine-2,4,6(1H,3H,5H)-trione
[0537] A solution of diethyl 2-cyclopropylmalonate (15.6g, 77.9mmol) and urea (4.68g, 77.9mmol) in MeOH (390mL) was kept at 23°C for 20 minutes. Then sodium methoxide (25% in MeOH, 17.8mL, 77.9mmol) was added to the reaction mixture. After completion of the addition, the reaction mixture was heated under reflux for 24 hours. The resulting mixture was stirred overnight at rt and concentrated to dryness. The reaction mixture was cooled to 0°C and water (25mL) was slowly added. The precipitate was collected by filtration and washed with water (4mL). The white solid was then dried under high vacuum. The filtrate still containing the desired product was concentrated to 5mL and extracted with Me-THF (3x20mL). The organic layers were combined and washed with brine, dried over Na2SO4, filtered, concentrated to dryness in vacuo, and combined with the precipitate collected by filtration to provide 5-cyclopropylpyrimidine-2,4,6(1H,3H,5H)-trione (7.40 g, 56% yield). UPLC-MS (+ESI): m / z=169.1 [M+H] + .
[0538] Step 2 / Intermediate 11
[0539] A mixture of 5-cyclopropylpyrimidine-2,4,6(1H,3H,5H)-trione (7.40 g, 44.0 mmol) and N,N-dimethylaniline (16.9 mL, 132 mmol) in POCl3 (82.0 mL, 880 mmol) was heated at reflux for 3 hours and then cooled to rt. The reaction mixture was slowly poured onto ice in a conical flask under vigorous stirring. After the addition was completed, the mixture was extracted with DCM (3x75 mL) and the combined organic layers were washed with brine, dried over Na2S04, and concentrated to dryness in vacuo. The residue was purified by silica gel chromatography, eluting with EtOAc (0-10%) in hexane. The desired fractions were combined and concentrated to dryness in vacuo to provide intermediate 11 (6.0 g, yield 61%). UPLC-MS (+ESI): m / z=223.9[M+H] + .
[0540] Intermediate 12 / 2,6-dichloro-5-cyclopropyl-N-(4-methoxybenzyl)-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)pyrimidin-4-amine
[0541]
[0542] Step 1 / 2, 6-dichloro-5-cyclopropyl-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)pyrimidin-4-amine
[0543] To a solution of intermediate 11 (6.00 g, 26.8 mmol) and intermediate 1 (5.35, 29.5 mmol) in anhydrous THF (67 mL) was added NaHMDS solution (1 M in THF, 26.8 mL, 26.8 mmol) at -78 °C under an inert atmosphere. The resulting reaction mixture was stirred at this temperature for 30 minutes, then poured into water (100 mL) at 0 °C and diluted with DCM (100 mL). The layers were distributed. Brine was added to the aqueous layer and back-extracted with DCM (2x100 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The crude material was purified by silica gel chromatography, eluted with EtOAc (0-30%) in hexane. The desired fractions were combined and concentrated to dryness in vacuo to provide 2,6-dichloro-5-cyclopropyl-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)pyrimidin-4-amine (4.10 g, yield 41%). UPLC-MS (+ESI): m / z=368.1 [M+H] + .
[0544] Step 2 / Intermediate 12
[0545] To a solution of 2,6-dichloro-5-cyclopropyl-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)pyrimidin-4-amine (1.70 g, 4.62 mmol) in DMA (10 mL) was added K2CO3 (1.91 g, 13.9 mmol). The mixture was purged with nitrogen for 5 min at rt. 1-(Chloromethyl)-4-methoxy-benzene (1.45 g, 9.23 mmol, 1.25 mL) was added and the mixture was heated to 85 °C for 18 h. The resulting mixture was filtered and purified by preparative HPLC eluting with a gradient of MeCN (10%-100%) in water (both containing 0.1% formic acid). The appropriate fractions were combined and lyophilized to provide intermediate 12 (1.69 g, 75% yield). UPLC-MS (+ESI) m / z = 488.1 (M+H) + .
[0546] Intermediate 13 / 6-Chloro-5-cyclopropyl-N-(5-cyclopropyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-N-(4-methoxybenzyl)-2-(methylsulfonyl)pyrimidin-4-amine
[0547]
[0548] Step 1 / 6-Chloro-5-cyclopropyl-N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(methylthio)pyrimidin-4-amine
[0549] 5-cyclopropyl-1H-pyrazole-3-amine (517mg, 4.20mmol) and NaI (630mg, 4.20mmol) were added to a solution of intermediate 4 (705mg, 3.00mmol) in DMF (5mL). The mixture was stirred at 60°C for 72 hours. The reaction was quenched by adding water and extracted with EtOAc (3x15 mL). The combined organic extracts were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified on a silica gel column and eluted with EtOAc (50%-100%) in heptane. Suitable fractions were combined and concentrated in vacuo to provide 6-chloro-5-cyclopropyl-N-(5-cyclopropyl-1H-pyrazole-3-yl)-2-(methylthio)pyrimidine-4-amine (586mg, 61% yield) as a white solid.
[0550] Step 2 / 6-Chloro-5-cyclopropyl-N-(5-cyclopropyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-2-(methylthio)pyrimidin-4-amine
[0551] A mixture of 6-chloro-5-cyclopropyl-N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(methylthio)pyrimidin-4-amine (530 mg, 1.65 mmol), 4-methylbenzenesulfonic acid hydrate (60.0 mg, 315 μmol), 3,4-dihydro-2H-pyran (600 μL, 6.61 mmol) in EtOAc (12 mL) was refluxed for 18 hours. The reaction mixture was diluted with EtOAc (50 mL), washed with saturated aqueous NaHCO3 solution (2 mL) and brine (15 mL), dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography, eluting with a gradient of EtOAc (10%-70%) in heptane. The appropriate fractions were combined and concentrated to provide 6-chloro-5-cyclopropyl-N-(5-cyclopropyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-2-(methylthio)pyrimidin-4-amine (668 mg, 100% yield) as an off-white solid. UPLC-MS (+ESI): m / z = 406.5 [M+H] + .
[0552] Step 3 / 6-Chloro-5-cyclopropyl-N-(5-cyclopropyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-N-(4-methoxybenzyl)-2-(methylthio)pyrimidin-4-amine
[0553] To a solution of 6-chloro-5-cyclopropyl-N-(5-cyclopropyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-2-(methylthio)pyrimidin-4-amine (685 mg, 1.69 mmol) in DMF (8 mL) at 0°C was added NaH (60% dispersion) (84.0 mg, 2.19 mmol, 60% purity). The mixture was stirred at 0°C for 10 minutes, then (chloromethyl)-4-methoxy-benzene (300 μL, 2.21 mmol) and NEt4I (31 mg, 84 μmol) were added. The final mixture was stirred at rt for 18 hours. The mixture was diluted with EtOAc (100 mL), washed with water (20 mL) and brine (20 mL), dried over Na2SO4, filtered and concentrated to dryness. The residue was purified on a silica gel column eluting with a gradient of EtOAc (0-60%) in heptane. The appropriate fractions were combined and concentrated to give 6-chloro-5-cyclopropyl-N-(5-cyclopropyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-N-(4-methoxybenzyl)-2-(methylthio)pyrimidin-4-amine (650 mg, 73% yield) as a semi-solid. UPLC-MS (+ESI): m / z=526.6 [M+H] + .
[0554] Step 4 / Intermediate 13
[0555] 6-Chloro-5-cyclopropyl-N-(5-cyclopropyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-N-(4-methoxybenzyl)-2-(methylthio)pyrimidin-4-amine (650 mg, 1.24 mmol) was charged into a flask and dissolved in THF (10 mL) and EtOAc (10 mL). Tetrabutylammonium hydrogen sulfate (67.0 mg, 197 μmol), sodium tungstate dihydrate (41.0 mg, 124 μmol) and H2O2 (35% in water, 760 μL, 8.60 mmol) were added in sequence and the resulting solution was heated to 50°C for 5 hours. The reaction mixture was cooled to 5°C-10°C and poured onto 10% NaHSO3 aqueous solution (10 mL). The organic phase was separated and the aqueous phase was then back-extracted twice with ethyl acetate (20 mL). The pooled organic layers were washed with brine (20 mL), dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified on a silica gel column eluting with a gradient of EtOAc (20-80%) in heptane. The appropriate fractions were combined and concentrated in vacuo to provide intermediate 13 as a white solid (432 mg, 63% yield). UPLC-MS (+ESI): m / z=558.6 [M+H] + .
[0556] Compound
[0557] Compound 1 / Method A / N 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-5-methoxy-N 4 -(5-methyl-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrimidine-2,4-diamine
[0558]
[0559] Step 1 / 5-methoxy-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)-2-(methylsulfonyl)pyrimidin-4-amine
[0560] XPhosPdG2 (189 mg, 0.24 mmol), K3PO4 (51 mg, 0.24 mmol) and water (3 mL) were added to a solution of intermediate 5 (1.00 g, 2.40 mmol) and 1-methylpyrazol-4-ylboronic acid (454 mg, 3.6 mmol) in 1,4-dioxane (30 mL). The resulting mixture was stirred at 90 ° C under a nitrogen atmosphere for 16 hours. The solid was filtered off and the crude supernatant was purified by Prep-TLC (ethyl acetate / petroleum ether) to provide 5-methoxy-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)-2-(methylsulfonyl)pyrimidin-4-amine (562 mg, 51% yield) as a pink solid. UPLC-MS (+ESI) m / z = 448.1 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ10.11(s,1H),8.46(s,1H),8.09–8.11(s,1H),6.61(s,1H),5.33–5.36(m,1H),3.82–3.95(m,4H),3.67–3.77(m,3 H),3.37–3.62(m,1H),3.31–3.37(m,3H),2.50–2.51(m,4H),2.20–2.33(m,1H),1.97–2.00(m,1H),1.84–1.87(m,1H),1.74–1.84(m,2H).
[0561] Step 2 / N 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-5-methoxy-N 4-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrimidine-2,4-diamine
[0562] NaH (8.90 mg, 223 umol, 60% purity) was added to 4-methylsulfonylaniline (13.2 uL, 112 umol) in DMF (0.5 mL) and stirred at rt for 10 minutes. To this mixture was added 5-methoxy-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)-2-(methylsulfonyl)pyrimidin-4-amine (50 mg, 112 umol) and the resulting mixture was stirred at 80 ° C for 1 hour and then heated to 120 ° C and maintained for 15 hours to complete the reaction. The crude reaction mixture was diluted with water and then EtOAc and saturated NaHCO3 aqueous solution. The organic phase was separated, washed with brine, dried over Na2SO4, filtered, and finally evaporated in vacuo to provide N 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-5-methoxy-N 4 -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrimidine-2,4-diamine (45 mg, yield 75%), which was used in the next step without further purification. UPLC-MS (+ESI) m / z=539.2 (M+H) +
[0563] Step 3 / Compound 1
[0564] To N 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-5-methoxy-N 4 4M hydrochloric acid (2.0 mL) in dioxane was added to -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrimidine-2,4-diamine (46 mg, 82 umol). The reaction mixture was stirred at rt for 1 hour. The crude reaction mixture was concentrated. The residue was dissolved in DMSO and purified by preparative HPLC, eluting with a gradient of MeCN (25%-55%) in water (both containing 0.1% formic acid). The appropriate fractions were combined and lyophilized to provide Compound 1 (6.0 mg, 15% yield) as a white solid. UPLC-MS (+ESI) m / z=473.1 (M+H) + . 1H NMR(400MHz,DMSO-d6)δ8.90(s,1H),8.37(s,1H),8.08(s,1H),7.85–7.73 (m,2H),6.00(s,1H),3.96(s,3H),3.68(s,3H),3.23(s,3H),2.18(s,3H).
[0565] Compound 2 / Method B / N 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-5-methoxy-N 2 -Methyl-N 4 -(5-methyl-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrimidine-2,4-diamine
[0566]
[0567] Step 1 / 5-methoxy-N-(4-methoxybenzyl)-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)-2-(methylsulfonyl)pyrimidin-4-amine
[0568] To a solution of 5-methoxy-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)-2-(methylsulfonyl)pyrimidin-4-amine (see Compound 1, Step 1) (5.30 g, 11.8 mmol) in MeCN (20 mL) was added 1-(chloromethyl)-4-methoxy-benzene (2.40 mL, 17.8 mmol) and K2CO3 (4.91 g, 35.5 mmol) at rt. The reaction mixture was stirred at 80° C. for 3 h. The crude reaction mixture was diluted with EtOAc, quenched with saturated aqueous NaHCO3, and then extracted with EtOAc. The organic layer was evaporated in vacuo, and the residue was purified by silica gel chromatography, eluting with EtOAc (50%-100%) in heptane. The relevant fractions were evaporated to give 5-methoxy-N-(4-methoxybenzyl)-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)-2-(methylsulfonyl)pyrimidin-4-amine (6.40 g, yield 95%) as off-white foam. UPLC-MS (+ESI) m / z=568.3 (M+H) +
[0569] Step 2 / N 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-5-methoxy-N 4-(4-methoxybenzyl)-N 4 -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrimidine-2,4-diamine
[0570] To a solution of 5-methoxy-N-(4-methoxybenzyl)-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)-2-(methylsulfonyl)pyrimidin-4-amine (1.4 g, 2.47 mmol) in DMPU (7 mL) was added 2-fluoro-4-methylsulfonyl-aniline (933 mg, 4.93 mmol) and NaH (197 mg, 4.93 mmol, 60% purity). The reaction mixture was stirred at 120 °C for 15 hours. The crude reaction mixture was quenched with water, filtered, and purified by preparative HPLC eluting with a gradient of MeCN in water (both containing 0.1% formic acid). The appropriate fractions were combined and lyophilized to provide the desired product N as a yellow solid. 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-5-methoxy-N 4 -(4-methoxybenzyl)-N 4 -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrimidine-2,4-diamine (761 mg, yield 46%). UPLC-MS (+ESI) m / z=677.3 (M+H) + .
[0571] Step 3 / Compound 2
[0572] To N 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-5-methoxy-N 4 -(4-methoxybenzyl)-N 4 To a solution of -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrimidine-2,4-diamine (98.0 mg, 145 umol) in DMF (1 mL) was added NaH (10.4 mg, 434 umol, 60% dispersion), then after 10 minutes MeI (27 uL, 434 umol) was added, and the reaction mixture was stirred at rt for 1 hour. The crude reaction mixture was quenched with water, filtered, and purified by preparative HPLC, eluting with a gradient of MeCN in water (both containing 0.1% formic acid). The appropriate fractions were combined and lyophilized to provide intermediate N as a brown solid 2-(2-Fluoro-4-methylsulfonyl-phenyl)-5-methoxy-N 4 -[(4-methoxyphenyl)methyl]-N 2 -methyl-6-(1-methylpyrazol-4-yl)-N 4 -(5-methyl-1-tetrahydropyran-2-yl-pyrazol-3-yl)pyrimidine-2,4-diamine. TFA (0.5 mL) was added to this intermediate. The reaction mixture was stirred at 80 ° C for 1 hour. The crude reaction mixture was evaporated, diluted in DMSO, filtered and purified by preparative HPLC elution, eluting with a gradient of MeCN (10%-50%) in water (both containing 0.1% formic acid). The appropriate fractions were combined and lyophilized to provide compound 2 (18 mg, 24% yield, 94% purity) as a white solid. UPLC-MS (+ESI) m / z=487.2 (M+H) + . 1 HNMR(400MHz,DMSO-d6)δ11.88(s,1H),8.84(s,1H),8.27(s,1H),7.97(d,J=0.6Hz,1H),7.89–7.79(m ,2H),7.79–7.73(m,1H),5.65(s,1H),3.92(s,3H),3.62(s,3H),3.49(s,3H),3.31(s,3H),2.04(s,3H)
[0573] Compound 3 / Method B / N 2 -ethyl-N 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-5-methoxy-N 4 -(5-methyl-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrimidine-2,4-diamine
[0574]
[0575] Step 1 / N 2 -ethyl-N 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-5-methoxy-N 4 -(4-methoxybenzyl)-N 4 -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrimidine-2,4-diamine
[0576] To N 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-5-methoxy-N 4 -(4-methoxybenzyl)-N 4To a solution of -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrimidine-2,4-diamine (see Compound 2, Step 2) (37 mg, 54.67 umol) in DMF (0.5 mL) was added NaH (3.9 mg, 164 μmol), stirred for 10 minutes, iodoethane (8.8 μL, 109 μmol) was added, and the reaction mixture was stirred at rt for 1 hour. The crude reaction mixture was quenched with water, filtered, and purified by preparative HPLC, eluting with a gradient of MeCN in water (both containing 0.1% formic acid). The appropriate fractions were combined and lyophilized to provide intermediate N as a brown solid 2 -ethyl-N 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-5-methoxy-N 4 -(4-methoxybenzyl)-N 4 -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrimidine-2,4-diamine, which was used in the next step without purification.
[0577] Step 2 / Compound 3
[0578] To crude N 2 -ethyl-N 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-5-methoxy-N 4 -(4-methoxybenzyl)-N 4 -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrimidine-2,4-diamine was added TFA (0.5 mL). The reaction mixture was stirred at 80 °C for 1 hour. The crude reaction mixture was evaporated, diluted in DMSO, filtered and purified by preparative HPLC eluting with a gradient of MeCN (10%-50%) in water (both containing 0.1% formic acid). The appropriate fractions were combined and lyophilized to provide compound 3 (7 mg, 26% yield in step 1) as a white solid. UPLC-MS (+ESI) m / z=501.2 (M+H) + . 1H NMR (400MHz, DMSO-d6) δ11.86(s,1H),8.84(s,1H),8.26(s,1H),7.95(s,1H),7.86(ddd,J=13.2,8.9,2.1Hz,2H),7.7 4(t,J=7.8Hz,1H),5.54(s,1H),4.02(q,J=7.0Hz,2H),3.93(s,3H),3.61(s,3H),2.02(s,3H),1.19(t,J=7.0Hz,3H).
[0579] Compound 4 / Method B / N2-(2-fluoro-4-(methylsulfonyl)phenyl)-N 2 -(4-Fluorobenzyl)-5-methoxy-N 4 -(5-methyl-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrimidine-2,4-diamine
[0580]
[0581] Step 1 / N 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-N 2 -(4-Fluorobenzyl)-5-methoxy-N 4 -(4-methoxybenzyl)-N 4 -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrimidine-2,4-diamine
[0582] To N 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-5-methoxy-N 4 -(4-methoxybenzyl)-N 4 To a solution of -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrimidine-2,4-diamine (see Compound 2, Step 2) (33.0 mg, 48.7 μmol) in DMF (0.5 mL) was added NaH (5.1 mg, 146 μmol, 60% dispersion), stirred for 10 minutes, 1-(bromomethyl)-4-fluoro-benzene (18 uL, 146 μmol) was added, and the reaction mixture was stirred at rt for 15 hours. The crude reaction mixture was quenched with water, filtered, and purified by preparative HPLC, eluting with a gradient of MeCN in water (both containing 0.1% formic acid). The appropriate fractions were combined and lyophilized to provide intermediate N as a brown solid 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-N 2-(4-Fluorobenzyl)-5-methoxy-N 4 -(4-methoxybenzyl)-N 4 -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrimidine-2,4-diamine which was used in the next step without further purification.
[0583] Step 2 / Compound 4
[0584] To the crude N from the first step 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-N 2 -(4-Fluorobenzyl)-5-methoxy-N 4 -(4-methoxybenzyl)-N 4 -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrimidine-2,4-diamine was added TFA (0.5 mL). The reaction mixture was stirred at 80 °C for 1 hour. The crude reaction mixture was evaporated, diluted in DMSO, filtered and purified by preparative HPLC eluting with a gradient of MeCN (10%-50%) in water (both containing 0.1% formic acid). The appropriate fractions were combined and lyophilized to provide the desired product compound 4 (5.1 mg, step 1 yield 18%) as a white solid. UPLC-MS (+ESI) m / z=581.3 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ11.86(s,1H),8.84(s,1H),8.24(s,1H),7.91(s,1H),7.86–7.76(m,2H),7.72(t,J=7.7Hz,1H),7.3 7(dd,J=8.6,5.7Hz,2H),7.17–7.06(m,2H),5.49(s,1H),5.27(s,2H),3.91(s,3H),3.62(s,3H),3.28(s,3H),2.00(s,3H).
[0585] Compound 5 / Method A / 5-methoxy-N-(5-methyl-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)-2-(5-(methylsulfonyl)indol-1-yl)pyrimidin-4-amine
[0586]
[0587] Step 1 / 5-methoxy-N-(4-methoxybenzyl)-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)-2-(5-(methylsulfonyl)indol-1-yl)pyrimidin-4-amine
[0588] To a solution of 5-methoxy-N-(4-methoxybenzyl)-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)-2-(methylsulfonyl)pyrimidin-4-amine (see Compound 2, Step 2) (20.0 mg, 35.2 μmol) in DMPU (0.5 mL) was added NaH (2.8 mg, 71 mmol, 60% purity). The reaction mixture was stirred at 120° C. for 15 hours. The crude reaction mixture was quenched with water, filtered, and purified by preparative HPLC eluting with a gradient of MeCN (40%-70%) in water (both containing 0.1% formic acid). The appropriate fractions were combined and lyophilized to afford 5-methoxy-N-(4-methoxybenzyl)-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)-2-(5-(methylsulfonyl)indol-1-yl)pyrimidin-4-amine as a yellow solid which was used in the next step without further purification.
[0589] Step 2 / Compound 5
[0590] To the crude 5-methoxy-N-(4-methoxybenzyl)-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)-2-(5-(methylsulfonyl)indol-1-yl)pyrimidin-4-amine was added TFA (0.5 mL). The reaction mixture was stirred at 80 °C for 1 hour. The crude reaction mixture was evaporated, diluted in DMSO, filtered and purified by preparative HPLC eluting with a gradient of MeCN (10%-50%) in water (both containing 0.1% formic acid). The appropriate fractions were combined and lyophilized to provide Compound 5 (3.0 mg, 18% yield in step 1) as a white solid. UPLC-MS (+ESI) m / z=481.2 (M+H) + . 1H NMR (400MHz, DMSO-d6) δ9.10(s,1H),8.55(d,J=8.6Hz,1H),8.38(s,1H),8.09(s,1H),7.73(dd,J=8.6,2.1Hz,1H),7.66(d,J=1.9H z,1H),6.74(s,1H),6.37(s,1H),4.30(t,J=8.9Hz,2H),3.96(s,3H),3.68(s,3H),3.22(t,J=8.8Hz,2H),3.13(s,3H),2.27(s,3H).
[0591] Compound 6 / Method B / N 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-5-methoxy-N 2 -methyl-6-(1-methyl-1H-pyrazol-3-yl)-N 4 -(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine
[0592]
[0593] Step 1 / 5-methoxy-N-(4-methoxybenzyl)-N-(1-(4-methoxybenzyl)-5-methyl-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-3-yl)-2-(methylsulfonyl)pyrimidin-4-amine
[0594] To a solution of intermediate 10 (208 mg, 372 μmol) in dioxane (2 mL) was added tributyl-(1-methylpyrazol-3-yl)stannane (152 mg, 410 μmol) and Pd(PPh3)4 (43 mg, 37 μmol). The reaction mixture was stirred at 100°C for 5 hours. The crude reaction mixture was evaporated, dissolved in 2 mL DMSO, filtered and purified by preparative HPLC eluting with a gradient of MeCN (40%-70%) in water (both containing 0.1% formic acid). The appropriate fractions were combined and evaporated to provide 5-methoxy-N-(4-methoxybenzyl)-N-(1-(4-methoxybenzyl)-5-methyl-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-3-yl)-2-(methylsulfonyl)pyrimidin-4-amine (106 mg, 47% yield). UPLC-MS (+ESI) m / z = 604.3 (M+H) + .
[0595] Step 2 / N 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-5-methoxy-N 4 -(4-methoxybenzyl)-N 4-(1-(4-methoxybenzyl)-5-methyl-1H-pyrazol-3-yl)-N 2 -methyl-6-(1-methyl-1H-pyrazol-4-yl)pyrimidine-2,4-diamine
[0596] To 2-fluoro-4-methylsulfonyl-aniline (37 mg, 193 μmol) in DMPU (1 mL) was added NaH (4.4 mg, 193 μmol, 60% dispersion). The mixture was stirred at rt for 10 minutes. To this mixture was added 5-methoxy-N-(4-methoxybenzyl)-N-(1-(4-methoxybenzyl)-5-methyl-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-3-yl)-2-(methylsulfonyl)pyrimidin-4-amine (106 mg, 176 umol) and the reaction was heated at 130 °C for 5 hours. The mixture was then cooled to rt and MeI (56 uL, 897 umol) was added and the mixture was stirred at rt overnight. The crude mixture was filtered and purified by preparative HPLC eluting with a gradient of MeCN (40%-70%) in water (both containing 0.1% formic acid). Appropriate fractions were combined and evaporated to provide N 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-5-methoxy-N 4 -(4-methoxybenzyl)-N 4 -(1-(4-methoxybenzyl)-5-methyl-1H-pyrazol-3-yl)-N 2 -methyl-6-(1-methyl-1H-pyrazol-4-yl)pyrimidine-2,4-diamine (10 mg) and non-methylated intermediate N 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-5-methoxy-N 4 -(4-methoxybenzyl)-N 4 -(1-(4-methoxybenzyl)-5-methyl-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (48 mg). After dissolving in DMF (1.5 mL), NaH (3.2 mg, 135 μmol, 60% dispersion) was added, followed by MeI (8.4 μL, 135 μmol). The reaction was then stirred at rt for 15 minutes. The crude material was purified by preparative HPLC, eluting with a gradient of MeCN (40%-70%) in water (both containing 0.1% formic acid). The appropriate fractions were combined and evaporated to provide N 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-5-methoxy-N 4 -(4-methoxybenzyl)-N 4 -(1-(4-methoxybenzyl)-5-methyl-1H-pyrazol-3-yl)-N2 -methyl-6-(1-methyl-1H-pyrazol-4-yl)pyrimidine-2,4-diamine, which was combined with 10 mg isolated previously.
[0597] Step 3 / Compound 6
[0598] The merged N from the previous step 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-5-methoxy-N 4 -(4-methoxybenzyl)-N 4 -(1-(4-methoxybenzyl)-5-methyl-1H-pyrazol-3-yl)-N 2 -methyl-6-(1-methyl-1H-pyrazol-4-yl)pyrimidine-2,4-diamine was dissolved in TFA (2 mL) and heated at 120°C overnight. The reaction mixture was evaporated in vacuo, dissolved in DMSO, and purified by preparative HPLC, eluting with a gradient of MeCN (20%-50%) in water (both containing 0.1% formic acid). The appropriate fractions were combined and evaporated to provide compound 6 (1.7 mg, 5.2% yield for steps 2 and 3). UPLC-MS (+ESI) m / z=487.2 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ7.88–7.77(m,2H),7.74(q,J=2.8Hz,2H),7.71(s,0H),6.72(d,J= 2.2Hz,1H),5.63(s,1H),3.91(s,3H),3.62(s,3H),3.45(s,3H),3.27(s,4H),2.01(s,3H).
[0599] Compound 7 / Method B / N 2 -(4-(cyclopropylsulfonyl)-2-fluorophenyl)-5-methoxy-N 2 -Methyl-N 4 -(5-methyl-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrimidine-2,4-diamine
[0600]
[0601] Step 1 / N 2 -(4-(cyclopropylsulfonyl)-2-fluorophenyl)-5-methoxy-N 4 -(4-methoxybenzyl)-N 4 -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrimidine-2,4-diamine
[0602] To 5-methoxy-N-(4-methoxybenzyl)-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)-2-(methylsulfonyl)pyrimidin-4-amine (see Compound 2, Step 1) (87 mg, 153 μmol) in DMPU (1 mL) was added 4-cyclopropylsulfonyl-2-fluoro-aniline (73 mg, 339 μmol). Nitrogen was bubbled for 5 minutes, and then NaH (22 mg, 550 μmol, 60% purity) was added at rt. The vial was closed and the mixture was heated to 125 ° C and maintained for 18 hours. The mixture was cooled to rt and MeI (100 μL, 1.61 mmol,) was added, and the mixture was stirred at rt for 1 hour. 1 mL of MeOH was added to quench the reaction, and the mixture was filtered on a celite column. MeOH was removed under reduced pressure. The crude reaction mixture was filtered and purified by preparative HPLC eluting with a gradient of MeCN (35%-65%) in water (both containing 0.1% formic acid). Appropriate fractions were combined and lyophilized to provide N 2 -(4-Cyclopropylsulfonyl-2-fluoro-phenyl)-5-methoxy-N 4 -[(4-methoxyphenyl)methyl]-N 2 -methyl-6-(1-methylpyrazol-4-yl)-N 4 -(5-methyl-1-tetrahydropyran-2-yl-pyrazol-3-yl)pyrimidine-2,4-diamine (39 mg, yield 36%).
[0603] Step 2 / Compound 7
[0604] TFA (3.0 mL, 39.2 mmol) was added to N 2 -(4-Cyclopropylsulfonyl-2-fluoro-phenyl)-5-methoxy-N 4 -[(4-methoxyphenyl)methyl]-N 2 -methyl-6-(1-methylpyrazol-4-yl)-N 4 -(5-methyl-1-tetrahydropyran-2-yl-pyrazol-3-yl)pyrimidine-2,4-diamine (39 mg, 54.4 mmol), and the mixture was stirred at 90 ° C for 2 hours. The volatiles were removed under reduced pressure, and the residue was dissolved in DMSO and purified by preparative HPLC, eluting with a gradient of MeCN (25%-55%) in water (all containing 0.1% formic acid). The appropriate fractions were combined and lyophilized to provide compound 7 (14.6 mg, yield 19%). UPLC-MS (+ESI) m / z=513.2 (M+H) + . 1H NMR(400MHz,DMSO-d6)δ11.83(s,1H),8.77(s,1H),8.23(s,1H),7.92(s,1H),7.81–7.62(m,3H),5.6 1(s,1H),3.89(s,3H),3.58(s,3H),3.46(s,3H),2.01(s,3H),1.20–1.12(m,2H),1.10–1.00(m,2H).
[0605] Compound 8 / Method B / N 2 -(2,6-difluoro-4-(methylsulfonyl)phenyl)-5-methoxy-N 2 -Methyl-N 4 -(5-methyl-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrimidine-2,4-diamine
[0606]
[0607] Step 1 / N 2 -(2,6-difluoro-4-(methylsulfonyl)phenyl)-5-methoxy-N 4 -(4-methoxybenzyl)-N 2 -Methyl-N 4 -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrimidine-2,4-diamine
[0608] To a solution of 5-methoxy-N-(4-methoxybenzyl)-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)-2-(methylsulfonyl)pyrimidin-4-amine (see Compound 2, Step 1) (50 mg, 88 μmol) and 2,6-difluoro-4-methylsulfonyl-aniline (110 mg, 529 μmol) in DMPU (0.5 mL) was added NaH (21 mg, 529 μmol, 60% dispersion). The reaction mixture was stirred at 80 °C for 15 hours. The reaction was quenched with water (0.2 mL). The resulting reaction mixture was filtered and purified by preparative HPLC, eluting with a gradient of MeCN in water (both containing 0.1% formic acid). The appropriate fractions were combined and evaporated to provide N 2 -(2,6-difluoro-4-(methylsulfonyl)phenyl)-5-methoxy-N 4 -(4-methoxybenzyl)-N 4-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrimidine-2,4-diamine (19 mg, 31% yield, 27 μmol). It was then dissolved in DMF (0.5 mL) before adding NaH (10 mg, 250 μmol, 60% dispersion), followed by the addition of MeI (16.0 μL, 264 μmol) at rt. The reaction was stirred for 30 minutes and then quenched with water 0.2 mL. The crude reaction mixture was filtered and purified by preparative HPLC, eluting with a gradient of MeCN in water (both containing 0.1% formic acid). The appropriate fractions were combined and evaporated to provide N 2 -(2,6-difluoro-4-(methylsulfonyl)phenyl)-5-methoxy-N 4 -(4-methoxybenzyl)-N 2 -Methyl-N 4 -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrimidine-2,4-diamine (13 mg, yield 53%). UPLC-MS (+ESI) m / z=709.3 (M+H) + .
[0609] Step 2 / Compound 8
[0610] To N 2 -(2,6-difluoro-4-(methylsulfonyl)phenyl)-5-methoxy-N 4 -(4-methoxybenzyl)-N 2 -Methyl-N 4 -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrimidine-2,4-diamine (11 mg, 15.5 μmol) was added TFA (0.5 mL). The reaction mixture was stirred at 80 °C for 1 hour. The crude reaction mixture was concentrated, the residue was dissolved in DMSO and purified by preparative HPLC, eluting with a gradient of MeCN in water (both containing 0.1% formic acid). The appropriate fractions were combined and lyophilized to provide compound 8 (4.3 mg, 55% yield) as a white solid. UPLC-MS (+ESI) m / z=505.1 (M+H) + . 1H NMR (400MHz, DMSO-d6) δ11.89(s,1H),8.92(s,1H),8.28(s,1H),7.98(s,1H),7.85(d,J=6 .9Hz,2H),5.45(s,1H),3.92(s,3H),3.62(s,3H),3.42(s,3H),3.37(s,3H),2.04(s,3H).
[0611] Compound 9 / Method A / 2-(2-Fluoro-4-(methylsulfonyl)phenoxy)-5-methoxy-N-(5-methyl-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrimidin-4-amine
[0612]
[0613] Step 1 / 2-(2-Fluoro-4-(methylsulfonyl)phenoxy)-5-methoxy-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrimidin-4-amine
[0614] To 2-fluoro-4-methylsulfonylphenol (102 mg, 536 umol) in MeCN (3 mL) was added NaH (22 mg, 550 μmol, 60% dispersion) and the mixture was stirred at rt for 15 minutes. To this mixture was added 5-methoxy-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)-2(methylsulfonyl)pyrimidin-4-amine (see Compound 1, Step 1) (120 mg, 268 μmol) and the reaction was heated in a microwave at 170°C for 90 minutes. The reaction mixture was evaporated in vacuo, dissolved in DMSO and purified by preparative HPLC eluting with a gradient of MeCN in water (both containing 0.1% formic acid). The appropriate fractions were combined and lyophilized to provide 2-(2-fluoro-4-(methylsulfonyl)phenoxy)-5-methoxy-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrimidin-4-amine (18.6 mg, 13% yield).
[0615] Step 2 / Compound 9
[0616] To 2-(2-fluoro-4-(methylsulfonyl)phenoxy)-5-methoxy-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrimidin-4-amine (18.6 mg, 33.4 μmol) in dioxane (1 mL) was added HCl in dioxane (0.1 mL, 4N), and the mixture was heated at 50 °C overnight. The reaction mixture was evaporated in vacuo to give the desired product compound 9 (13.3 mg, 81% yield). UPLC-MS (+ESI) m / z = 474.1 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ9.80(s,1H),8.29(s,1H),7.99(dd,J=9.7,2.2Hz,1H),7.91(d,J=0.7Hz,1H),7.84(dt,J=8.4,1 .4Hz,1H),7.68(dd,J=8.4,7.6Hz,1H),5.63(d,J=0.8Hz,1H),3.89(s,3H),3.64(s,3H),3.29(s,3H),2.16–1.95(m,3H).
[0617] Compound 10 / Method A / 5-cyclopropyl-N 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-N 4 -(5-methyl-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrimidine-2,4-diamine
[0618]
[0619] Step 1 / 5-cyclopropyl-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)-2-(methylsulfonyl)pyrimidin-4-amine
[0620] To a solution of intermediate 7 (523 mg, 1.27 mmol) in dioxane / water (5 mL, 9 / 1) was added 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole (396 mg, 1.90 mmol), K2CO3 (526 mg, 3.81 mmol), Pd(dppf)Cl2 (93 mg, 127 μmol), and the mixture was degassed with nitrogen for 2 minutes. The reaction mixture was then stirred at 120°C for 5 hours. The crude reaction mixture was diluted with EtOAc, quenched with saturated NaHCO3, and then extracted with EtOAc. The combined organic phases were washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The crude mixture was purified by silica gel chromatography eluting with a gradient of MeOH (0-10%) in DCM. The appropriate fractions were combined and concentrated to provide 5-cyclopropyl-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)-2-(methylsulfonyl)pyrimidin-4-amine (388 mg, 67% yield) as a yellow solid. UPLC-MS (+ESI) m / z = 458.2 (M+H) + .
[0621] Step 2, 3 / Compound 10
[0622] To a solution of 5-cyclopropyl-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)-2-(methylsulfonyl)pyrimidin-4-amine (20.0 mg, 43.7 μmol) and 2-fluoro-4-methylsulfonyl-aniline (16.5 mg, 87.4 μmol) in DMPU (0.5 mL) was added NaH (3.5 mg, 87 μmol, 60% purity). The reaction mixture was stirred at 120 °C for 15 hours. The crude reaction mixture was quenched with water, filtered, and purified by preparative HPLC, eluting with a gradient of MeCN in water (both containing 0.1% formic acid). The appropriate fractions were combined and lyophilized to provide the intermediate 5-cyclopropyl-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)-2-(methylsulfonyl)pyrimidin-4-amine as a yellow solid. 2 -(2-Fluoro-4-methylsulfonyl-phenyl)-6-(1-methylpyrazol-4-yl)-N 4-(5-methyl-1-tetrahydropyran-2-yl-pyrazol-3-yl)pyrimidine-2,4-diamine. HCl (2 mL, 4 M) and MeOH (0.1 mL) in dioxane were then added thereto. The reaction mixture was stirred at rt for 5 hours. The crude reaction mixture was concentrated, diluted in DMSO, filtered and purified by preparative HPLC elution, eluting with a gradient of MeCN (15%-45%) in water (both containing 0.1% formic acid). The appropriate fractions were combined and lyophilized to provide compound 10 (8.0 mg, 38% yield) as a white solid. UPLC-MS (+ESI) m / z=483.1 (M+H) + . 1 HNMR(400MHz,DMSO-d6)δ8.90(s,1H),8.33(s,1H),8.06(s,1H),7.86–7.70(m,2H),5.89(s,1H),3.94(s, 3H), 3.23 (s, 3H), 2.19 (s, 3H), 1.80 (td, J = 7.8, 3.8Hz, 1H), 1.18 (d, J = 6.6Hz, 2H), 0.23 (d, J = 5.1Hz, 2H).
[0623] Compound 11 / Method B / 5-cyclopropyl-N 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-N 2 -Methyl-N 4 -(5-methyl-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrimidine-2,4-diamine
[0624]
[0625] Step 1 / 5-cyclopropyl-N-(4-methoxybenzyl)-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)-2-(methylsulfonyl)pyrimidin-4-amine
[0626] To a solution of intermediate 8 (2.00 g, 3.76 mmol) in dioxane (10 mL) and H2O (3 mL) was added 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole (939 mg, 4.51 mmol), Pd(dppf)Cl2 (550 mg, 752 μmol) and Cs2CO3 (3.06 g, 9.40 mmol). The resulting mixture was degassed in vacuo and then backfilled with nitrogen. The resulting reaction mixture was stirred at 90 °C for 3 hours, then cooled to rt and diluted with EtOAc. The organic phase was extracted, washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by preparative HPLC eluting with a gradient of MeCN (10%-100%) in water (both containing 0.1% formic acid). The appropriate fractions were combined and lyophilized to provide 5-cyclopropyl-N-(4-methoxybenzyl)-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)-2-(methylsulfonyl)pyrimidin-4-amine (1.45 g, 51% yield, 77% purity). UPLC-MS (+ESI) m / z = 578.2 (M+H) +
[0627] Step 2 / 5-Cyclopropyl-N 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-N 4 -(4-methoxybenzyl)-N 2 -methyl-N4-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrimidine-2,4-diamine
[0628] To 5-cyclopropyl-N-(4-methoxybenzyl)-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)-2-(methylsulfonyl)pyrimidin-4-amine (690 mg, 1.05 mmol) in DMPU (6 mL) was added 2-fluoro-4-methylsulfonyl-aniline (259 mg, 1.37 mmol). Nitrogen was bubbled through the reaction mixture for 5 minutes, then LiHMDS (1 M in THF, 3.15 mL, 3.15 mmol) was slowly added at rt. The vial was closed and the mixture was heated to 80 ° C and maintained for 1 hour. The mixture was cooled to rt, MeI (327 μL, 5.26 mmol) was added, and the mixture was stirred at rt for 1 hour. 1 mL of MeOH was added to quench the reaction, and the mixture was filtered on a celite cartridge and evaporated to dryness. The filtrate was purified by preparative HPLC eluting with a gradient of MeCN (10%-100%) in water (both containing 0.1% formic acid). Appropriate fractions were combined and lyophilized to provide 5-cyclopropyl-N-(2-(4-cyclopropyl)-3-yl)-4-nitropropane-5-nitropropane-1-nitropropane-2-nitropropane-3-nitropropane-1-nitropropane-2-nitropropane-3-nitropropane-4-nitropropane-5 ... 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-N 4 -(4-methoxybenzyl)-N 2 -Methyl-N 4 -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrimidine-2,4-diamine (358 mg, yield 49%). UPLC-MS (+ESI) m / z=701.4 (M+H) + .
[0629] Step 3 / Compound 11
[0630] To 5-cyclopropyl-N 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-N 4 -(4-methoxybenzyl)-N 2 -Methyl-N 4 -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrimidine-2,4-diamine (938 mg, 1.34 mmol) was added TFA (21 mL, 268 mmol), and the reaction mixture was stirred at 120 ° C for 6 hours. TFA was removed under reduced pressure and the residue was purified by preparative HPLC, eluting with a gradient of MeCN (10%-100%) in water (both containing 0.1% formic acid). The appropriate fractions were combined and lyophilized to provide compound 11 (430 mg, yield 65%). UPLC-MS (+ESI) m / z=497.2 (M+H)+ . 1 H NMR (400MHz, DMSO-d6) δ8.21(s,1H),7.92(d,J=0.7Hz,1H),7.85–7.77(m,2H),7.71(dd,J=8.2,7.3Hz,1H),5.58(s,1H ),3.87(s,3H),3.45(s,3H),3.27(s,3H),2.05–1.95(m,3H),1.77–1.65(m,1H),1.16–1.00(m,2H),0.18–0.12(m,2H).
[0631] Compound 12 / Method B / 5-cyclopropyl-N 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-N 2 -methyl-6-(1-methyl-1H-pyrazol-3-yl)-N 4 -(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine
[0632]
[0633] Step 1 / 5-cyclopropyl-N-(4-methoxybenzyl)-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-3-yl)-2-(methylsulfonyl)pyrimidin-4-amine
[0634] To a solution of intermediate 8 (312 mg, 586 μmol) in dioxane (2 mL) was added tributyl-(1-methylpyrazol-3-yl)stannane (239 mg, 645 μmol), Pd(PPh3)4 (68 mg, 59 μmol). The reaction mixture was then stirred at 100°C overnight. The crude material was purified by preparative HPLC, eluting with a gradient of MeCN (15%-45%) in water (both containing 0.1% formic acid). The appropriate fractions were combined and lyophilized to provide the desired product 5-cyclopropyl-N-(4-methoxybenzyl)-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-3-yl)-2-(methylsulfonyl)pyrimidin-4-amine (142 mg, 42% yield). UPLC-MS (+ESI) m / z = 578.3 (M+H) + .
[0635] Step 2 / 5-Cyclopropyl-N 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-N 4 -(4-methoxybenzyl)-N 4-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine
[0636] A mixture of 2-fluoro-4-methylsulfonyl-aniline (70.0 mg, 370 μmol) and NaH (9.0 mg, 391 μmol, 60% dispersion) in DMPU (1.5 mL) was stirred at rt for 10 minutes. 5-Cyclopropyl-N-(4-methoxybenzyl)-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-3-yl)-2-(methylsulfonyl)pyrimidin-4-amine (142 mg, 246 μmol) was added and the reaction mixture was heated at 130 °C overnight. The reaction mixture was cooled to rt, quenched with a drop of water, and purified by preparative HPLC eluting with a gradient of MeCN in water (both containing 0.1% formic acid). The appropriate fractions were combined and lyophilized to provide 5-cyclopropyl-N-(4-methoxybenzyl)-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-3-yl)-2-(methylsulfonyl)pyrimidin-4-amine (142 mg, 246 μmol). 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-N 4 -(4-methoxybenzyl)-N 4 -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (50 mg, yield 30%).
[0637] Step 3 / 5-Cyclopropyl-N 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-N 4 -(4-methoxybenzyl)-N 2 -Methyl-N 4 -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine
[0638] To 5-cyclopropyl-N- 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-N 4 -(4-methoxybenzyl)-N 4NaH (9.0 mg, 391 μmol, 60% dispersion) and MeI (40 μL, 643 μmol) were added to 5-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (50 mg, 73 μmol) and the reaction was stirred overnight at rt. The reaction mixture was quenched with water (0.2 mL), filtered and purified by preparative HPLC, eluting with a gradient of MeCN (30%-80%) in water (both containing 0.1% formic acid). The appropriate fractions were combined and lyophilized to provide 5-cyclopropyl-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)pyrimidine-2,4-diamine. 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-N 4 -(4-methoxybenzyl)-N 2 -Methyl-N 4 -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (35 mg, yield 69%). UPLC-MS (+ESI) m / z=701.4 (M+H) + .
[0639] Step 4 / Compound 12
[0640] To 5-cyclopropyl-N 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-N 4 -(4-methoxybenzyl)-N 2 -Methyl-N 4 -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (35 mg, 50 μmol) was added TFA (3 mL), and the mixture was heated at 90 ° C for 2 hours. The reaction mixture was concentrated, the residue was dissolved in DMSO, and purified by preparative HPLC, eluting with a gradient of MeCN (20%-70%) in water (both containing 0.1% formic acid). The appropriate fractions were combined and lyophilized to provide the desired product compound 12 (13 mg, yield 52%). UPLC-MS (+ESI) m / z=497.2 (M+H) + . 1H NMR (400MHz, DMSO-d6) δ11.84(s,1H),8.22(s,1H),7.89–7.77(m,2H),7.77–7.62(m,2H),6.55(d,J=2.2Hz,1H),5.5 9(s,1H),3.87(s,3H),3.43(s,3H),2.01(s,3H),1.85–1.58(m,1H),0.95–0.73(m,2H),0.00(dt,J=5.7,3.0Hz,2H).
[0641] Compound 13 / Method B / 5-cyclopropyl-N 2 -(2,6-difluoro-4-(methylsulfonyl)phenyl)-N 2 -methyl-6-(1-methyl-1H-pyrazol-3-yl)-N 4 -(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine
[0642]
[0643] Step 1 / 5-cyclopropyl-N-(4-methoxybenzyl)-N-(1-(4-methoxybenzyl)-5-methyl-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-3-yl)-2-(methylsulfonyl)pyrimidin-4-amine
[0644] To a solution of intermediate 9 (1.15 g, 2.02 mmol) in dioxane (10 mL) was added tributyl-(1-methylpyrazol-3-yl)stannane (790 mg, 2.13 mmol), Pd(PPh3)4 (240 mg, 208 μmol). The reaction mixture was then stirred at 85 °C overnight. The crude mixture was purified by silica gel column chromatography eluting with EtOAc (70%) in heptane. The appropriate fractions were combined and evaporated to provide the desired product 5-cyclopropyl-N-(4-methoxybenzyl)-N-(1-(4-methoxybenzyl)-5-methyl-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-3-yl)-2-(methylsulfonyl)pyrimidin-4-amine (217 mg, 18% yield). UPLC-MS (+ESI) m / z=614.0 (M+H) + .
[0645] Step 2 / 5-Cyclopropyl-N 2 -(2,6-difluoro-4-(methylsulfonyl)phenyl)-N 4 -(4-methoxybenzyl)-N 4-(1-(4-methoxybenzyl)-5-methyl-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine
[0646] A mixture of 2,6-difluoro-4-methylsulfonyl-aniline (90 mg, 434 μmol) and NaH (18.0 mg, 470 μmol, 60% dispersion) in DMPU (1 mL) was stirred at rt for 10 minutes. To the resulting mixture was added 5-cyclopropyl-N-(4-methoxybenzyl)-N-(1-(4-methoxybenzyl)-5-methyl-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-3-yl)-2-(methylsulfonyl)pyrimidin-4-amine (217 mg, 353 μmol) and the reaction was heated at 130 °C. ℃ The reaction mixture was purified by preparative HPLC eluting with a gradient of MeCN (30%-70%) in water (both containing 0.1% formic acid). The appropriate fractions were combined and lyophilized to provide the intermediate 5-cyclopropyl-N- 2 -(2,6-difluoro-4-(methylsulfonyl)phenyl)-N 4 -(4-methoxybenzyl)-N 4 -(1-(4-methoxybenzyl)-5-methyl-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (65 mg, yield 25%). UPLC-MS (+ESI) m / z=741.3 (M+H) + .
[0647] Step 3 / 5-Cyclopropyl-N 2 -(2,6-difluoro-4-(methylsulfonyl)phenyl)-N 4 -(4-methoxybenzyl)-N 4 -(1-(4-methoxybenzyl)-5-methyl-1H-pyrazol-3-yl)-N 2 -methyl-6-(1-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine
[0648] To 5-cyclopropyl-N- 2 -(2,6-difluoro-4-(methylsulfonyl)phenyl)-N 4 -(4-methoxybenzyl)-N 4NaH (4.0 mg, 104 μmol, 60% dispersion), MeI (20 μL, 321 μmol) were added to 5-(1-(4-methoxybenzyl)-5-methyl-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (65 mg, 87 μmol). The reaction mixture was stirred at rt for 1.5 hours. The reaction mixture was quenched with water (0.2 ml) and purified by preparative HPLC, eluting with a gradient of MeCN (30%-70%) in water (both containing 0.1% formic acid). The appropriate fractions were combined and lyophilized to provide 5-cyclopropyl-N 2 -(2,6-difluoro-4-(methylsulfonyl)phenyl)-N 4 -(4-methoxybenzyl)-N 4 -(1-(4-methoxybenzyl)-5-methyl-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine, which was used directly in the next step.
[0649] Step 4 / Compound 13
[0650] To the 5-cyclopropyl-N- 2 -(2,6-difluoro-4-(methylsulfonyl)phenyl)-N 4 -(4-methoxybenzyl)-N 4 -(1-(4-methoxybenzyl)-5-methyl-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine was added TFA (2 mL) and the mixture was heated at 120°C for 15 hours. The reaction mixture was evaporated, diluted in DMSO, and purified by preparative HPLC eluting with a gradient of MeCN (30%-70%) in water (both containing 0.1% formic acid). The appropriate fractions were combined and lyophilized to provide the desired product compound 13 (5 mg, 3% yield). UPLC-MS (+ESI) m / z=515.2 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ11.86(s,1H),8.29(d,J=26.1Hz,1H),7.82(d,J=6.8Hz,2H),7.68(s,1H),6.56(s,0.3H),5.33 (s,1H),3.88(s,3H),3.35(s,3H),3.33(s,3H),2.00(s,3H),1.78–1.67(m,1H),0.93–0.83(m,2H),0.04–-0.04(m,2H).
[0651] Compound 14 / Method B / 5-cyclopropyl-N 2 -(2,6-difluoro-4-(methylsulfonyl)phenyl)-N 2 -Methyl-N 4 -(5-methyl-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrimidine-2,4-diamine
[0652]
[0653] Step 1 / 5-cyclopropyl-N-(4-methoxybenzyl)-N-(1-(4-methoxybenzyl)-5-methyl-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)-2-(methylsulfonyl)pyrimidin-4-amine
[0654] To a solution of intermediate 9 (1.60 g, 2.82 mmol) in dioxane (40 mL) was added 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole (704 mg, 3.38 mmol), Pd(dppf)Cl2 (206 mg, 282 μmol), Cs2CO3 (1.84 g, 5.63 mmol) and water (10 mL). The reaction mixture was then stirred at 80°C for 1.5 hours. A second portion of 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole (250 mg, 1.20 mmol) and Pd(dppf)Cl2 (100 mg, 39 μmol) were added and the reaction mixture was stirred at 80°C for 1.5 hours. The reaction mixture was extracted with EtOAc and the organic phase was evaporated in vacuo. The crude material was purified by silica gel chromatography eluting with EtOAc (100%). The appropriate fractions were combined and evaporated to provide 5-cyclopropyl-N-(4-methoxybenzyl)-N-(1-(4-methoxybenzyl)-5-methyl-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)-2-(methylsulfonyl)pyrimidin-4-amine (800 mg, 46% yield). UPLC-MS (+ESI) m / z=614.3 (M+H) + .
[0655] Step 2 / 5-Cyclopropyl-N 2 -(2,6-difluoro-4-(methylsulfonyl)phenyl)-N 4 -(4-methoxybenzyl)-N 4 -(1-(4-methoxybenzyl)-5-methyl-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrimidine-2,4-diamine
[0656] A mixture of 2,6-difluoro-4-methylsulfonyl-aniline (122 mg, 589 μmol) and NaH (24.0 mg, 626 μmol, 60% dispersion) in DMPU (1 mL) was stirred at rt for 10 minutes. To this was added 5-cyclopropyl-N-(4-methoxybenzyl)-N-(1-(4-methoxybenzyl)-5-methyl-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)-2-(methylsulfonyl)pyrimidin-4-amine (300 mg, 489 μmol) and the reaction was heated at 130 °C overnight. The reaction mixture was purified by preparative HPLC eluting with a gradient of MeCN (30%-70%) in water (both containing 0.1% formic acid). The appropriate fractions were combined and lyophilized to provide 5-cyclopropyl-N-(4-methoxybenzyl)-N-(1-(4-methoxybenzyl)-5-methyl-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)-2-(methylsulfonyl)pyrimidin-4-amine (300 mg, 489 μmol). 2 -(2,6-difluoro-4-(methylsulfonyl)phenyl)-N 4 -(4-methoxybenzyl)-N 4 -(1-(4-methoxybenzyl)-5-methyl-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrimidine-2,4-diamine (29 mg, yield 8%). UPLC-MS (+ESI) m / z=741.3 (M+H) + .
[0657] Step 3, 4 / 5-cyclopropyl-N 2 -(2,6-difluoro-4-(methylsulfonyl)phenyl)-N 4 -(4-methoxybenzyl)-N 4 -(1-(4-methoxybenzyl)-5-methyl-1H-pyrazol-3-yl)-N 2 -methyl-6-(1-methyl-1H-pyrazol-4-yl)pyrimidine-2,4-diamine
[0658] To 5-cyclopropyl-N- 2 -(2,6-difluoro-4-(methylsulfonyl)phenyl)-N 4 -(4-methoxybenzyl)-N 4 NaH (3 mg, 75 μmol, 60% dispersion), MeI (10 μL, 161 μmol) were added to 1-(1-(4-methoxybenzyl)-5-methyl-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrimidine-2,4-diamine (29 mg, 39 μmol) and the reaction was stirred at rt for 1 hour. The reaction mixture was purified by preparative HPLC eluting with a gradient of MeCN (30%-70%) in water (both containing 0.1% formic acid). The appropriate fractions were combined and lyophilized to provide the intermediate 5-cyclopropyl-N ... 2-(2,6-difluoro-4-(methylsulfonyl)phenyl)-N 4 -(4-methoxybenzyl)-N 4 -(1-(4-methoxybenzyl)-5-methyl-1H-pyrazol-3-yl)-N 2 -Methyl-6-(1-methyl-1H-pyrazol-4-yl)pyrimidine-2,4-diamine. UPLC-MS (+ESI) m / z=755.9 (M+H) + . TFA (2 mL) was then added to the intermediate, and the mixture was heated at 120 °C overnight. The reaction mixture was evaporated, diluted in DMSO, and purified by preparative HPLC eluting with a gradient of MeCN (20%-70%) in water (both containing 0.1% formic acid). The appropriate fractions were combined and lyophilized to provide compound 14 (1.4 mg, 7% yield for two steps). UPLC-MS (+ESI) m / z=515.2 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ11.83(s,1H),8.26(d,J=16.6Hz,2H),7.98(d,J=25.5Hz,1H),7.82(d,J=6.8Hz,2H),6.58(s,0.2H),5.2 9(s,1H),3.87(s,3H),3.37(s,3H),3.33(s,3H),2.03(s,3H),1.72(tt,J=7.9,5.5Hz,1H),1.19–0.86(m,2H),0.34–0.07(m,2H).
[0659] Compound 15 / Method B / 5-cyclopropyl-N 2 -(4-(cyclopropylsulfonyl)-2-fluorophenyl)-N 2 -Methyl-N 4 -(5-methyl-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrimidine-2,4-diamine
[0660]
[0661] Step 1 / 5-Cyclopropyl-N 2 -(4-(cyclopropylsulfonyl)-2-fluorophenyl)-N 4 -(4-methoxybenzyl)-N 4 -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrimidine-2,4-diamine
[0662] To a solution of 5-cyclopropyl-N-(4-methoxybenzyl)-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)-2-(methylsulfonyl)pyrimidin-4-amine (see Compound 11, Step 1) (50.0 mg, 86.6 μmol) and 4-cyclopropylsulfonyl-2-fluoro-aniline (55.9 mg, 260 μmol) in DMPU (0.5 mL) was added NaH (10.4 mg, 260 μmol, 60% dispersion). The reaction mixture was stirred at 120 °C for 3 hours. The crude reaction mixture was quenched with water, diluted with EtOAc, quenched with saturated NaHCO3, and then extracted with EtOAc. The organic phase was washed with brine, dried over Na2SO4, filtered and evaporated to give the desired crude product 5-cyclopropyl-N-(4-methoxybenzyl)-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)-2-(methylsulfonyl)pyrimidin-4-amine as a yellow solid. 2 -(4-(cyclopropylsulfonyl)-2-fluorophenyl)-N 4 -(4-methoxybenzyl)-N 4 -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrimidine-2,4-diamine (60 mg) was used in the next step without purification. UPLC-MS (+ESI) m / z=713.4 (M+H) + .
[0663] Step 2 / 5-Cyclopropyl-N 2 -(4-(cyclopropylsulfonyl)-2-fluorophenyl)-N 4 -(4-methoxybenzyl)-N 2 -Methyl-N 4 -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrimidine-2,4-diamine
[0664] To the crude 5-cyclopropyl-N- 2 -(4-(cyclopropylsulfonyl)-2-fluorophenyl)-N 4 -(4-methoxybenzyl)-N 4-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrimidine-2,4-diamine (60 mg) was added NaH (10 mg, 240 μmol) followed by MeI (82 μL, 253 μmol) at rt for 1 hour. The crude reaction mixture was quenched with water, filtered, and purified by preparative HPLC eluting with a gradient of MeCN in water (both containing 0.1% formic acid). The appropriate fractions were combined and lyophilized to provide 5-cyclopropyl-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrimidine-2,4-diamine as a beige solid. 2 -(4-(cyclopropylsulfonyl)-2-fluorophenyl)-N 4 -(4-methoxybenzyl)-N 2 -Methyl-N 4 -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrimidine-2,4-diamine (23 mg, step 1 yield 37%). UPLC-MS (+ESI) m / z=727.4 (M+H) + .
[0665] Step 3 / Compound 15
[0666] To 5-cyclopropyl-N 2 -(4-(cyclopropylsulfonyl)-2-fluorophenyl)-N 4 -(4-methoxybenzyl)-N 2 -Methyl-N 4 -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrimidine-2,4-diamine (20.0 mg, 27.5 μmol) was added TFA (0.5 mL). The reaction mixture was stirred at 80 °C for 1 hour. The crude reaction mixture was evaporated, the residue was dissolved in DMSO and purified by preparative HPLC, eluting with a gradient of MeCN in water (both containing 0.1% formic acid). The appropriate fractions were combined and lyophilized to provide the desired product compound 15 (5.2 mg, 36% yield) as a white solid. UPLC-MS (+ESI) m / z=523.2 (M+H) + . 1H NMR (400MHz, DMSO-d6) δ11.86 (s, 1H), 8.27 (d, J = 3.9Hz, 1H), 8.24 (s, 1H), 7. 95(s,1H),7.84–7.77(m,2H),7.74(dd,J=8.7,7.0Hz,1H),5.63(s,1H),3.91 (s,3H),3.49(s,3H),2.96(td,J=8.0,4.8Hz,1H),2.04(s,3H),1.82–1.70(m ,1H),1.19(qd,J=4.9,2.3Hz,2H),1.16–1.03(m,4H),0.20(h,J=4.0Hz,2H).
[0667] Compound 16 / Method A / 5-cyclopropyl-N 2 -(2-fluoro-4-(methylsulfonyl)phenyl)-6-(1-methyl-1H-imidazol-4-yl)-N 4 -(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine
[0668]
[0669] Step 1 / 5-cyclopropyl-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-imidazol-4-yl)-2-(methylsulfonyl)pyrimidin-4-amine
[0670] To a solution of intermediate 7 (200 mg, 486 μmol) in dioxane (2 mL) was added tributyl-(1-methylimidazol-4-yl)stannane (198 mg, 534 μmol) and Pd(PPh3)4 (337 mg, 291 μmol). Nitrogen was bubbled through the reaction mixture, which was then stirred at 100°C for 18 hours. The crude reaction mixture was filtered and purified by preparative HPLC, eluting with a gradient of MeCN (10%-100%) in water (both containing 0.1% formic acid). The appropriate fractions were combined and lyophilized to provide 5-cyclopropyl-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-imidazol-4-yl)-2-(methylsulfonyl)pyrimidin-4-amine (30 mg, 14% yield). UPLC-MS (+ESI) m / z = 458.3 (M+H) + .
[0671] Step 2, 3 / Compound 16
[0672] To a solution of 5-cyclopropyl-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-imidazol-4-yl)-2-(methylsulfonyl)pyrimidin-4-amine (24 mg, 53 μmol) and 2-fluoro-4-methylsulfonyl-aniline (12 mg, 63 μmol) in DMPU (0.5 mL) was added NaH (4.2 mg, 115 μmol, 60% dispersion). The reaction mixture was stirred at 120 °C for 15 hours. The crude reaction mixture was quenched with water, filtered, and purified by preparative HPLC, eluting with a gradient of MeCN in water (both containing 0.1% formic acid). The appropriate fractions were combined and lyophilized to provide the intermediate 5-cyclopropyl-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-imidazol-4-yl)-2-(methylsulfonyl)pyrimidin-4-amine as a yellow solid. 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-N 4 -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-imidazol-4-yl)pyrimidine-2,4-diamine. UPLC-MS (+ESI) m / z=567.3 (M+H) + . TFA (0.5 mL) was then added thereto. The reaction mixture was stirred at rt for 15 hours. The crude reaction mixture was evaporated, diluted in DMSO, filtered and purified by preparative HPLC elution with a gradient of MeCN in water (both containing 0.1% formic acid). The appropriate fractions were combined and lyophilized to provide the desired product compound 16 (1.0 mg, 3.8% yield for steps 2 and 3) as a white solid. UPLC-MS (+ESI) m / z=483.2 (M+H) + .
[0673] Compound 17 / Method B / 5-cyclopropyl-N 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-N 2 -methyl-6-(1-methyl-1H-imidazol-4-yl)-N 4 -(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine
[0674]
[0675] Step 1 / 6-chloro-5-cyclopropyl-N 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-N 4 -(4-methoxybenzyl)-N 2 -Methyl-N 4 -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)pyrimidine-2,4-diamine
[0676] To a solution of intermediate 11 (390 mg, 798 μmol) in DMPU (3 mL) was added 2-fluoro-4-methylsulfonyl-aniline (302 mg, 1.60 mmol) at rt, followed by NaH (96 mg, 2.4 mmol, 60% dispersion). The mixture was heated to 120 °C and maintained for 4 hours. The mixture was cooled to rt, MeI (500 μL, 7.99 mmol) was added, and the mixture was stirred at rt for 1 hour. MeOH (1 mL) was added and the mixture was filtered on a celite column, concentrated, and purified by preparative HPLC using a gradient of MeCN (10%-100%) in water (both containing 0.1% formic acid). The appropriate fractions were combined and lyophilized to provide 6-chloro-5-cyclopropyl-N-(2-chloro-5-cyclopropyl)-1-yl-1-yl-2-thiazolyl-4-ol. 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-N 4 -(4-methoxybenzyl)-N 2 -Methyl-N 4 -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (255 mg, 49% yield) as a 9 / 1 mixture favoring the regioisomers of the title compound. Used as is in the next step. UPLC-MS (+ESI) m / z = 655.3 (M) + .
[0677] Step 2, 3 / Compound 17
[0678] To a solution of tributyl-(1-methylimidazol-4-yl)stannane (203 mg, 547 μmol) in dioxane (2 mL) was added 6-chloro-5-cyclopropyl-N 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-N 4 -(4-methoxybenzyl)-N 2 -Methyl-N 4 -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (112 mg, 171 μmol) and Pd(PPh3)4 (99 mg, 86 μmol). The mixture was degassed (in vacuum, then in nitrogen) and stirred at 130°C for 4 days. The crude reaction mixture was filtered and the supernatant was purified by preparative HPLC eluting with a gradient of MeCN (10%-100%) in water (both containing 0.1% formic acid). The appropriate fractions were combined and lyophilized to provide 5-cyclopropyl-N 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-N 4 -(4-methoxybenzyl)-N 2 -Methyl-N 4-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-imidazol-4-yl)pyrimidine-2,4-diamine (45 mg, yield 38%). TFA (1.5 mL) was then added thereto and the resulting mixture was stirred at 90°C for 4 hours. The mixture was concentrated and the residue was purified by preparative HPLC, eluting with a gradient of MeCN (10%-25%) in water (both containing 0.1% formic acid). The appropriate fractions were combined and lyophilized to provide compound 17 (20 mg, yield 63%). UPLC-MS (+ESI) m / z=497.2 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ9.33(s,1H),8.25(s,1H),8.11(s,1H),8.07–7.98(m,1H),7.83(s,1H),7.78(dd,J=8.1,1.9Hz,1H),7.71(dd,J=8.1,1 .9Hz,1H),5.48(s,1H),3.97(ddd,J=19.3,10.2,6.0Hz,3H),3.87(s,3H),3.61(s,3H),3.51(dd,J=9.0,4.1Hz,2H),3.03(s,3H),2.03(s,3H).
[0679] Compound 18 / Method A / 5-cyclopropyl-2-(2-fluoro-4-(methylsulfonyl)phenoxy)-N-(5-methyl-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrimidin-4-amine
[0680]
[0681] Step 1 / 5-cyclopropyl-2-(2-fluoro-4-(methylsulfonyl)phenoxy)-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrimidin-4-amine
[0682] To 2-fluoro-4-methylsulfonyl-phenol (42 mg, 221 μmol) in MeCN (3 mL) was added NaH (10 mg, 250 μmol, 60% dispersion) and stirred at rt for 10 minutes. To this mixture was added 5-cyclopropyl-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)-2-(methylsulfonyl)pyrimidin-4-amine (see Compound 10, Step 1) (50 mg, 110 μmol) and the reaction mixture was heated in a microwave at 170° C. for 75 minutes. The reaction mixture was evaporated in vacuo, dissolved in DMSO and purified by preparative HPLC eluting with a gradient of MeCN (40%-70%) in water (both containing 0.1% formic acid). The relevant fractions were combined and lyophilized to give 5-cyclopropyl-2-(2-fluoro-4-(methylsulfonyl)phenoxy)-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrimidin-4-amine (9.2 mg, yield 15%). UPLC-MS (+ESI) m / z=568.2 (M+H) + .
[0683] Step 2 / Compound 18
[0684] To 5-cyclopropyl-2-(2-fluoro-4-(methylsulfonyl)phenoxy)-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrimidin-4-amine (9.2 mg, 16 μmol) in dioxane (1 mL) was added HCl / dioxane (0.1 mL, 4N), and the mixture was stirred at rt overnight. The solvent was evaporated in vacuo to give compound 18 (5.8 mg, yield 74%). UPLC-MS (+ESI) m / z=484.1 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ8.84(s,1H),8.27(s,1H),7.98(dd,J=9.7,2.1Hz,1H),7.92(d,J=0.7Hz,1H),7.87–7.81(m,1H),7.66(dd,J=8.4,7.6 Hz,1H),3.87(s,3H),3.29(s,3H),2.01(d,J=0.7Hz,3H),1.78(ddd,J=13.7,8.1,5.7Hz,1H),1.25–1.08(m,2H),0.19(dt,J=6.0,2.9Hz,2H).
[0685] Compound 19 / Method C / N 6 -(2-Fluoro-4-(methylsulfonyl)phenyl)-3-methoxy-N 6 -Methyl-N 2 -(5-methyl-1H-pyrazol-3-yl)-4-(1-methyl-1H-pyrazol-4-yl)pyridine-2,6-diamine
[0686]
[0687] Step 1 / 4-Bromo-6-chloro-2-fluoropyridin-3-ol
[0688] 6-Chloro-2-fluoropyridin-3-ol (3.00 g, 20.3 mmol) in a mixture of MeCN (50 mL) and water (25 mL) was dissolved in a round-bottom flask. Br2 (1.04 mL, 20.3 mmol) was then added dropwise and the reaction was stirred at rt. After 2 hours, the crude material was evaporated to dryness and directly purified by silica gel chromatography, eluting with EtOAc (0-30%) in heptane. The appropriate fractions were combined and concentrated to provide 4-bromo-6-chloro-2-fluoropyridin-3-ol (5.0 g, yield 99%) as an orange oil. UPLC-MS (+ESI) m / z=228.0 (M+H) + . 1 H NMR (400MHz, CDCl3) δppm 6.42 (br s, 1H), 7.38 (s, 1H). 19 F NMR (377MHz, CDCl3) δppm-83.73 (s, 1F).
[0689] Step 2 / 4-Bromo-6-chloro-2-fluoro-3-methoxypyridine
[0690] In a round-bottom flask, Cs2CO3 (411mg, 1.26mmol) was added to a solution of 4-bromo-6-chloro-2-fluoropyridine-3-ol (500mg, 2.21mmol) in DMF (14mL). Then MeI (275μL, 4.42mmol) was added, and the reaction mixture was stirred at rt for 18 hours. The reaction mixture was diluted in MeTHF and washed with saturated NaHCO3 solution. The aqueous layer was extracted with MeTHF (3x). The combined organic layer was washed with brine, dried over Na2SO4, filtered and concentrated under vacuum. The crude mixture was purified by silica gel chromatography and eluted with EtOAc (0-30%) in heptane. Suitable fractions were combined and concentrated to obtain 4-bromo-6-chloro-2-fluoro-3-methoxypyridine (500mg, 95% yield) as a pale yellow solid. 1H NMR (400MHz, CDCl3) δppm 4.00 (d, J = 2.2Hz, 3H), 7.42 (s, 1H). 19 F NMR (377MHz, CDCl3) δppm-77.15 (s, 1F).
[0691] Step 3 / 6-Chloro-2-fluoro-3-methoxy-4-(1-methyl-1H-pyrazol-4-yl)pyridine
[0692] 4-Bromo-6-chloro-2-fluoro-3-methoxypyridine (500 mg, 2.08 mmol) in 1,4-dioxane / water (3 / 1) was loaded in a sealable tube. (1-Methyl-1H-pyrazol-4-yl)boronic acid (288 mg, 2.29 mmol) and Cs2CO3 (2.00 g, 6.24 mmol) were then added, and the mixture was purged with nitrogen for 10 minutes. Pd(dppf)Cl2 (170 mg, 0.21 mmol) was added, and the suspension was purged with nitrogen for another 10 minutes. The reaction mixture was stirred at 90 °C for 18 hours. The reaction was filtered through a pad of celite and washed with EtOAc. The combined supernatant was concentrated in vacuo. The residue was purified by preparative HPLC, eluting with a gradient of MeCN (5%-95%) in water (both containing 0.1% formic acid). The appropriate fractions were combined and lyophilized to provide 6-chloro-2-fluoro-3-methoxy-4-(1-methyl-1H-pyrazol-4-yl)pyridine (375 mg, 75% yield) as a yellow solid. UPLC-MS (+ESI) m / z = 242.2 (M+H) + . 1 H NMR (400MHz, CDCl3) δppm 3.95 (d, J = 2.2Hz, 3H), 4.00 (s, 3H), 7.31 (s, 1H), 7.94 (s, 1H), 7.98 (s, 1H). 19 F NMR (377MHz, CDCl3) δppm-79.93 (s, 1F).
[0693] Step 4 / 6-Chloro-3-methoxy-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-4-(1-methyl-1H-pyrazol-4-yl)pyridin-2-amine
[0694] In a sealed tube, 1M NaHMDS in THF (6.21 mL, 6.21 mmol) was added to a solution of 6-chloro-2-fluoro-3-methoxy-4-(1-methyl-1H-pyrazol-4-yl)pyridine (422 mg, 2.33 mmol) in THF (39 mL) at rt. Intermediate 1 (375 mg, 1.55 mmol) was then added and the reaction was sealed and stirred at 80 °C for 3 hours. The reaction was quenched with H2O and the aqueous layer was extracted with EtOAc (3x). The combined organic layers were dried over Na2SO4, filtered and concentrated under vacuum. The residue was purified by preparative HPLC, eluting with a gradient of MeCN (5%-95%) in water (both containing 0.1% formic acid). The appropriate fractions were combined and lyophilized to provide 6-chloro-3-methoxy-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-4-(1-methyl-1H-pyrazol-4-yl)pyridin-2-amine (484 mg, 77% yield) as a brown solid. UPLC-MS (+ESI) m / z = 403.2 (M+H) + . 1 H NMR (400MHz, CDCl3) δppm 1.55-1.62(m,1H),1.65-1.79(m,2H),1.83-1.93(m,1H),2.05-2.16(m,1H),2.37(s,3H),2.38-2.43(m,1H),3.65(s,3H),3.66-3.72 (m,1H),3.99(s,3H),4.08-4.17(m,1H),5.18(dd,J=10.3,2.2Hz,1H),6.78(s,1H),6.80(s,1H),7.74(s,1H),7.90(d,J=3.9Hz,2H).
[0695] Step 5 / N 6 -(2-Fluoro-4-(methylsulfonyl)phenyl)-3-methoxy-N 6 -Methyl-N 2 -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-4-(1-methyl-1H-pyrazol-4-yl)pyridine-2,6-diamine
[0696] A flame-dried sealed tube was charged with 6-chloro-3-methoxy-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-4-(1-methyl-1H-pyrazol-4-yl)pyridin-2-amine (50.0 mg, 0.12 mmol) in toluene (1.20 mL). 2-Fluoro-4-methanesulfonyl-N-methylaniline (37.8 mg, 0.190 mmol), Cs2CO3 (121 mg, 0.370 mmol) and + / -BINAP (31 mg, 0.050 mmol) were added and the mixture was purged with nitrogen for 10 minutes. Pd(OAc)2 (5.6 mg, 0.025 mmol) was added and the suspension was purged with nitrogen for another 10 minutes. The reaction mixture was stirred at 95 °C for 18 hours. The reaction mixture was filtered through a pad of celite and washed with EtOAc. The solvent was removed in vacuo and the crude residue was purified by preparative HPLC eluting with a gradient of MeCN (5-95%) in water (both containing 0.1% formic acid). The appropriate fractions were combined and lyophilized to provide N 6 -(2-Fluoro-4-(methylsulfonyl)phenyl)-3-methoxy-N 6 -Methyl-N 2 -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-4-(1-methyl-1H-pyrazol-4-yl)pyridine-2,6-diamine (35 mg, 50% yield). UPLC-MS (+ESI) m / z=570.2 (M+H) + . 1 H NMR (400MHz, CDCl3) δppm1.82-1.90(m,2H),2.03-2.13(m,2H),2.22(s,3H),2.33-2.41(m,1H),3.11(s,3H),3.47(s,3H),3.60(s,3H),3.62- 3.69(m,1H),3.98(s,3H),4.07-4.13(m,1H),5.09-5.15(m,1H),6.05( s,1H),6.17(s,1H),7.52-7.55(m,2H),7.68-7.77(m,2H),7.87(s,2H).
[0697] Step 6 / Compound 19
[0698] A 37% HCl solution in MeOH (735 μL) was added to N 6 -(2-Fluoro-4-(methylsulfonyl)phenyl)-3-methoxy-N 6 -Methyl-N 2-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-4-(1-methyl-1H-pyrazol-4-yl)pyridine-2,6-diamine (34.0 mg, 0.060 mmol) in MeOH (1 mL). The reaction mixture was stirred at 50 °C for 4 hours. The reaction was concentrated under vacuum and co-evaporated with MeCN (2x). The crude residue was purified by preparative HPLC, eluting with a gradient of MeCN (5%-95%) in water (both containing 0.1% formic acid). The appropriate fractions were combined and lyophilized to provide compound 19 as a white solid (13 mg, 45% yield). UPLC-MS (+ESI) m / z=486.1 (M+H) + . 1 HNMR(400MHz,DMSO-d6)δppm 2.00(s,3H),3.30(s,3H),3.41(s,3H),3.56(s,3H),3.91(s,3H),5.55(s,1H),6 .43(s,1H),7.66(t,J=7.9Hz,1H),7.75-7.84(m,2H),8.01(s,1H),8.28(s,1H). 19 F NMR (377MHz, CDCl3) δppm-114.57 (br s, 1F).
[0699] Compound 20 / Method C / 3-cyclopropyl-N 6 -(2-Fluoro-4-(methylsulfonyl)phenyl)-N 6 -Methyl-N 2 -(5-methyl-1H-pyrazol-3-yl)-4-(1-methyl-1H-pyrazol-4-yl)pyridine-2,6-diamine
[0700]
[0701] Step 1 / 6-Chloro-2-fluoro-4-(1-methyl-1H-pyrazol-4-yl)pyridin-3-ol
[0702] Under nitrogen, 4-bromo-6-chloro-2-fluoropyridin-3-ol (Compound 19, Step 1) (600 mg, 2.60 mmol), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (607 mg, 2.90 mmol), tri-tert-butylphosphine (530 μL, 0.50 mmol) and K3PO4 (1.10 g, 5.30 mmol) in dioxane (12 mL) and water (6 mL) were dissolved in a Schlenk flask. The solution was purged with nitrogen for 10 minutes. Pd(dba)3 (243 mg, 0.260 mmol) was then added. The mixture was purged with nitrogen for another 10 minutes, and the reaction was sealed and stirred at 90°C. After 3 hours, the reaction was cooled to rt and filtered through a pad of celite, washing with EtOAc. The organic layer was concentrated and the residue was purified by preparative HPLC eluting with a gradient of MeCN (5%-100%) in water (both containing 0.1% formic acid). The appropriate fractions were combined and lyophilized to provide 6-chloro-2-fluoro-4-(1-methyl-1H-pyrazol-4-yl)pyridin-3-ol (166 mg, 28% yield) as a light yellow solid. UPLC-MS (+ESI) m / z=228.2 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δppm 3.91 (s, 3H), 7.67 (s, 1H), 8.17 (s, 1H), 8.41 (s, 1H), 10.74 (br s, 1H). 19 F NMR (377MHz, DMSO-d6) δppm-86.28 (s, 1F).
[0703] Step 2 / 6-Chloro-2-fluoro-4-(1-methyl-1H-pyrazol-4-yl)pyridin-3-yl trifluoromethanesulfonate
[0704] Under nitrogen, 6-chloro-2-fluoro-4-(1-methyl-1H-pyrazol-4-yl)pyridin-3-ol (166 mg, 0.72 mmol) in anhydrous DCM (5 mL) was dissolved in a round bottom flask. Pyridine (176 μL, 2.20 mmol) was then added, followed by dropwise addition of Tf2O (135 μL, 0.80 mmol). The reaction was stirred at rt for 2 hours, then evaporated to dryness and purified on silica gel chromatography, eluting with EtOAc (0-80%) in heptane. The appropriate fractions were combined and concentrated in vacuo to provide 6-chloro-2-fluoro-4-(1-methyl-1H-pyrazol-4-yl)pyridin-3-yl trifluoromethanesulfonate (126 mg, 48% yield) as a white solid. UPLC-MS (+ESI) m / z=360.0 (M+H) + .1 H NMR (400MHz, CDCl3) δppm 4.02 (s, 3H), 7.39 (s, 1H), 7.90 (s, 1H), 7.96 (s, 1H). 19 F NMR (377MHz, CDCl3) δppm -76.41 (q, J=15.9Hz, 1F), -72.60 (d, J=15.0Hz, 3F).
[0705] Step 3 / 6-Chloro-3-cyclopropyl-2-fluoro-4-(1-methyl-1H-pyrazol-4-yl)pyridine
[0706] Under N2, 6-chloro-2-fluoro-4-(1-methyl-1H-pyrazol-4-yl)pyridin-3-yl trifluoromethanesulfonate (126 mg, 0.35 mmol), cyclopropyl-BF3K (62.2 mg, 0.42 mmol), K2CO3 (145 mg, 1.05 mmol) and Ruphos (32.7 mg, 0.070 mmol) in a mixture of toluene (3 mL) and water (1.5 mL) were dissolved in a Schlenk flask. The reaction mixture was purged with nitrogen for 10 minutes, then Pd(OAc)2 (7.9 mg, 0.030 mmol) was added, and the reaction was purged for another 10 minutes. The flask was sealed and heated at 90°C. After 3 hours, the reaction was cooled to rt, filtered through a celite pad, and washed with EtOAc. The supernatant was concentrated and the residue was purified by preparative HPLC eluting with a gradient of MeCN (5%-100%) in water (both containing 0.1% formic acid). The appropriate fractions were combined and lyophilized to provide 6-chloro-3-cyclopropyl-2-fluoro-4-(1-methyl-1H-pyrazol-4-yl)pyridine (34 mg, 39% yield) as an off-white solid. UPLC-MS (+ESI) m / z = 252.2 (M+H) + . 1 H NMR (400MHz, CDCl3) δppm 0.60-0.66(m,2H),1.00-1.07(m,2H),1.73-1.81(m,1H),4.01(s,3H),7.21(s,1H),7.76(s,1H),7.84(s,1H). 19 F NMR (377MHz, CDCl3) δppm-66.57 (s, 1F).
[0707] Step 4 / 6-Chloro-3-cyclopropyl-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-4-(1-methyl-1H-pyrazol-4-yl)pyridin-2-amine
[0708] Under nitrogen, 6-chloro-3-cyclopropyl-2-fluoro-4-(1-methyl-1H-pyrazol-4-yl)pyridine (47.5 mg, 0.260 mmol) in anhydrous THF (3 mL) was dissolved in a vial. NaHMDS (700 μL, 0.700 mmol) was then added dropwise and stirred at rt for 5 minutes. Intermediate 1 (44.0 mg, 0.17 mmol) was then added and the reaction mixture was sealed and stirred at 80 °C. The reaction was stopped after 1.5 hours and evaporated to dryness. The crude residue was purified by preparative HPLC, eluting with a gradient of MeCN (5%-100%) in water (both containing 0.1% formic acid). The appropriate fractions were combined and lyophilized to provide 6-chloro-3-cyclopropyl-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-4-(1-methyl-1H-pyrazol-4-yl)pyridin-2-amine (53 mg, 73% yield) as a yellow solid. UPLC-MS (+ESI) m / z = 413.2 (M+H) + . 1 H NMR (400MHz, CDCl3) δppm 0.34-0.40(m,2H),1.07-1.13(m,2H),1.64-1.69(m,4H),1.86-1.92(m,1H),2.06-2.13(m,1H),2.37(s,3H),2.39-2.49(m,1H),3. 63-3.71(m,1H),3.99(s,3H),4.10-4.16(m,1H),5.18(dd,J=10.4,2.3Hz,1H),6.72(s,1H),6.78(s,1H),7.62(s,1H),7.73(s,2H).
[0709] Step 5 / 3-Cyclopropyl-N 6 -(2-Fluoro-4-(methylsulfonyl)phenyl)-N 6 -Methyl-N 2 -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-4-(1-methyl-1H-pyrazol-4-yl)pyridine-2,6-diamine
[0710] 6-Chloro-3-cyclopropyl-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-4-(1-methyl-1H-pyrazol-4-yl)pyridin-2-amine (53 mg, 0.12 mmol) and 2-fluoro-N-methyl-4-(methylsulfonyl)aniline (39 mg, 0.19 mmol) in anhydrous toluene (1.25 mL) were dissolved in a vial. Cs2CO3 (126 mg, 0.38 mmol) and + / -BINAP (32 mg, 0.051 mmol) were then added. The solution was purged with nitrogen for 15 minutes. Pd(OAc)2 (5.8 mg, 0.02 mmol) was added and purged for 5 minutes. The flask was sealed and heated at 95°C. After 3 hours, the reaction mixture was cooled to rt, filtered through a celite pad and washed with EtOAc. The supernatant was concentrated and the residue was purified by preparative HPLC eluting with a gradient of MeCN (5%-100%) in water (both containing 0.1% formic acid). Appropriate fractions were combined and lyophilized to provide 3-cyclopropyl-N-(2-(4-nitropropane)-1-yl)-1-nitropropane as a pale yellow solid. 6 -(2-Fluoro-4-(methylsulfonyl)phenyl)-N 6 -Methyl-N 2 -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-4-(1-methyl-1H-pyrazol-4-yl)pyridine-2,6-diamine (30.0 mg, yield 40%). UPLC-MS (+ESI) m / z=580.2 (M+H) + . 1 H NMR (400MHz, CDCl3) δppm 0.29-0.35(m,2H),0.97-1.04(m,2H),1.67-1.73(m,J=9.5Hz,4H),1.84-1.8 8(m,1H),2.05-2.12(m,1H),2.22(s,3H),2.34-2.47(m,1H),3.10(s,3H),3.4 6(s,3H),3.59-3.69(m,1H),3.97(s,3H),4.07-4.13(m,1H),5.12(dd,J=10.5 ,2.2Hz,1H),6.05(s,1H),6.08(s,1H),7.52-7.57(m,2H),7.65-7.73(m,3H). 19 F NMR (377MHz, CDCl3) δppm-113.50 (s, 1F).
[0711] Step 6 / Compound 20
[0712] 3-Cyclopropyl-N 6-(2-Fluoro-4-(methylsulfonyl)phenyl)-N 6 -Methyl-N 2 -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-4-(1-methyl-1H-pyrazol-4-yl)pyridine-2,6-diamine (27 mg, 0.04 mmol) was dissolved in 3M HCl solution in MeOH (776 μL, 2.32 mmol) and stirred at rt for 1 hour, then warmed to 50°C for 4 hours. The crude mixture was evaporated to dryness and the residue was purified by preparative HPLC eluting with a gradient of MeCN (5%-100%) in water (both containing 0.1% formic acid). The appropriate fractions were combined and lyophilized to provide compound 20 (14.7 mg, 65% yield) as a white solid. UPLC-MS (+ESI) m / z=496.1 (M+H) + . 1 H NMR(400MHz,DMSO-d6)δppm 0.09-0.15(m,2H),1.03-1.10(m,2H),1.77-1.84(m,1H),2.11-2.15(m,3H),3.32(s,3H),3.43(s,3H ),3.90(s,3H),5.78(s,1H),6.42(s,1H),7.71-7.77(m,1H),7.84-7.90(m,3H),8.19(s,1H),8.95(br s,1H). 19 F NMR (377MHz, DMSO-d6) δppm-115.14 (s, 1F).
[0713] Compound 21 / Method C / 6-((2-Fluoro-4-(methylsulfonyl)phenyl)thio)-3-methoxy-N-(5-methyl-1H-pyrazol-3-yl)-4-(1-methyl-1H-pyrazol-4-yl)pyridin-2-amine
[0714]
[0715] Step 1 / 6-Chloro-3-methoxy-N-(5-methyl-1H-pyrazol-3-yl)-4-(1-methyl-1H-pyrazol-4-yl)pyridin-2-amine
[0716] 3M HCl in MeOH (10.7 mL, 42.7 mmol) was added to a mixture of 6-chloro-3-methoxy-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-4-(1-methyl-1H-pyrazol-4-yl)pyridin-2-amine (Compound 19, Step 4) (344 mg, 0.85 mmol) in MeOH (8.3 mL, 0.1 M). The reaction mixture was stirred at 50 °C for 2 hours. The reaction mixture was concentrated under vacuum and co-evaporated twice with MeCN. The residue was purified by reverse phase preparative HPLC eluting with a gradient of MeCN (5%-95%) in water (both containing 0.1% formic acid). The appropriate fractions were combined and lyophilized to provide 6-chloro-3-methoxy-N-(5-methyl-1H-pyrazol-3-yl)-4-(1-methyl-1H-pyrazol-4-yl)pyridin-2-amine (228 mg, 84% yield) as a brown solid. UPLC-MS (+ESI) m / z = 319.2 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δppm 2.35(s,3H),3.67(s,3H),3.92(s,3H),6.44(s,1H),7.33(s,1H),8.12(s,1H),8.41(s,1H),10.03(s,1H).
[0717] Step 2 / Compound 21
[0718] In a sealed tube, pivalic acid (160 mg, 1.57 mmol) was added to a solution of 6-chloro-3-methoxy-N-(5-methyl-1H-pyrazol-3-yl)-4-(1-methyl-1H-pyrazol-4-yl)pyridine-2-amine (100 mg, 0.31 mmol) in dioxane (1 mL, 0.3 M). Then 2-fluoro-4-methylsulfonylbenzene-1-thiol (97.1 mg, 0.47 mmol) was added, and the reaction mixture was stirred at 120 ° C for 6 hours. 2-fluoro-4-methylsulfonylbenzene-1-thiol (97.1 mg, 0.47 mmol) was added again, and the reaction mixture was stirred at 120 ° C for another 18 hours. The reaction was quenched with saturated NaHCO3 aqueous solution and extracted with MeTHF (3X). The combined organic layer was washed with brine, dried over Na2SO4, filtered and concentrated under vacuum. The residue was purified by preparative HPLC eluting with a gradient of MeCN (5%-95%) in water (both containing 0.1% formic acid). The appropriate fractions were combined and lyophilized to provide compound 21 as a white solid (17 mg, 11% yield). UPLC-MS (+ESI) m / z = 489.1 (M+H) + .1 HNMR(400MHz,DMSO-d6)δppm 2.02(s,3H),3.29(br s,3H),3.63(s,3H),3.91(s,3H),5.54(s,1H),7.16(br s,1H),7.77-7.83(m,1H),7.83-7.92(m,2H),8.03(s,1H),8.33(s,2H),11.70-11.85(m,1H). 19 F NMR (377MHz, CDCl3) δppm-104.75 (br s, 1F).
[0719] Compound 22 / Method D / 6-((2-Fluoro-4-(methylsulfonyl)phenyl)thio)-3-methoxy-5-methyl-N-(5-methyl-1H-pyrazol-3-yl)-4-(1-methyl-1H-pyrazol-4-yl)pyridin-2-amine
[0720]
[0721] Step 1 / 2, 4-dibromo-6-chloro-5-methylpyridin-3-ol
[0722] To a solution of 6-chloro-5-methylpyridin-3-ol (4.67 g, 32.5 mmol) in MeCN (103 mL) and water (34 mL) was added bromine (3.74 mL, 72.9 mmol) dropwise at rt under nitrogen atmosphere (10 min). The reaction mixture was stirred at rt for 20 h. A 10% aqueous solution of Na2S2O3 was added until the red color disappeared, the volatiles were removed under vacuum and the resulting mixture was extracted with DCM (3x). The combined organic phases were washed with H2O, brine, dried over Na2SO4, filtered and concentrated to give 2,4-dibromo-6-chloro-5-methylpyridin-3-ol (10.39 g, quantitative, crude) as a light yellow solid. The product was used in the next step without further purification. UPLC-MS (+ESI) m / z=301.8 (M+H) + . 1 H NMR (400MHz, CDCl3) δppm 2.51 (s, 3H), 5.88 (br s, 1H).
[0723] Step 2 / 2,4-Dibromo-6-chloro-3-methoxy-5-methylpyridine
[0724] At rt and under nitrogen atmosphere, MeI (4.64 mL, 74.6 mmol) was added dropwise to a suspension of 2,4-dibromo-6-chloro-5-methylpyridine-3-ol (11.24 g, 37.30 mmol) and Cs2CO3 (24.3 g, 74.6 mmol) in DMF (233 mL). The reaction mixture was stirred at rt for 15 hours and then poured into water (1000 mL). The mixture was stirred for 5 minutes and the precipitate was collected by filtration. The filter cake was washed with water and dried in vacuo on a Buchner funnel for 1 hour to obtain a wet solid. It was then dissolved in DCM (200 mL). The solution was dried over Na2SO4, filtered and concentrated to obtain 2,4-dibromo-6-chloro-3-methoxy-5-methylpyridine (9.68 g, crude material) as an off-white solid. The product was used in the next step without further purification. UPLC-MS (+ESI) m / z = 315.8 (M+H) + . 1 H NMR (400MHz, CDCl3) δppm 2.50 (s, 3H), 3.92 (s, 3H).
[0725] Step 3 / 4-Bromo-6-chloro-3-methoxy-5-methyl-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)pyridin-2-amine
[0726] A solution of intermediate 1 (1.90 g, 10.5 mmol), 2,4-dibromo-6-chloro-3-methoxy-5-methylpyridine (3.00 g, 9.51 mmol), Xanthphos (1.65 g, 2.85 mmol) and K2CO3 (3.94 g, 28.5 mmol) in dioxane (51 mL) was purged with nitrogen for 10 minutes, and then Pd(OAc)2 (320 mg, 1.43 mmol) was added to the mixture. Purging was continued for 5 minutes, the vial was sealed and stirred at 100°C for 18 hours. The reaction mixture was filtered on celite, concentrated to dryness, and purified by silica gel chromatography, eluting with EtOAc (0-60%) in heptane. The appropriate fractions were combined and concentrated in vacuo to provide 4-bromo-6-chloro-3-methoxy-5-methyl-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)pyridin-2-amine (2.31 g, 58% yield) as a yellow solid. UPLC-MS (+ESI) m / z = 415 (M+H) +. 1HNMR (400MHz, CDCl3) δppm 1.63-1.79(m,2H),1.83-1.91(m,1H),2.06-2.13(m,1H),2.31-2.38(m,4H),2.38-2.44(m,4H),3.62(dt,J =11.5,2.2Hz,1H),3.84(s,3H),4.05-4.17(m,1H),5.18(dd,J=10.5,2.4Hz,1H),6.72(s,1H),7.43(s,1H).
[0727] Step 4 / 6-Chloro-3-methoxy-5-methyl-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-4-(1-methyl-1H-pyrazol-4-yl)pyridin-2-amine
[0728] A solution of 4-bromo-6-chloro-3-methoxy-5-methyl-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)pyridin-2-amine (2.31 g, 5.56 mmol), 1-methylpyrazol-4-ylboronic acid (735 mg, 5.83 mmol), NaHCO3 (1.87 g, 22.2 mmol) in water (11 mL) and dioxane (32 mL) was purged with nitrogen for 10 minutes, then Pd(PPh3)4 (642 mg, 0.56 mmol) was added and purging continued for 5 minutes. The vial was sealed and heated at 100°C for 18 hours. The reaction mixture was filtered on a pad of celite, concentrated to dryness, and the residue was purified by preparative HPLC eluting with a gradient of MeCN (5%-100%) in water (both containing 0.1% formic acid). The appropriate fractions were combined and lyophilized to provide 6-chloro-3-methoxy-5-methyl-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-4-(1-methyl-1H-pyrazol-4-yl)pyridin-2-amine (584 mg, 25% yield) as a light yellow solid. UPLC-MS (+ESI) m / z = 417.2 (M+H) + . 1H NMR (400MHz, CDCl3) δppm 1.57-1.60(m,1H),1.62-1.81(m,2H),1.84-1.91(m,1H),2.05-2.13(m,1H),2.24(s,3H),2.33-2.45(m,4H),3.38(s,3H),3 .66(dt,J=11.2,2.0Hz,1H),4.00(s,3H),4.11(dt,J=11.6,1.9Hz,1H),5.17(dd,J=10.3,2.4Hz,1H),6.77(s,1H),7.47(br s,1H),7.56(s,1H),7.63(s,1H).
[0729] Step 5 / Compound 22
[0730] In a sealed tube, a solution of 6-chloro-3-methoxy-5-methyl-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-4-(1-methyl-1H-pyrazol-4-yl)pyridin-2-amine (220 mg, 0.53 mmol) and 2-fluoro-4-(methylsulfonyl)benzenethiol (163 mg, 0.79 mmol) in iPrOH (1 mL) was purged with nitrogen for 5 minutes. The tube was sealed and the mixture was stirred at 120 ° C for 15 hours. The mixture was concentrated and the residue was purified by preparative HPLC, eluting with a gradient of MeCN (5%-100%) in water (both containing 0.1% formic acid). The appropriate fractions were combined and lyophilized to provide Compound 22 (48 mg, 17% yield) as a light yellow solid. UPLC-MS (+ESI) m / z = 503.1 (M+H) + . 1 H NMR(400MHz,DMSO-d6)δppm 1.93-2.03(m,3H),2.22(s,3H),3.31(s,3H),3.34(s,3H),3.93(s,3H),5.29(s,1H),7.65(s,1H),7.80-7.92(m,3H),7.98(s,1H),8.34(br s,1H),11.58(br s,1H). 19 FNMR (377MHz, DMSO-d6) δppm-103.61 (br s, 1F).
[0731] Compound 23 / Method D / N 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-5-methoxy-3-methyl-N 6-(5-methyl-1H-pyrazol-3-yl)-4-(1-methyl-1H-pyrazol-4-yl)pyridine-2,6-diamine
[0732]
[0733] Step 1 / N 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-5-methoxy-3-methyl-N 6 -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-4-(1-methyl-1H-pyrazol-4-yl)pyridine-2,6-diamine
[0734] A solution of 6-chloro-3-methoxy-5-methyl-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-4-(1-methyl-1H-pyrazol-4-yl)pyridin-2-amine (see Compound 22, Step 3) (100 mg, 0.24 mmol), 2-fluoro-4-(methylsulfonyl)aniline (68 mg, 0.36 mmol), Cs2CO3 (235 mg, 0.72 mmol), + / -BINAP (60 mg, 0.096 mmol) in toluene (2.3 mL) was purged with nitrogen for 15 minutes, then Pd(OAc)2 (11 mg, 0.048 mmol) was added and purging was continued for 5 minutes. The vial was sealed and heated at 95°C for 18 hours. The reaction mixture was filtered through a pad of celite, concentrated to dryness, and the residue was purified by preparative HPLC eluting with a gradient of MeCN (5%-100%) in water (both containing 0.1% formic acid). Appropriate fractions were combined and lyophilized to provide N 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-5-methoxy-3-methyl-N 6 -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-4-(1-methyl-1H-pyrazol-4-yl)pyridine-2,6-diamine (120 mg, yield 85%). UPLC-MS (+ESI) m / z=570.2 (M+H) + . 1H NMR (400MHz, CDCl3) δppm 1.59-1.63(m,1H),1.66-1.80(m,2H),1.88-1.96(m,1H),2.07-2.14(m,1H),2.18(s,3H),2.32(s,3H),2.36-2.49 (m,1H),3.06(s,3H),3.39(s,3H),3.64-3.69(m,1H),4.02(s,3H),4.14-4.16(m,1H),5.14-5.23(m,1H),6.46(br s,1H),6.57-6.62(m,1H),7.41(s,1H),7.56-7.68(m,4H),8.43(s,1H).
[0735] Step 2 / Compound 23
[0736] To N 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-5-methoxy-3-methyl-N 6 To a solution of -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-4-(1-methyl-1H-pyrazol-4-yl)pyridine-2,6-diamine (120 mg, 0.18 mmol) in MeOH (5.4 mL) was added HCl solution (37% in water, 1.0 mL, 12 mmol), and the reaction mixture was stirred at 50 °C until completion by UPLC-MS analysis (approximately 1.5 hours). The reaction was quenched with NaOH (1 M), concentrated to dryness, and purified by preparative HPLC eluting with a gradient of MeCN (5%-100%) in water (both containing 0.1% formic acid). The appropriate fractions were combined and lyophilized to provide Compound 23 (34 mg, 98% yield) as a light yellow solid. UPLC-MS (+ESI) m / z=486.1 (M+H) + . 1 H NMR (400MHz, DMSO) δppm 2.03-2.12 (m, J=2.9Hz, 6H), 3.21 (s, 3H), 3.35 (s, 3H), 3.93 (s, 3H), 5.89 (br s,1H),7.40-7.66(m,3H),7.70(d,J=1.0Hz,1H),7.95(s,1H),8.15(br s,1H),11.73(br s,1H). 19 F NMR (377MHz, DMSO) δppm-123.22 (brs, 1F).
[0737] Compound 24 / Method D / 3-Fluoro-N 2-(2-Fluoro-4-(methylsulfonyl)phenyl)-5-methoxy-N 2 -Methyl-N 6 -(5-methyl-1H-pyrazol-3-yl)-4-(1-methyl-1H-pyrazol-4-yl)pyridine-2,6-diamine
[0738]
[0739] Step 1 / 2, 4-dibromo-6-chloro-5-fluoropyridin-3-ol
[0740] To a solution of 2-chloro-3-fluoro-5-hydroxypyridine (1.35 g, 9.12 mol) in MeCN (30 mL) and water (10 mL) was added Br2 (1.17 mL, 22.81 mmol) at rt. The mixture was then stirred at rt overnight. The mixture was quenched with 10% Na2S2O3, extracted with DCM (3x), washed with brine, dried over Na2SO4, filtered and concentrated. The crude material was purified by silica gel chromatography, eluting with EtOAc (0-30%) in heptane. The appropriate fractions were combined and concentrated in vacuo to provide 2,4-dibromo-6-chloro-5-fluoropyridine-3-ol (2.18 g, 78%) as a white solid. UPLC-MS (+ESI) m / z=305.8 (M+H) + . 19 F NMR (377MHz, CDCl3) δppm-110.55 (s, 1F).
[0741] Step 2 / 2,4-Dibromo-6-chloro-5-fluoro-3-methoxypyridine
[0742] To a mixture of 2,4-dibromo-6-chloro-5-fluoropyridine-3-ol (2.18 g, 7.14 mmol) and Cs2CO3 (4.65 g, 14.3 mmol) in DMF (45 mL) was added I2 (0.890 mL, 14.3 mmol) at rt. The mixture was then stirred overnight at rt. Water was added and the precipitate was collected by filtration using a Buchner funnel. The solid was rinsed with water and then heptane and dried under vacuum to give 2,4-dibromo-6-chloro-5-fluoro-3-methoxypyridine (2.02 g, 89% yield) as a white solid. UPLC-MS (+ESI) m / z=319.4 (M+H) + . 1 H NMR (400MHz, CDCl3) δppm 3.97 (s, 3H). 19 F NMR (377MHz, CDCl3) δppm-109.88 (s, 1F).
[0743] Step 3 / 4-Bromo-6-chloro-5-fluoro-3-methoxy-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)pyridin-2-amine
[0744] A vial was charged with intermediate 1 (1.25 g, 6.89 mmol), 2,4-dibromo-6-chloro-5-fluoro-3-methoxypyridine (2.00 g, 6.26 mmol), Xantphos (1.09 g, 1.88 mmol) and K2CO3 (2.60 g, 18.8 mmol) in dioxane (33 mL), and the mixture was purged with nitrogen for 10 minutes. Pd(OAc)2 (211 mg, 0.94 mmol) was added and the purge was continued for 5 minutes. The vial was sealed and stirred at 100 °C overnight. The reaction mixture was filtered on celite, concentrated to dryness, and purified by silica gel chromatography, eluting with EtOAc (0-30%) in heptane. The appropriate fractions were combined and concentrated in vacuo to provide 4-bromo-6-chloro-5-fluoro-3-methoxy-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)pyridin-2-amine (1.19 g, 45% yield) as a light yellow solid. UPLC-MS (+ESI) m / z = 421 (M+H) + . 1 H NMR (400MHz, CDCl3) δppm 1.59-1.77(m,3H),1.85-1.92(m,1H),2.06-2.13(m,1H),2.32-2.41(m,4H),3.62-3.70(m,1 H), 3.91 (s, 3H), 4.08-4.14 (m, 1H), 5.18 (dd, J = 10.3, 2.4Hz, 1H), 6.70 (s, 1H), 7.46 (s, 1H).
[0745] Step 4 / 6-Chloro-5-fluoro-3-methoxy-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-4-(1-methyl-1H-pyrazol-4-yl)pyridin-2-amine
[0746] A vial was charged with 4-bromo-6-chloro-5-fluoro-3-methoxy-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)pyridin-2-amine (1.19 g, 2.83 mmol), (1-methyl-1H-pyrazol-4-yl)boronic acid (374 mg, 2.97 mmol), NaHCO3 (950 mg, 11.3 mmol) in dioxane (18 mL) and water (6 mL). The mixture was purged with N2 for 10 minutes. Pd(PPh3)4 (490 mg, 0.42 mmol) was added and the purging was continued for 5 minutes. The vial was sealed and stirred at 100°C overnight. The reaction mixture was filtered on celite, concentrated to dryness, and purified by silica gel chromatography, eluting with EtOAc (0-70%) in heptane. The appropriate fractions were combined and concentrated in vacuo to provide 6-chloro-5-fluoro-3-methoxy-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-4-(1-methyl-1H-pyrazol-4-yl)pyridin-2-amine (464 mg, 39% yield) as a light yellow solid. UPLC-MS (+ESI) m / z = 421.2 (M+H) + . 1 H NMR (400MHz, CDCl3) δppm 1.69-1.79(m,3H),1.85-1.92(m,1H),2.06-2.13(m,1H),2.34-2.44(m,4H),3.63-3.70(m,4H),4.01(s,3H),4.08- 4.14(m,1H),5.18(dd,J=10.3,2.4Hz,1H),6.74(s,1H),7.51(s,1H),7.98(d,J=2.2Hz,1H),8.10(d,J=1.7Hz,1H). 19 F NMR (377MHz, CDCl3) δppm-133.84 (s, 1F).
[0747] Step 5 / 3-Fluoro-N 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-5-methoxy-N 2 -Methyl-N 6 -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-4-(1-methyl-1H-pyrazol-4-yl)pyridine-2,6-diamine
[0748] A vial was charged with 6-chloro-5-fluoro-3-methoxy-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-4-(1-methyl-1H-pyrazol-4-yl)pyridin-2-amine (75 mg, 0.18 mmol), 2-fluoro-4-methanesulfonyl-N-methylaniline (54.3 mg, 0.27 mmol), Cs2CO3 (174 mg, 0.53 mmol) and + / -BINAP (44.4 mg, 0.070 mmol) in toluene (1.7 mL). The mixture was purged with nitrogen for 10 minutes. Pd(OAc)2 (8.0 mg, 0.040 mmol) was added and purging was continued for 5 minutes. The vial was sealed and stirred at 100°C overnight. The reaction mixture was filtered over celite, concentrated to dryness, and purified by preparative HPLC eluting with a gradient of MeCN (5%-100%) in water (both containing 0.1% formic acid) to provide, after combining the appropriate fractions and lyophilizing, 3-fluoro-N-(2-(2-fluoro-4 ... 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-5-methoxy-N 2 -Methyl-N 6 -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-4-(1-methyl-1H-pyrazol-4-yl)pyridine-2,6-diamine (36 mg, yield 33%). UPLC-MS (+ESI) m / z=588.2 (M+H) + . 1 H NMR (400MHz, CDCl3) δppm 1.55-1.60(m,1H),1.64-1.69(m,1H),1.84-1.90(m,2H),2.05-2.12(m,1H),2.25(s,3H),2 .31-2.43(m,1H),3.08(s,3H),3.52(s,3H),3.60-3.69(m,4H),3.98(s,3H),4.07-4.13(m,1 H),5.14(dd,J=10.4,2.3Hz,1H),6.24(s,1H),7.23-7.26(m,1H),7.51(s,1H),7.60(dd,J= 11.1, 2.1Hz, 1H), 7.69 (dd, J = 8.6, 1.5Hz, 1H), 7.94 (d, J = 1.7Hz, 1H), 8.06 (d, J = 1.5Hz, 1H).
[0749] Step 6 / Compound 24
[0750] To a solution of 3-fluoro-N2-(2-fluoro-4-(methylsulfonyl)phenyl)-5-methoxy-N2-methyl-N6-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-4-(1-methyl-1H-pyrazol-4-yl)pyridine-2,6-diamine (35.0 mg, 0.060 mmol) in MeOH (600 μL) was added HCl solution (320 μL, 1.28 mmol, 4M in dioxane). The mixture was then heated at 50°C for 2 hours. The solvent was evaporated and the crude material was neutralized with 5M NaOH until pH 7-8 and then purified by preparative HPLC eluting with MeCN (5%-100%) in 10 mM NH4HCO3 aqueous solution to give Compound 24 (12 mg, 39% yield) as a light orange solid after lyophilization of the appropriate fractions. UPLC-MS (+ESI) m / z = 504.1 (M+H) + . 1 HNMR(400MHz,DMSO-d6)δppm 2.07(br s,3H),3.24(s,3H),3.42(s,3H),3.59(s,3H),3.92(s,3H),5.89(br s,1H),7.46-7.55(m,1H),7.66-7.71(m,1H),7.72-7.77(m,1H),7.93(s,1H),8.12(br s,1H),8.24(s,1H),11.75(s,1H). 19 F NMR (377MHz, DMSO-d6) δppm -141.64 (s, 0.8F), -140.40 (s, 0.2F), -118.55 (s, 1F). exist 19 Rotamers were observed in the F NMR spectrum.
[0751] Compound 25 / Method E / 3-cyclopropyl-N 6 -(2,6-difluoro-4-(methylsulfonyl)phenyl)-N 6 -methyl-4-(1-methyl-1H-imidazol-4-yl)-N 2 -(5-methyl-1H-pyrazol-3-yl)pyridine-2,6-diamine
[0752]
[0753] Step 1 / 4-chloro-3-cyclopropyl-N 6 -(2,6-difluoro-4-(methylsulfonyl)phenyl)-N 2 -(4-methoxybenzyl)-N 6 -Methyl-N 2-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)pyridine-2,6-diamine
[0754] 2,6-difluoro-4-methylsulfonyl-aniline (191 mg, 921 μmol) was added to intermediate 12 (300 mg, 614 μmol) in DMPU (3 mL). Nitrogen was bubbled for 5 minutes, then NaH (73 mg, 1.84 mmol, 60% purity) was added at rt. The vial was sealed and the mixture was heated to 120 ° C and kept for 4 hours. The mixture was cooled to rt, MeI (0.38 mL, 6.1 mmol) was added, and the resulting mixture was stirred at rt for 1 hour. 1 mL of MeOH was added and the mixture was filtered on a diatomaceous earth filter cartridge. The volatiles were removed under reduced pressure, and the residue was purified by preparative HPLC, eluting with a gradient of MeCN (10%-100%) in water (both containing 0.1% formic acid). The appropriate fractions were combined and lyophilized to provide 6-chloro-5-cyclopropyl-N 2 -(2,6-difluoro-4-methylsulfonyl-phenyl)-N 4 -[(4-methoxyphenyl)methyl]-N 2 -Methyl-N 4 -(5-Methyl-1-tetrahydropyran-2-yl-pyrazol-3-yl)pyrimidine-2,4-diamine (210 mg, 51% yield) as a mixture of regioisomers (9 / 1) favoring the title compound. UPLC-MS (+ESI) m / z = 673.3 (M+H) + .
[0755] Step 2 / 5-Cyclopropyl-N 2 -(2,6-difluoro-4-(methylsulfonyl)phenyl)-N 4 -(4-methoxybenzyl)-N 2 -Methyl-N 4 -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-imidazol-4-yl)pyrimidine-2,4-diamine
[0756] To a solution of tributyl-(1-methylimidazol-4-yl)stannane (176 mg, 475 μmol) in dioxane (1.00 mL) was added 6-chloro-5-cyclopropyl-N 2 -(2,6-difluoro-4-methylsulfonyl-phenyl)-N 4 -[(4-methoxyphenyl)methyl]-N 2 -Methyl-N 4-(5-methyl-1-tetrahydropyran-2-yl-pyrazol-3-yl)pyrimidine-2,4-diamine (100 mg, 149 μmol) and Pd(PPh3)4 (86 mg, 74 μmol). The mixture was degassed in vacuo, then backfilled with nitrogen and finally stirred at 130°C for 48 hours. The crude reaction mixture was cooled to rt, filtered, and the filtrate was purified by preparative HPLC, eluting with a gradient of MeCN (30%-60%) in water (both containing 0.1% formic acid). The appropriate fractions were combined and lyophilized to provide 5-cyclopropyl-N 2 -(2,6-difluoro-4-(methylsulfonyl)phenyl)-N 4 -(4-methoxybenzyl)-N 2 -Methyl-N 4 -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-imidazol-4-yl)pyrimidine-2,4-diamine (26 mg, yield 24%). UPLC-MS (+ESI) m / z=673.3 (M+H) + .
[0757] Step 3 / Compound 25
[0758] To 5-cyclopropyl-N 2 -(2,6-difluoro-4-(methylsulfonyl)phenyl)-N 4 -(4-methoxybenzyl)-N 2 -Methyl-N 4 Trifluoroacetic acid (6 mL) was added to 5-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-imidazol-4-yl)pyrimidine-2,4-diamine (26 mg, 36 μmol), and the resulting mixture was stirred at 90° C. for 4 hours. The reaction mixture was concentrated and the residue was purified by preparative HPLC eluting with a gradient of MeCN (10%-25%) in water (both containing 0.1% formic acid). The appropriate fractions were combined and lyophilized to provide compound 25 as a white solid (15 mg, 83% yield). UPLC-MS (+ESI) m / z=515.2 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ11.91(s,1H),8.56(s,1H),8.09(s,1H),7.84(d,J=6.8Hz,2H),5.25(s ,1H),3.86(s,3H),1.98(s,3H),1.74(td,J=7.9,3.9Hz,1H),1.10(s,2H),0.19(d,J=5.0Hz,2H)
[0759] Compound 26 / Method B (RP-11710) / 5-cyclopropyl-N 2 -(2-Fluoro-4-((propan-2-yl-1,1,1,3,3,3-d6)sulfonyl)phenyl)-N 2 -Methyl-N 4 -(5-methyl-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrimidine-2,4-diamine
[0760]
[0761] Step 1 / 3-Fluoro-N,N-bis(methyl-d3)-4-nitrobenzenesulfonamide
[0762] To a mixture of dimethyl-d-6-amine HCl (53.7 mg, 0.607 mmol) in DCM (3 mL) at 0°C was added triethylamine (187 μL, 1.34 mmol). The resulting reaction mixture was stirred at 0°C for 5 minutes before 3-fluoro-4-nitrobenzenesulfonyl chloride (150 mg, 0.607 mmol) was added. The reaction mixture was stirred at 0°C for an additional 30 minutes. The volatiles were removed in vacuo to provide 143 mg of 3-fluoro-N,N-bis(methyl-d3)-4-nitrobenzenesulfonamide, which was used as is in the subsequent step without further purification. 1 HNMR (DMSO-d6, 400MHz): δ8.37 (1H, t, J = 7.9Hz), 7.98 (1H, d, J = 10.4Hz), 7.78 (1H, d, J = 8.6Hz),
[0763] Step 2 / 4-Amino-3-fluoro-N,N-bis(methyl-d3)benzenesulfonamide
[0764] To a solution of 3-fluoro-N,N-bis(methyl-d3)-4-nitrobenzenesulfonamide (143 mg, 0.562 mmol) in EtOH (4 mL) and water (2 mL) was added NH4Cl (301 mg, 5.62 mmol) and zinc (263 mg, 3.94 mmol). The resulting reaction mixture was stirred at 80 ° C for 1 hour. The reaction mixture was then filtered through celite. EtOAc and saturated NaHCO3 aqueous solution were added to the filtrate. The layers were distributed, and the organic layer was washed with brine, dried over anhydrous MgSO4, and concentrated in vacuo to provide 130 mg 4-amino-3-fluoro-N,N-bis(methyl-d3)benzenesulfonamide, which was used as is in the subsequent step without further purification. UPLC-MS (+ESI): m / z=225.1 [M+H] + .
[0765] Step 3 / 5-Cyclopropyl-N2 -(2-Fluoro-4-((propan-2-yl-1,1,1,3,3,3-d6)sulfonyl)phenyl)-N 4 -(4-methoxybenzyl)-N 2 -Methyl-N 4 -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrimidine-2,4-diamine
[0766] To a solution of 5-cyclopropyl-N-(4-methoxybenzyl)-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)-2-(methylsulfonyl)pyrimidin-4-amine (see Compound 11, Step 1) (180 mg, 0.312 mmol), 4-amino-3-fluoro-N,N-bis(methyl-d3)benzenesulfonamide (154 mg, 0.685 mmol) in NMP (1.56 mL) was added NaH (37 mg, 1.6 mmol). The resulting reaction mixture was stirred at 125° C. for 16 hours. The conversion was not complete. Additional NaH (37 mg, 1.6 mmol) was added and the reaction mixture was stirred at 125° C. for 16 hours. After the reaction mixture was cooled to rt, MeI (194 μL, 3.12 mmol) was added and stirred at rt for 18 hours. The conversion was not completed. Additional NaH (37 mg, 1.6 mmol) was added and the reaction mixture was stirred for 5 hours. Crushed ice and EtOAc (25 mL) were added. The layers were distributed and the aqueous layer was extracted with EtOAc (25 mL). The combined organic layers were washed with brine, dried over MgSO4, and concentrated in vacuo. The residue was purified by silica gel chromatography, eluted with EtOAc (40-100%) in hexane. The desired fractions were combined and concentrated to dryness to provide 5-cyclopropyl-N-(2-cyclopropyl)-4-yl)-2-nitropropane. 2 -(2-Fluoro-4-((propan-2-yl-1,1,1,3,3,3-d6)sulfonyl)phenyl)-N 4 -(4-methoxybenzyl)-N 2 -Methyl-N 4 -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrimidine-2,4-diamine (71 mg, yield 31%). UPLC-MS (+ESI): m / z=736.5 [M+H] + .
[0767] Step 4 / Compound 26
[0768] 5-Cyclopropyl-N 2-(2-Fluoro-4-((propan-2-yl-1,1,1,3,3,3-d6)sulfonyl)phenyl)-N 4 -(4-methoxybenzyl)-N 2 -Methyl-N 4 -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrimidine-2,4-diamine (71 mg, 97 μmol) was dissolved in TFA (2.2 mL, 29 mmol). The reaction mixture was heated at 80 ° C for 1 hour. After the reaction mixture was cooled to rt, the volatiles were removed in vacuo. The residue was co-evaporated with NEt3 (3x) and the residue was purified by silica gel chromatography, eluting with MeCN in DCM (10%-100%). The desired fractions were combined, concentrated to dryness and lyophilized by redissolving in MeCN / water to provide compound 26 (34 mg, yield 66%) as an off-white solid. 1 H-NMR (400MHz, DMSO-d6): δ11.85 (s; 1H); 8.22 (s; 2H); 7.91 (s; 1H); 7.72 (t; J=7.94Hz; 1H); 7.63-7.65 (m; 2H); 5.6 4 (s; 1H); 3.88 (s; 3H); 3.47 (s; 3H); 2.04 (s; 3H); 1.72-1.75 (m; 1H); 1.12 (d; J=7.42Hz; 2H); 0.18 (d; J=5.30Hz; 2H). UPLC-MS(+ESI):m / z=532.0[M+H] +
[0769] Compound 108 / Method B / 5-cyclopropyl-N 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-N 2 -Methyl-N 4 -(5-methyl-1H-pyrazol-3-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)pyrimidine-2,4-diamine
[0770]
[0771] Step 1 / 5-cyclopropyl-N-(4-methoxybenzyl)-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-2-(methylsulfonyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)pyrimidin-4-amine
[0772] A mixture of intermediate 8 (150 mg, 282 μmol), Cs2CO3 (2M in H2O, 423 μL, 846 μmol), 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-a]pyrimidine (104 mg, 423 μmol), Pd(dppf)Cl2 (26 mg, 31 μmol) in dioxane (1.5 mL) was degassed in a microwave reaction bottle (3 vacuum / argon atmosphere cycles). The reaction mixture was then heated at 85 °C for 16 hours. After the reaction mixture was cooled to rt, EtOAc was added and the mixture was filtered on celite and washed with EtOAc. The filtrate was concentrated to dryness in vacuo. The residue was purified by flash chromatography on silica gel eluting with EtOAc (0-100%) in hexanes. The desired fractions were combined and concentrated to dryness in vacuo to provide 5-cyclopropyl-N-(4-methoxybenzyl)-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-2-(methylsulfonyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)pyrimidin-4-amine (65 mg, 38% yield). UPLC-MS (+ESI): m / z=615.3 [M+H] + .
[0773] Step 2 / 5-Cyclopropyl-N 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-N 4 -(4-methoxybenzyl)-N 2 -Methyl-N 4 -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)pyrimidine-2,4-diamine.
[0774] Sodium hydride (60% in mineral oil, 16.9 mg, 423 μmol) was added to a solution of 5-cyclopropyl-N-(4-methoxybenzyl)-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-2-(methylsulfonyl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)pyrimidin-4-amine (65 mg, 106 μmol) and 2-fluoro-4-(methylsulfonyl)aniline (46.3 mg, 233 μmol) in NMP (1 mL). The reaction was purged with nitrogen for 5 minutes and heated at 50 °C for 1 hour. After the reaction mixture was cooled to rt, iodomethane (65.8 μL, 1.06 mmol) was added and the resulting mixture was stirred at rt for 1 hour. The reaction mixture was then poured into water and extracted with EtOAc (3x). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness in vacuo. The residue was purified by silica gel chromatography eluting with EtOAc (0-100%) in hexanes. The desired fractions were combined and concentrated to dryness to provide 5-cyclopropyl-N-(2-(4-cyclopropyl)-3-yl)-4-nitropropane. 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-N 4 -(4-methoxybenzyl)-N 2 -Methyl-N 4 -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)pyrimidine-2,4-diamine (27 mg, yield 35%). UPLC-MS (+ESI): m / z=738.4 [M+H]+.
[0775] Step 3 / Compound 108
[0776] 5-Cyclopropyl-N 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-N 4 -(4-methoxybenzyl)-N 2 -Methyl-N 4 A solution of -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(pyrazolo[1,5-a]pyrimidin-3-yl)pyrimidine-2,4-diamine (27.0 mg, 36.6 μmol) in trifluoroacetic acid (2.0 mL, 26.1 mmol) was heated at 80 °C for 1 hour. After the reaction mixture was cooled to rt, the volatiles were removed in vacuo. The residue was purified by preparative HPLC, eluting with MeCN (40%-60%) in 10 mM NH4HCO3 aqueous solution (pH 3.8). The desired fractions were combined and lyophilized to provide compound 108 (2.4 mg, 12% yield). 1H-NMR (400MHz, DMSO-d6): δ9.18 (1H, d, J = 7.1Hz), 8.63 (1H, s), 8.47 (1H, s), 8.28-8.42 (1H, m), 7.77-7.87 (3H, m), 7.08-7.17 (1H, m), 5.69 (1H, s), 3.48 (3H, s), 2.05 (3H, s), 1.94 (1H, s), 0.63 (2H, d, J = 4.3Hz), -0.05 (2H, d, J = 3.9Hz). 4 protons are blocked by water peak UPLC-MS (+ESI): m / z = 534.3 [M+H] + .
[0777] Compound 110 / Method F / 5-cyclopropyl-6-(2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazin-4-yl)-N 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-N 2 -Methyl-N 4 -(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine
[0778]
[0779] Step 1 / 6-chloro-5-cyclopropyl-N 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-N 4 -(4-methoxybenzyl)-N 2 -Methyl-N 4 -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)pyrimidine-2,4-diamine
[0780] Sodium hydride (60% in mineral oil, 376 mg, 9.40 mmol) was added to a solution of intermediate 8 (1.00 g, 1.88 mmol) and 2-fluoro-4-(methylsulfonyl)aniline (449 mg, 2.26 mmol) in NMP (2 mL). The reaction was purged with nitrogen for 5 minutes and heated at 125 ° C for 16 hours. After the reaction was cooled to rt, MeI (1.23 mL, 19.7 mmol) was added, and the resulting mixture was stirred at rt for 1 hour. The reaction mixture was then diluted with water, EtOAc and brine. Each layer was distributed, the organic layer was washed with brine (3x), dried over anhydrous MgSO4, filtered and concentrated to dryness in vacuo. The residue was purified by silica gel chromatography, eluted with MeCN (0-100%) in DCM. The desired fractions were combined and concentrated to dryness to provide 6-chloro-5-cyclopropyl-N 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-N 4-(4-methoxybenzyl)-N 2 -Methyl-N 4 -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (566 mg, yield 46%). UPLC-MS (+ESI): m / z=655.3 [M+H] + .
[0781] Step 2 / 5-cyclopropyl-6-(2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazin-4-yl)-N 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-N 4 -(4-methoxybenzyl)-N 2 -Methyl-N 4 -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)pyrimidine-2,4-diamine
[0782] Xantphos (17.7 mg, 30.5 μmol) was added to 6-chloro-5-cyclopropyl-N 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-N 4 -(4-methoxybenzyl)-N 2 -Methyl-N 4 -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (100 mg, 153 μmol), 3,4-dihydro-2H-pyrido[4,3-b][1,4]oxazine (54.7 mg, 382 μmol), Pd2(dba)3 (14.0 mg, 15.3 μmol) and Cs2CO3 (149 mg, 0.458 mmol) in toluene (1.5 mL). The reactants were purged with nitrogen for 5 minutes and heated to 115 ° C and maintained for 16 hours. After the reaction mixture was cooled to rt, the volatiles were removed in vacuo. The residue was diluted with EtOAc and water. The layers were distributed, and the organic layer was washed with brine (2x), dried over anhydrous MgSO4, filtered and concentrated to dryness in vacuo. The residue was purified by silica gel chromatography eluting with MeCN in DCM (0-100%). The desired fractions were combined and concentrated to dryness to provide 5-cyclopropyl-6-(2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazin-4-yl)-N- 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-N 4 -(4-methoxybenzyl)-N 2 -Methyl-N 4-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (56.1 mg, yield 49%). UPLC-MS (+ESI): m / z=755.4 [M+H] + .
[0783] Step 3 / Compound 110
[0784] 5-cyclopropyl-6-(2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazin-4-yl)-N 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-N 4 -(4-methoxybenzyl)-N 2 -Methyl-N 4 -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (56.1 mg, 74.2 μmol) in TFA (0.5 mL) was heated at 80 ° C for 1 hour. After the reaction mixture was cooled to rt, the volatiles were removed and co-evaporated with triethylamine (3x 1 mL). The residue was purified by silica gel chromatography, eluting first with MeCN (0-100%) in DCM and then with 10% MeOH in DCM. The desired fractions were combined and concentrated to dryness in vacuo. The residue was then purified by preparative HPLC, eluting with MeCN (35%-55%) in 10 mM NH4HCO3 (pH=10). The desired fractions were combined and lyophilized to provide compound 110 (10 mg, yield 24%). 1 H-NMR (400MHz, DMSO-d6): δ11.84(1H,s),8.33(1H,s),8.01(1H,s),7.88(1H,s),7.82(2H,t,J=9.8Hz),7.74(1H,t,J=7.7Hz),6.86(1H,s ),5.67(1H,s),4.35-4.44(2H,m),3.90(2H,s),3.39(3H,s),3.29(3H,s),2.05(3H,s),1.39(1H,s),0.65-0.80(2H,m),0.20-0.35(2H,m). UPLC-MS(+ESI):m / z=551.3[M+H] + .
[0785] Compound 111 / Method G / 5-cyclopropyl-N 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-N 2 -Methyl-N 4-(5-methyl-1H-pyrazol-3-yl)-6-(3-(methylsulfonyl)piperidin-1-yl)pyrimidine-2,4-diamine
[0786]
[0787] Step 1 / 5-cyclopropyl-N-(4-methoxybenzyl)-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(3-(methylsulfonyl)piperidin-1-yl)-2-(methylthio)pyrimidin-4-amine
[0788] N,N-Diisopropylethylamine (190 μL, 1.09 mmol) was added to a solution of 6-chloro-5-cyclopropyl-N-(4-methoxybenzyl)-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-2-(methylthio)pyrimidin-4-amine (see Intermediate 8, Step 1) (260 mg, 520 μmol) and 3-(methylsulfonyl)piperidine (163 uL, 780 μmol) in DMSO (1 mL). The resulting reaction mixture was stirred at 140 °C for 16 hours. After cooling to rt, the reaction mixture was diluted with EtOAc and brine. The layers were distributed, the organic layer was washed with brine, dried over anhydrous MgSO4, filtered and concentrated to dryness in vacuo. The residue was purified by silica gel chromatography eluting with EtOAc (0-100%) in hexanes. The desired fractions were combined and concentrated to dryness to provide 5-cyclopropyl-N-(4-methoxybenzyl)-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(3-(methylsulfonyl)piperidin-1-yl)-2-(methylthio)pyrimidin-4-amine (226 mg, yield 69%). UPLC-MS (+ESI): m / z=627.4 [M+H] + .
[0789] Step 2 / 5-cyclopropyl-N-(4-methoxybenzyl)-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-2-(methylsulfonyl)-6-(3-(methylsulfonyl)piperidin-1-yl)pyrimidin-4-amine
[0790] Hydrogen peroxide (258 μL, 2.52 mmol) was added to a mixture of 5-cyclopropyl-N-(4-methoxybenzyl)-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(3-(methylsulfonyl)piperidin-1-yl)-2-(methylthio)pyrimidin-4-amine (226 mg, 0.360 mmol), Na2WO4.2H2O (11.9 mg, 36.0 μmol) and NBu4(HSO4) (19.6 mg, 57.6 μmol) in THF (7 mL) and EtOAc (7 mL). The reaction mixture was stirred at 50 °C for 3 hours. After cooling to rt, the reaction mixture was quenched with 5% NaHSO3. The resulting mixture was diluted with EtOAc and brine. The layers were partitioned and the organic layer was washed with brine, dried over anhydrous MgSO4, filtered and concentrated to dryness to provide crude 5-cyclopropyl-N-(4-methoxybenzyl)-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-2-(methylsulfonyl)-6-(3-(methylsulfonyl)piperidin-1-yl)pyrimidin-4-amine (211 mg), which was used as is in the next step without further purification. UPLC-MS (+ESI): m / z=659.4 [M+H] + .
[0791] Step 3 / 5-Cyclopropyl-N 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-N 4 -(4-methoxybenzyl)-N 2 -Methyl-N 4 -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(3-(methylsulfonyl)piperidin-1-yl)pyrimidine-2,4-diamine
[0792] Sodium hydride (60% in mineral oil, 27.9 mg, 0.698 mmol) was added to a solution of 5-cyclopropyl-N-(4-methoxybenzyl)-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-2-(methylsulfonyl)-6-(3-(methylsulfonyl)piperidin-1-yl)pyrimidin-4-amine (100 mg, 0.152 mmol) and 2-fluoro-4-(methylsulfonyl)aniline (34.5 mg, 0.182 mmol) in NMP (760 μL). The reaction mixture was purged with nitrogen for 5 minutes and heated at 125 °C for 16 hours. After the reaction mixture was cooled to rt, iodomethane (100 μL, 1.59 mmol) was added and the resulting mixture was stirred at rt for 1 hour. The reaction mixture was diluted with water, EtOAc and brine. The layers were partitioned and the organic layer was washed with brine (3x), dried over anhydrous MgSO4, filtered and concentrated to dryness in vacuo. The residue was purified by silica gel chromatography eluting with MeCN in DCM (0-100%). The desired fractions were combined and concentrated to dryness to provide 5-cyclopropyl-N-(2-(4-cyclopropyl)-3-yl)-4-nitropropane. 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-N 4 -(4-methoxybenzyl)-N 2 -Methyl-N 4 -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(3-(methylsulfonyl)piperidin-1-yl)pyrimidine-2,4-diamine (21 mg). UPLC-MS (+ESI): m / z=782.3 [M+H]+.
[0793] Step 4 / Compound 111
[0794] 5-Cyclopropyl-N 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-N 4 -(4-methoxybenzyl)-N 2 -Methyl-N 4 A solution of -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(3-(methylsulfonyl)piperidin-1-yl)pyrimidine-2,4-diamine (21 mg, 27 μmol) in TFA (2.0 mL) was heated at 80 °C for 1 hour. After the reaction mixture was cooled to rt, the volatiles were removed in vacuo. The residue was purified by preparative HPLC eluting with a gradient of MeCN (35%-75%) in H2O (both containing 0.1% formic acid). The desired fractions were combined and lyophilized to provide compound 111 (2.5 mg, 16% yield). 1H-NMR (400 MHz, DMSO-d6): δ8.06 (1H, s), 7.80 (2H, t, J = 8.5 Hz), 7.71 (1H, t, J = 7.8 Hz), 5.66 (1H, s), 4.45 (1H, d, J = 12.3 Hz), 4.09 (1H, d, J = 12.9 Hz), 3.41 (3H, s), 3.29 (3H, s), 2.86-2.94 (6H, m), 2.16-2.19 (1H, m), 2.04 (3H, s), 1.78 (1H, d, J = 11.9 Hz), 1.53-1.67 (3H, m), 1.00-1.02 (2H, m), 0.35-0.40 (2H, m). One proton was blocked by the water peak. UPLC-MS(+ESI):m / z=578.3[M+H] + .
[0795] Compound 121 / Method H / 5-cyclopropyl-N 2 -(2,6-difluoro-4-(methylsulfonyl)phenyl)-6-(1,3-dimethyl-1H-pyrazol-4-yl)-N 2 -Methyl-N 4 -(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine
[0796]
[0797] Step 1 / 6-chloro-5-cyclopropyl-N 2 -(2,6-difluoro-4-(methylsulfonyl)phenyl)-N 4 -(4-methoxybenzyl)-N 2 -Methyl-N 4 -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)pyrimidine-2,4-diamine
[0798] To a nitrogen purged solution of 2,6-difluoro-4-methylsulfonyl-aniline (2.34 g, 11.3 mmol) and intermediate 8 (5.62 g, 10.3 mmol) in DMPU (48 mL) was added NaHMDS (1 M, 22.5 mL, 22.5 mmol) at rt. The reaction was heated to 160 °C for 30 minutes. The reaction mixture was cooled to rt and iodomethane (3.19 mL, 51.2 mmol) was slowly added. The residual mixture was stirred at rt for 30 minutes. The resulting mixture was poured onto a mixture of water (800 mL) and ethyl acetate (200 mL). The phases were separated and the aqueous phase was washed with ethyl acetate (2x 10% ethyl acetate). The crude product was purified by silica gel chromatography, eluting with EtOAc (5%-10%) in heptane. The appropriate fractions were pooled and concentrated to dryness. The residue was then purified by reverse phase flash chromatography (HP C18 Rf gold) and eluted with a gradient of CH3CN (0 to 100%) in water (both containing 0.1% formic acid). The appropriate fractions were combined and concentrated to about 20 mL volume under reduced pressure. Poured into saturated aqueous NaHCO3 and extracted with EtOAc (3x). The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under vacuum, then dried on a vacuum pump to provide 6-chloro-5-cyclopropyl-N 2 -(2,6-difluoro-4-(methylsulfonyl)phenyl)-N 4 -(4-methoxybenzyl)-N 2 -Methyl-N 4 -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (3.50 g, yield 51%). 1H NMR (400MHz, DMSO-d6) δ7.76(d,J=8.0Hz,2H),6.64(s,4H),5.92(s,1H),5.21(d,J=9.4Hz,1H),4.55(s,1 H),3.80(d,J=11.5Hz,1H),3.65(s,3H),3.58–3.44(m,1H),3.27(s,3H),3.26(s,3H),2.18(s,3H),2.13– 1.97(m,1H),1.89(d,J=12.5Hz,1H),1.68(d,J=12.9Hz,1H),1.56(d,J=11.1Hz,1H),1.44(s,2H),0.94(d dd,J=13.8,8.3,5.5Hz,1H),0.43(p,J=9.2Hz,2H),0.26–-0.01(m,2H).UPLC-MS(+ESI):m / z=673.7[M+H] + .
[0799] Step 2 / 5-Cyclopropyl-N 2 -(2,6-difluoro-4-(methylsulfonyl)phenyl)-6-(1,3-dimethyl-1H-pyrazol-4-yl)-N 4 -(4-methoxybenzyl)-N 2 -Methyl-N 4 -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)pyrimidine-2,4-diamine
[0800] To 1,3-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole (85.8 mg, 386 μmol) in dioxane (1 mL) and H2O (250 μL) was added 6-chloro-5-cyclopropyl-N-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole (85.8 mg, 386 μmol). 2 -(2,6-difluoro-4-(methylsulfonyl)phenyl)-N 4 -(4-methoxybenzyl)-N 2 -Methyl-N 4-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (200 mg, 297 μmol), Cs2CO3 (242 mg, 743 μmol) and PdCl2(dppf) (43.5 mg, 59.4 μmol). The mixture was degassed in vacuo, then backfilled with N2, sealed, and stirred at 120°C for 1 hour. The crude reaction mixture was filtered and the filtrate was purified by preparative HPLC, eluting with a gradient of CH3CN (55%-85%) in water (both containing 0.1% formic acid). The appropriate fractions were combined and lyophilized to provide 5-cyclopropyl-N 2 -(2,6-difluoro-4-(methylsulfonyl)phenyl)-6-(1,3-dimethyl-1H-pyrazol-4-yl)-N 4 -(4-methoxybenzyl)-N 2 -Methyl-N 4 -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (73.0 mg, yield 34%). UPLC-MS (+ESI): m / z=733.0 [M+H] + .
[0801] Step 3 / Compound 121
[0802] To 5-cyclopropyl-N- 2 -(2,6-difluoro-4-(methylsulfonyl)phenyl)-6-(1,3-dimethyl-1H-pyrazol-4-yl)-N 4 -(4-methoxybenzyl)-N 2 -Methyl-N 4 -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (73.0 mg, 99.6 μmol) was added trifluoroacetic acid (115 μL, 1.49 mmol). The resulting mixture was heated to 90 °C for 6 hours. The volatiles were removed in vacuo and the residue was co-evaporated with DCM twice. The residue was dissolved in DCM, washed with NaHCO3, dried over Na2SO4, filtered and concentrated. The residue was purified by reverse phase flash chromatography, eluting with a gradient of CH3CN (15%-60%) in water (both containing 0.1% formic acid). The appropriate fractions were combined and lyophilized to provide compound 121 (16.0 mg, 30% yield). 1H NMR (400MHz, DMSO-d6) δ11.83 (brs; 1H); 8.22 (br s; 1H); 8.01 (s; 1H); 7.79 (d; J=6.80Hz; 2H); 5.27 (br s; 1H); 3.75 (s; 3H); 3.33 (s; 3H); 3.30 (s; 3H); 2.00 (br s; 3H); 1.59-1.67 (m; 1H); 0.96 (d; J=7.60Hz; 2H); 0.05 (d; J=5.20Hz; 2H). UPLC-MS(+ESI):m / z=528.8[M+H] + .
[0803] Compound 125 / Method H / 5-cyclopropyl-N 2 -(2,5-difluoro-4-(methylsulfonyl)phenyl)-N 2 -methyl-6-(1-methyl-1H-imidazol-4-yl)-N 4 -(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine
[0804]
[0805] Step 1 / 6-chloro-5-cyclopropyl-N 2 -(2,5-difluoro-4-(methylsulfonyl)phenyl)-N 4 -(4-methoxybenzyl)-N 2 -Methyl-N 4 -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)pyrimidine-2,4-diamine
[0806] NaHMDS (1M, 21.1 mL, 21.4 mmol) was added to intermediate 8 (5.00 g, 9.40 mmol) and 2,5-difluoro-4-methylsulfonyl-aniline (2.92 g, 14.1 mmol) in DMPU (60 mL), and the reaction mixture was heated to 110 ° C and kept for 10 minutes. The resulting mixture was cooled to rt, then MeI (5.9 mL, 94 mmol) was added within 15 minutes, and the reaction was stirred at rt for 45 minutes. The reaction mixture was poured on a mixture of water (400 mL) and ethyl acetate (200 mL). The organic phase was separated, and the aqueous phase was then stripped twice with EtOAc (2 x 100 mL). The collected organic phase was washed with brine (200 mL), then dried over anhydrous MgSO4, filtered with a porous glass Buchner filter, and the filter cake was rinsed with ethyl acetate (100 mL). The filtrate was concentrated and the residue was purified by silica gel chromatography eluting with EtOAc in hexanes (5%-10%), followed by a second purification by silica gel chromatography eluting with MeOH in DCM (10%-20%). The appropriate fractions were combined and the residue was further purified by reverse phase flash chromatography (HP C18 Rf gold) and eluted with a gradient of CH3CN (10%-100%) in water (both containing 0.1% formic acid). Appropriate fractions were combined and lyophilized to provide 6-chloro-5-cyclopropyl-N 2 -(2,5-difluoro-4-(methylsulfonyl)phenyl)-N 4 -(4-methoxybenzyl)-N 2 -Methyl-N 4 -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (4.00 g, yield 63%). UPLC-MS (+ESI): m / z=674.2 [M+H] + .
[0807] Step 2 / 5-Cyclopropyl-N 2 -(2,5-difluoro-4-(methylsulfonyl)phenyl)-N 4 -(4-methoxybenzyl)-N 2 -Methyl-N 4 -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-imidazol-4-yl)pyrimidine-2,4-diamine
[0808] Nitrogen was bubbled through the 6-chloro-5-cyclopropyl-N 2 -(2,5-difluoro-4-(methylsulfonyl)phenyl)-N 4 -(4-methoxybenzyl)-N 2-Methyl-N 4 -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (600 mg, 891 μmol), tributyl-(1-methylimidazol-4-yl)stannane (700 mg, 1.89 mmol) in 1,4-dioxane (10 mL) was added and sonicated for 15 minutes. XPhosPdG2 (210 mg, 223 μmol) was then added and nitrogen was bubbled through the resulting suspension for another 10 minutes under sonication. The final reaction mixture was sealed and stirred at 130°C for 2 hours. The resulting suspension was diluted with 10 mL EtOAc and 3 mL 1M KF, filtered through celite, and the organic phase was separated, washed with brine, dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel chromatography eluting with a gradient of MeOH (1%-8%) in DCM. The appropriate fractions were combined and concentrated in vacuo to provide 5-cyclopropyl-N 2 -(2,5-difluoro-4-(methylsulfonyl)phenyl)-N 4 -(4-methoxybenzyl)-N 2 -Methyl-N 4 -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-imidazol-4-yl)pyrimidine-2,4-diamine (525 mg, yield 79%)
[0809] Step 3 / Compound 125
[0810] 5-Cyclopropyl-N 2 -(2,5-difluoro-4-(methylsulfonyl)phenyl)-N 4 -(4-methoxybenzyl)-N 2 -Methyl-N 4-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-imidazol-4-yl)pyrimidine-2,4-diamine (525 mg, 730 μmol) and L-cysteine (180 mg, 1.49 mmol) were dissolved in DCE (5 mL), to which TFA (2.25 mL, 29.21 mmol) was added. The mixture was heated at 80 ° C. for 1 hour under reflux. The volatiles were removed in vacuo, co-evaporated twice with CH3CN, dissolved in DCM and neutralized with saturated aqueous NaHCO3 solution. The organic layer was separated and concentrated in vacuo. The residue was dissolved in DMSO and purified by preparative HPLC, eluting with a gradient of CH3CN (15%-45%) in water (containing 10 mM NH4HCO3, pH adjusted to 10 with NH4OH). Appropriate fractions were combined and lyophilized to provide compound 125 as a white solid (71 mg, 19% yield). 1HNMR (400MHz, DMSO-d6) δ12.45–11.67(m,1H),8.23(s,1H),7.79(dd,J=10.9,5.9Hz,1H),7.72–7.64(m,2H),7.60(d,J=1.4Hz,1H),5.72(s,1H ),3.73(s,3H),3.54–3.43(m,3H),3.39(s,3H),2.08(d,J=4.9Hz,3H),1 .82(p,J=7.5Hz,1H), 0.96(h,J=4.3Hz,2H), 0.09(td,J=6.0,4.2Hz,2H). UPLC-MS(+ESI):m / z=515.2[M+H] + .
[0811] Compound 144 / Method I / 2-(5-cyclopropyl-4-((5-methyl-1H-pyrazol-3-yl)amino)-6-(1-methyl-1H-pyrazol-4-yl)pyrimidin-2-yl)-2-(4-(methylsulfonyl)phenyl)acetonitrile
[0812]
[0813] Step 1 / 2-(5-cyclopropyl-4-((4-methoxybenzyl)(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)amino)-6-(1-methyl-1H-pyrazol-4-yl)pyrimidin-2-yl)-2-(4-(methylsulfonyl)phenyl)acetonitrile
[0814] A 4 mL vial was charged with 5-cyclopropyl-N-[(4-methoxyphenyl)methyl]-6-(1-methylpyrazol-4-yl)-2-methylsulfonyl-N-(5-methyl-1-tetrahydropyran-2-yl-pyrazol-3-yl)pyrimidin-4-amine (see Compound 11, Step 1) (100 mg, 173 μmol), 2-(4-methylsulfonylphenyl)acetonitrile (50.0 mg, 256 μmol) and DMPU (500 μL). NaHMDS (1 M, 350 μL, 350 μmol) was added and the mixture was stirred at 120 °C for 30 minutes. The cooled reaction mixture was diluted with EtOAc and washed with water and brine, dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel chromatography, eluting with a gradient of EtOAc (0-10%) in heptane, then with a gradient of MeOH (0-20%) in DCM. The appropriate fractions were combined and concentrated in vacuo to provide 2-(5-cyclopropyl-4-((4-methoxybenzyl)(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)amino)-6-(1-methyl-1H-pyrazol-4-yl)pyrimidin-2-yl)-2-(4-(methylsulfonyl)phenyl)acetonitrile (28 mg, 23% yield). UPLC-MS (+ESI): m / z=693.0 [M+H] + .
[0815] Step 2 / Compound 144
[0816] 2-(5-Cyclopropyl-4-((4-methoxybenzyl)(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)amino)-6-(1-methyl-1H-pyrazol-4-yl)pyrimidin-2-yl)-2-(4-(methylsulfonyl)phenyl)acetonitrile (28.0 mg, 40.4 μmol) was dissolved in DCM (1 mL) and TFA (1 mL). L-cysteine (10.0 mg, 82.5 μmol) was added and the mixture was stirred at 50 °C for 90 minutes. The mixture was concentrated, then dissolved in DMSO and neutralized with Et3N. The reaction mixture was filtered and the filtrate was purified by preparative HPLC eluting with CH3CN (25%-55%) in water (containing 10 mM NH4HCO3, pH adjusted to 10 with NH4OH). The appropriate fractions were combined and lyophilized to provide compound 144 (6.0 mg, 30% yield) 1H NMR(DMSO-d6)δ:11.98(s,1H),8.65(s,1H),8.25(s,1H),7.99–7.93(m,3H),7.75(d,J=8.2Hz,2H),6.33(s,1H) ,5.90(s,1H),3.88(s,3H),3.16(s,3H),2.17(s,3H),1.85–1.75(m,1H),1.20–1.11(m,2H),0.23–0.15(m,2H). UPLC-MS(+ESI):m / z=489.3[M+H] + .
[0817] Compound 158 / Method I / 5-cyclopropyl-N-(5-methyl-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)-2-(4-(methylsulfonyl)benzyl)pyrimidin-4-amine
[0818]
[0819] Step 1 / methyl 2-(5-cyclopropyl-4-((4-methoxybenzyl)(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)amino)-6-(1-methyl-1H-pyrazol-4-yl)pyrimidin-2-yl)-2-(4-(methylsulfonyl)phenyl)acetate
[0820] 5-Cyclopropyl-N-[(4-methoxyphenyl)methyl]-6-(1-methylpyrazol-4-yl)-2-methylsulfonyl-N-(5-methyl-1-tetrahydropyran-2-yl-pyrazol-3-yl)pyrimidin-4-amine (see Compound 11, Step 1) (100 mg, 173 μmol), 2-(4-methylsulfonylphenyl)acetic acid methyl ester (60.0 mg, 263 μmol) and DMPU (500 μL) were charged into a 4 mL vial. NaHMDS (1M, 350 μL, 350 μmol) was added and the mixture was stirred at 90 ° C for 90 minutes. The mixture was stirred at rt overnight. The mixture was diluted with EtOAc, washed with water and brine, dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel chromatography, eluting first with a gradient of EtOAc (30%-100%) in heptane and then with a gradient of MeOH (0-20%) in DCM to provide methyl 2-(5-cyclopropyl-4-((4-methoxybenzyl)(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)amino)-6-(1-methyl-1H-pyrazol-4-yl)pyrimidin-2-yl)-2-(4-(methylsulfonyl)phenyl)acetate (62.0 mg, 49% yield). UPLC-MS (+ESI): m / z=727.0 [M+H]+ .
[0821] Step 2 / Compound 158
[0822] Methyl 2-(5-cyclopropyl-4-((4-methoxybenzyl)(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)amino)-6-(1-methyl-1H-pyrazol-4-yl)pyrimidin-2-yl)-2-(4-(methylsulfonyl)phenyl)acetate (62.0 mg, 85.4 μmol) was dissolved in methanol (250 μL) and THF (750 μL) and then treated with LiOH (1 M, 250 μL, 250 μmol). The mixture was stirred at rt for 2 hours. The reaction mixture was neutralized with 250 uL of 10% aqueous HCl and then concentrated to dryness in vacuo. L-cysteine (21.0 mg, 173 μmol) was added to the crude product followed by DCM (1 mL) and TFA (1 mL). The mixture was stirred at 60 °C under reflux overnight. The volatiles were evaporated, the crude residue was redissolved in DMSO and basified with a few drops of EtN. The reaction mixture was filtered, and the filtrate was purified by preparative HPLC, eluting with a gradient of CHCN (25%-55%) in water (containing 10 mM ammonium bicarbonate, pH adjusted to 10 with NHOH). The appropriate fractions were combined and lyophilized to provide compound 158 (8 mg, 20% yield). 1 H NMR(DMSO-d6)δ:11.88(s,1H),8.34(s,1H),8.23(s,1H),7.94(s,1H),7.86–7.80(m,2H),7.62–7.54(m,2H),6.11(s,1H ),4.09(s,2H),3.87(s,3H),3.13(s,3H),2.12(s,3H),1.78(h,J=6.2,5.4Hz,1H),1.16–1.08(m,2H),0.20–0.13(m,2H). UPLC-MS(+ESI):m / z=464.6[M+H] + .
[0823] Compound 228 / Method H / 5-cyclopropyl-N 4 -(5-cyclopropyl-1H-pyrazol-3-yl)-N 2 -(2,6-difluoro-4-(methylsulfonyl)phenyl)-N 2 -methyl-6-(1-methyl-1H-imidazol-4-yl)pyrimidine-2,4-diamine
[0824]
[0825] Step 1 / 6-chloro-5-cyclopropyl-N 4 -(5-cyclopropyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-N 2 -(2,6-difluoro-4-(methylsulfonyl)phenyl)-N 4 -(4-methoxybenzyl)-N 2 -Methylpyrimidine-2,4-diamine
[0826] To a solution of 2,6-difluoro-4-methylsulfonyl-aniline (100 mg, 483 μmol) in DMPU (1.5 mL) was added NaHMDS (1 M, 900 μL, 900 μmol) at rt. Intermediate 13 (223 mg, 400 μmol) was then added and the resulting reaction mixture was stirred at rt for 1 hour. CH3I (125 μL, 2.01 mmol) was added dropwise and the resulting mixture was stirred at rt for 30 minutes. The reaction was diluted with EtOAc, washed with water, brine (10 mL), dried over Na2SO4, filtered and concentrated to dryness. The residue was purified on a silica gel column eluted with a gradient of EtOAc (50-100%) in heptane. The appropriate fractions were combined and concentrated, and the residue was further purified by preparative HPLC (Phenomenex Gemini), eluting with a gradient of CH3CN (25%-100%) in water (containing 10 mM ammonium bicarbonate, pH adjusted to 10 with NH4OH). The appropriate fractions were combined and lyophilized to provide 6-chloro-5-cyclopropyl-N-(2-(2-chloro-3-yl)-1-yl)-4-nitropropane as an off-white solid. 4 -(5-cyclopropyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-N 2 -(2,6-difluoro-4-(methylsulfonyl)phenyl)-N 4 -(4-methoxybenzyl)-N 2 -methylpyrimidine-2,4-diamine (128 mg, yield 46%). UPLC-MS (+ESI): m / z = 699.8 [M+H] + .
[0827] Step 2 / 5-Cyclopropyl-N 4 -(5-cyclopropyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-N 2 -(2,6-difluoro-4-(methylsulfonyl)phenyl)-N 4 -(4-methoxybenzyl)-N-methyl-6-(1-methyl-1H-imidazol-4-yl)pyrimidine-2,4-diamine
[0828] To 6-chloro-5-cyclopropyl-N 4-(5-cyclopropyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-N 2 -(2,6-difluoro-4-(methylsulfonyl)phenyl)-N 4 -(4-methoxybenzyl)-N 2 -methylpyrimidine-2,4-diamine (60.0 mg, 85.8 μmol) in a solution of dioxane (2 mL) was added tributyl-(1-methylimidazol-4-yl) stannane (65.0 mg, 175 μmol) and XPhosPdG3 (16.0 mg, 17.0 μmol). The mixture was degassed in vacuo and backfilled with N2 three times, and then the resulting mixture was stirred at 120 ° C for 1 hour. Additional XPhosPdG3 (16 mg, 16.99 μmol) was added and the mixture was stirred at 120 ° C for another hour. The resulting mixture was cooled to rt and concentrated. The residue was purified on a silica gel column, eluting with a gradient of EtOAc (60%-100%) in hexane. A second purification was performed on a silica gel column, eluting with a gradient of MeOH (0-10%) in DCM. The appropriate fractions were combined and concentrated to provide 5-cyclopropyl-N-(4-nitropropane)-1,4-diamine (60.0 mg, 85.8 μmol). 4 -(5-cyclopropyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-N 2 -(2,6-difluoro-4(methylsulfonyl)phenyl)-N 4 -(4-methoxybenzyl)-N-methyl-6-(1-methyl-1H-imidazol-4-yl)pyrimidine-2,4-diamine (31 mg, yield 49%). UPLC-MS (+ESI): m / z=746.0 [M+H] + .
[0829] Step 3 / Compound 228
[0830] To 5-cyclopropyl-N 4 -(5-cyclopropyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-N 2 -(2,6-difluoro-4-(methylsulfonyl)phenyl)-N 4 To a solution of -(4-methoxybenzyl)-N-methyl-6-(1-methyl-1H-imidazol-4-yl)pyrimidine-2,4-diamine (31.0 mg, 41.6 μmol) in DCE (500 μL) was added TFA (500 μL, 6.49 mmol) and L-cysteine (11.0 mg, 90.8 μmol). The resulting mixture was stirred at 80 °C under N2 for 4 hours. After cooling to rt, the volatiles were removed in vacuo and the residue was co-evaporated with MeOH and then with MeOH and TEA. The residue was purified by reverse phase flash chromatography (HP C18 Rf gold) was purified by gradient elution with CH3CN (25%-100%) in water (containing 10 mM ammonium bicarbonate, pH adjusted to 10 with NH4OH). Appropriate fractions were combined and lyophilized to afford compound 228 (18.0 mg, 80% yield) as an off-white solid. 1 H NMR (400MHz, DMSO-d6) δ11.82(s,1H),8.17(s,1H),7.81(d,J=6.9Hz,2H),7.60(2s,2H),5.58(bs,1H),3.67(s,3H ),3.34(s,3H),3.30(s,3H),1.76(m,1H),1.66(m,1H),1.04–0.82(m,2H),0.79(m,2H),0.44(m,2H),0.06(m,2H). UPLC-MS(+ESI):m / z=541.3[M+H] + .
[0831] Compound 287 / Method H / 4-(5-cyclopropyl-6-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-2-((2,6-difluoro-4-(methylsulfonyl)phenyl)(methyl)amino)pyrimidin-4-yl)-1-methyl-1H-imidazole-2-carbonitrile
[0832]
[0833] Step 1 / 6-(2-(((tert-butyldimethylsilyl)oxy)methyl)-1-methyl-1H-imidazol-4-yl)-5-cyclopropyl-N 4 -(5-cyclopropyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-N 2 -(2,6-difluoro-4-(methylsulfonyl)phenyl)-N 4 -(4-methoxybenzyl)-N 2 -Methylpyrimidine-2,4-diamine
[0834] In a 2-5 mL microwave vial equipped with a stir bar, 6-chloro-5-cyclopropyl-N 4 -(5-cyclopropyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-N 2 -(2,6-difluoro-4-(methylsulfonyl)phenyl)-N 4 -(4-methoxybenzyl)-N 2-methylpyrimidine-2,4-diamine (see compound 228, step 1) (170 mg, 243 μmol) was dissolved in 1,4-dioxane (2.5 mL). Tert-butyl-dimethyl-[(1-methyl-4-tributylstannyl-imidazol-2-yl)methoxy]silane (360 mg, 489 μmol) was added to the reaction mixture. The reaction mixture was degassed with a stream of N2 for 10 minutes and Pd(PPh3)4 (70.2 mg, 60.8 μmol) was added. The mixture was degassed again with a stream of nitrogen for 15 minutes and finally the vial was sealed and the reaction was heated at 130°C for 16 hours. The resulting mixture was cooled to rt, diluted with EtOAc and washed with 1M KF. The organic layer was separated, dried over Na2SO4, filtered on diatomaceous earth and concentrated. The residue was purified by silica gel chromatography eluting with a gradient of EtOAc (0-75%) in heptane. The appropriate fractions were combined and concentrated in vacuo to provide 6-(2-(((tert-butyldimethylsilyl)oxy)methyl)-1-methyl-1H-imidazol-4-yl)-5-cyclopropyl-N ... 4 -(5-cyclopropyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-N 2 -(2,6-difluoro-4-(methylsulfonyl)phenyl)-N 4 -(4-methoxybenzyl)-N 2 -methylpyrimidine-2,4-diamine (124 mg, yield 57%). UPLC-MS (+ESI): m / z = 889.5 [M+H] + .
[0835] Step 2 / (4-(5-cyclopropyl-6-((5-cyclopropyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)(4-methoxybenzyl)amino)-2-((2,6-difluoro-4-(methylsulfonyl)phenyl)(methyl)amino)pyrimidin-4-yl)-1-methyl-1H-imidazol-2-yl)methanol
[0836] 6-(2-(((tert-butyldimethylsilyl)oxy)methyl)-1-methyl-1H-imidazol-4-yl)-5-cyclopropyl-N 4 -(5-cyclopropyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-N 2 -(2,6-difluoro-4-(methylsulfonyl)phenyl)-N 4 -(4-methoxybenzyl)-N 2 -Methylpyrimidine-2,4-diamine (123 mg, 138 μmol) was dissolved in THF (1.4 mL) and cooled to 0 ℃. TBAF solution (1M, 166 μL, 166 μmol) was added and the reaction mixture was warmed to rt and then stirred for 1 hour. The reaction mixture was poured into H2O and extracted with EtOAc (2x). The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo, and dried under high vacuum for 1 hour to provide (4-(5-cyclopropyl-6-((5-cyclopropyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)(4-methoxybenzyl)amino)-2-((2,6-difluoro-4-methylsulfonyl)phenyl)(methyl)amino)pyrimidin-4-yl)-1-methyl-1H-imidazole-2-yl)methanol (108 mg), which was used as is in the next step without further purification. UPLC-MS (+ESI): m / z=775.2[M+H] + .
[0837] Step 3 / 4-(5-cyclopropyl-6-((5-cyclopropyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)(4-methoxybenzyl)amino)-2-((2,6-difluoro-4-(methylsulfonyl)phenyl)(methyl)amino)pyrimidin-4-yl)-1-methyl-1H-imidazole-2-carbaldehyde
[0838] (4-(5-cyclopropyl-6-((5-cyclopropyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)(4-methoxybenzyl)amino)-2-((2,6-difluoro-4-methylsulfonyl)phenyl)(methyl)amino)pyrimidin-4-yl)-1-methyl-1H-imidazol-2-yl)methanol (108 mg, 139 μmol) was dissolved in DCM (1.5 mL) and cooled to 0°C. Dess-Martin periodinane (70.9 mg, 167 μmol) was added and the resulting mixture was stirred for 1 hour. To complete the reaction, additional Dess-Martin periodinane (29.6 mg, 69.7 μmol) was added and the final mixture was stirred for another 1 hour. The reaction mixture was quenched by the addition of iPrOH (250 μL) and stirred for 5 minutes. Na2S2O3 aqueous solution (10 mL) was added to the reaction mixture, followed by extraction with CH2Cl2 (3x). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo, dried under high vacuum to provide 4-(5-cyclopropyl-6-((5-cyclopropyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)(4-methoxybenzyl)amino)-2-((2,6-difluoro-4-(methylsulfonyl)phenyl)(methyl)amino)pyrimidin-4-yl)-1-methyl-1H-imidazole-2-carbaldehyde (107 mg), which was used in the next step without further purification. UPLC-MS (+ESI): m / z=773.2 [M+H] + .
[0839] Step 4 / 4-(5-cyclopropyl-6-((5-cyclopropyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)(4-methoxybenzyl)amino)-2-((2,6-difluoro-4-(methylsulfonyl)phenyl)(methyl)amino)pyrimidin-4-yl)-1-methyl-1H-imidazole-2-carbonitrile
[0840] 4-(5-cyclopropyl-6-((5-cyclopropyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)(4-methoxybenzyl)amino)-2-((2,6-difluoro-4-(methylsulfonyl)phenyl)(methyl)amino)pyrimidin-4-yl)-1-methyl-1H-imidazole-2-carbaldehyde (107 mg, 139 μmol) was dissolved in MeOH (1 mL). HONH2·HCl (20 mg, 288 μmol) and NaOAc (25.0 mg, 305 μmol) were added in single portions. The final mixture was stirred vigorously for 1 hour. The resulting mixture was concentrated under reduced pressure. The crude material was dissolved in DCM (1.45 mL), pyridine (55.8 μL, 692.23 μmol) was added, followed by 2,2,2-trifluoroacetyl (2,2,2-trifluoroacetate (78.06 μL, 554 μmol). The reaction mixture was stirred at rt for 16 hours. Additional pyridine (22.3 μL, 277 μmol) was added and the reaction mixture was heated to 35 ° C and kept for 2 hours, but the reaction did not proceed further. The volatiles were evaporated under reduced pressure, the crude residue was dissolved in DMSO and purified by reverse phase flash chromatography (HP C18 Rf gold) and eluted with a gradient of CH3CN (0-100%) in water (both containing 0.1% formic acid). Appropriate fractions were combined and lyophilized to provide 4-(5-cyclopropyl-6-((5-cyclopropyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)(4-methoxybenzyl)amino)-2-((2,6-difluoro-4-(methylsulfonyl)phenyl)(methyl)amino)pyrimidin-4-yl)-1-methyl-1H-imidazole-2-carbonitrile (45.0 mg, 42% yield). UPLC-MS (+ESI): m / z=770.4 [M+H] + .
[0841] Step 5 / Compound 287
[0842] 4-(5-cyclopropyl-6-((5-cyclopropyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)(4-methoxybenzyl)amino)-2-((2,6-difluoro-4-(methylsulfonyl)phenyl)(methyl)amino)pyrimidin-4-yl)-1-methyl-1H-imidazole-2-carbonitrile (45.0 mg, 58.5 μmol) was dissolved in 1,2-dichloroethane (1.5 mL). L-cysteine (21.3 mg, 175 μmol) was added followed by TFA (313 μL, 4.09 mmol). The reaction mixture was stirred at 80 °C for 6 hours. The volatiles were evaporated to dryness. The reaction mixture was neutralized with saturated aqueous NaHCO3 and extracted with DCM (3x). The combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by preparative HPLC (Phenomenex Gemini) eluting with a gradient of CH3CN (10%-55%) in water (both containing 0.1% formic acid). Appropriate fractions were combined and lyophilized to provide compound 287 (24 mg, 73% yield). 1 H NMR (400MHz, DMSO) δ11.85(s,1H),8.34(s,1H),8.02(s,1H),7.82(d,J=6.9Hz,2H),5.40(s,1H),3.87(s,3H),3.35(s,3H),3.3 1(s,3H),1.85–1.72(m,1H),1.66(s,1H),1.02–0.86(m,2H),0.87–0.65(m,2H),0.61–0.28(m,2H),0.02(dd,J=6.0,4.2Hz,2H). 19 F NMR (376MHz, DMSO) δ-113.26.2F. UPLC-MS(+ESI):m / z=566.2[M+H] + .
[0843] Compound 344 / Method G / 5-cyclopropyloxy-N 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-N 2 -Methyl-N 4 -(5-methyl-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrimidine-2,4-diamine
[0844]
[0845] Step 1 / 2-Diethyl cyclopropoxymalonate
[0846] Rhodium (II) acetate dimer (563 mg, 1.27 mmol) was added to a solution of diethyl 2-diazomalonate (4.74 g, 25.5 mmol) in DCM (100 mL), followed by cyclopropanol (8.41 mL, 129 mmol). The reaction mixture was stirred at 50 ° C for 24 hours. The volatiles were concentrated and the crude material was purified by silica gel chromatography, eluting with EtOAc (0-50%) in hexane. The desired fractions were combined and concentrated to dryness in vacuo to provide diethyl 2-cyclopropoxymalonate (3.37 g, 61% yield) as a colorless oil. 1 H-NMR (400MHz, CDCl3): δ4.56 (s; 1H); 4.21-4.31 (m; 4H); 3.55-3.60 (m; 1H); 1.27-1.31 (m; 6H); 0.74-0.75 (m; 2H); 0.49-0.54 (m; 2H). UPLC-MS(+ESI):m / z=217.1[M+H] + .
[0847] Step 2 / 5-Cyclopropyloxy-2-(methylthio)pyrimidine-4,6(1H,5H)-dione
[0848] Sodium methoxide (25% w / w in MeOH, 3.56 mL, 15.6 mmol) was added to a solution of thiourea (1.19 g, 15.6 mmol) and diethyl 2-cyclopropyloxymalonate (3.37 g, 15.6 mmol) in MeOH (62 mL). The reaction mixture was stirred at reflux for 1 hour. The reaction mixture was cooled to rt and MeI (1.46 mL, 23.4 mmol) was added dropwise. After stirring at rt for 5 hours, the reaction mixture was quenched with water (minimum amount) and the solvent was removed under reduced pressure to provide 3.34 g of crude 5-cyclopropyloxy-2-(methylthio)pyrimidine-4,6(1H,5H)-dione (yellow foamy solid), which was used as is in the next step without further purification. 1 H-NMR (400MHz, DMSO-d6): δ3.96-3.99 (m; 1H); 2.35 (s; 3H); 0.62-0.67 (m; 2H); 0.27-0.32 (m; 2H). UPLC-MS(+ESI):m / z=215.1[M+H] + .
[0849] Step 3 / 4, 6-dichloro-5-cyclopropyloxy-2-(methylthio)pyrimidine
[0850] A suspension of 5-cyclopropyloxy-2-(methylthio)pyrimidine-4,6(1H,5H)-dione (3.30 g, 15.4 mmol) in POCl (29.0 mL, 308 mmol) was stirred at 80 ° C for 3 hours. After the reaction mixture was cooled to rt, the volatiles were removed under reduced pressure and the residue was dissolved in DCM. This mixture was slowly added to ice water while stirring (exothermicity was observed). The mixture was extracted with DCM (3x 75 mL), and the combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to provide a crude product. The crude material was purified by silica gel chromatography, eluted with EtOAc (0-40%) in hexane. The desired fractions were combined and concentrated to dryness in vacuo. The purified residue was redissolved in DCM and washed with 20% Na2S2O3 aqueous solution (20 mL). The organic layer was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to provide 4,6-dichloro-5-cyclopropyloxy-2-(methylthio)pyrimidine (1.40 g) as a yellow / brown oil. UPLC-MS (+ESI): m / z = 251.0 [M+H]+.
[0851] Step 4 / 6-Chloro-5-cyclopropyloxy-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-2-(methylthio)pyrimidin-4-amine
[0852] To a solution of 4,6-dichloro-5-cyclopropyloxy-2-(methylthio)pyrimidine (1.15 g, 4.58 mmol) and 5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-amine (913 mg, 5.04 mmol) was added NaHMDS (1 M in THF, 5.50 mL, 5.50 mmol) dropwise at rt. The reaction mixture was stirred at 50 °C for 2 hours. At this point, additional NaHMDS (1 M in THF, 3.66 mL, 3.66 mmol) was added and the reaction was stirred at 50 °C for another hour. Saturated aqueous NH4Cl solution (10 mL) was added and the aqueous layer was extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The crude material was purified by silica gel chromatography eluting with EtOAc (0-100%) in hexanes. The desired fractions were combined and concentrated in vacuo to afford 6-chloro-5-cyclopropyloxy-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-2-(methylthio)pyrimidin-4-amine as a white solid (1.00 g, 55% yield). 1H-NMR (400MHz, CDCl3): δ7.58 (s; 1H); 6.66 (s; 1H); 5.17 (dd; J=10.36; 2.3 6Hz; 1H); 4.15-4.20 (m; 1H); 4.07-4.13 (m; 1H); 3.62-3.68 (m; 1H); 2.55 (s ;3H);2.34(s;3H);2.04-2.12(m;1H);1.82-1.90(m;1H);1.63-1.78(m;2H ); 0.90-0.98 (m; 2H); 0.62-0.68 (m; 2H)..UPLC-MS (+ESI): m / z=396.2[M+H] + .
[0853] Step 5 / 6-Chloro-5-cyclopropyloxy-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-2-(methylthio)-N-((2-(trimethylsilyl)ethoxy)methyl)pyrimidin-4-amine
[0854] At rt, to a mixture of sodium hydride (60% in mineral oil, 40.0 mg, 1.00 mmol) in THF (1 mL) was added dropwise a solution of 6-chloro-5-cyclopropyloxy-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-2-(methylthio)pyrimidin-4-amine (170 mg, 429 μmol) in THF (2 mL), followed by the addition of 2-(trimethylsilyl)ethoxymethyl chloride (200 μL, 1.13 mmol). The resulting solution was stirred at rt for 2 hours. The reaction was quenched with H2O (1 mL) and diluted with EtOAc (3 mL). The layers were separated and the aqueous layer was stripped with EtOAc (3 x 5 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The crude material was purified by silica gel chromatography eluting with EtOAc (0-40%) in hexanes. The desired fractions were combined and concentrated to dryness to provide 6-chloro-5-cyclopropyloxy-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-2-(methylthio)-N-((2-(trimethylsilyl)ethoxy)methyl)pyrimidin-4-amine (180 mg, 80% yield) as a viscous oil. UPLC-MS (+ESI): m / z=548.2 [M+Na] + .
[0855] Step 6 / 5-Cyclopropyloxy-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)-2-(methylthio)-N-((2-(trimethylsilyl)ethoxy)methyl)pyrimidin-4-amine
[0856] In a vial, a mixture of 6-chloro-5-cyclopropyloxy-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-2-(methylthio)-N-((2-(trimethylsilyl)ethoxy)methyl)pyrimidin-4-amine (175 mg, 333 μmol), (1-methyl-1H-pyrazol-4-yl)boronic acid (50.3 mg, 399 μmol), NaHCO3 (55.9 mg, 665 μmol) and Pd(PPh3)4 (28.8 mg, 24.9 μmol) in a solvent mixture of DME (1.4 mL) and H2O (200 μL) was first degassed and heated at 85°C for 18 hours. After cooling to rt, the reaction was diluted with a 1:1 mixture of brine and water (2 mL) and the aqueous mixture was extracted with EtOAc (3x5 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography eluting with EtOAc (0-80%) in hexanes. The desired fractions were combined and concentrated to dryness to provide 5-cyclopropyloxy-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)-2-(methylthio)-N-((2-(trimethylsilyl)ethoxy)methyl)pyrimidin-4-amine (100 mg, 53% yield) as a yellow oil. UPLC-MS (+ESI): m / z=572.3 [M+H] + .
[0857] Step 7 / 5-cyclopropyloxy-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)-2-(methylsulfonyl)-N-((2-(trimethylsilyl)ethoxy)methyl)pyrimidin-4-amine
[0858] To a mixture of 5-cyclopropyloxy-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)-2-(methylthio)-N-((2-(trimethylsilyl)ethoxy)methyl)pyrimidin-4-amine (100 mg, 175 μmol), NEt4(HSO4) (9.50 mg, 28.0 μmol) and Na2WO4.2H2O (5.77 mg, 17.5 μmol) in EtOAc (1.5 mL) and THF (1.5 mL) was added H2O2 (179 μL, 1.75 mmol) at rt. The reaction mixture was heated at 50°C for 2 hours. After cooling to rt, the reaction mixture was quenched with 5% NaHSO3 (2 mL). The layers were partitioned and the aqueous layer was extracted with EtOAc (3 x 5 mL). The combined organic layers were washed with water (5 mL), brine, dried over anhydrous Na2SO4, filtered, and concentrated to dryness under reduced pressure to provide 105 mg of crude 5-cyclopropyloxy-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)-2-(methylsulfonyl)-N-((2-(trimethylsilyl)ethoxy)methyl)pyrimidin-4-amine (foamy solid), which was used in the next step without further purification. UPLC-MS (+ESI): m / z=604.3 [M+H] + .
[0859] Step 8 / 5-Cyclopropyloxy-N 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-N 2 -Methyl-N 4 -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)-N 4 -((2-(Trimethylsilyl)ethoxy)methyl)pyrimidine-2,4-diamine
[0860] Under an inert atmosphere, to a solution of 5-cyclopropoxy-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)-2-(methylsulfonyl)-N-((2-(trimethylsilyl)ethoxy)methyl)pyrimidin-4-amine (105 mg, 174 μmol) and 2-fluoro-4-(methylsulfonyl)aniline (34.6 mg, 174 μmol) in anhydrous NMP (900 μL) was added LiHMDS (1M in THF, 522 μL, 522 μmol) and the resulting mixture was stirred at 80° C. for 3 hours. The reaction was then cooled to rt and MeI (54 μL, 869 μmol) was added. The resulting mixture was stirred at rt for 1 hour. The reaction was quenched with saturated NH4Cl (0.5mL) aqueous solution, and the aqueous layer was extracted with EtOAc (3x 5mL). The combined organic layers were washed with water (5mL), brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness under reduced pressure. The crude material was purified by silica gel chromatography, eluted with EtOAc (0-100%) in hexane. The desired fractions were combined and concentrated to dryness to provide 5-cyclopropyloxy-N-(2-(4-cyclopropoxy)-4-yl)-1,2-dihydro-1,4 ... 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-N 2 -Methyl-N 4 -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)-N 4- ((2-(Trimethylsilyl)ethoxy)methyl)pyrimidine-2,4-diamine (60.0 mg, 48% yield). UPLC-MS (+ESI): m / z=727.4 [M+H] + .
[0861] Step 9 / Compound 344
[0862] 5-Cyclopropyloxy-N 2 -(2-Fluoro-4-(methylsulfonyl)phenyl)-N 2 -Methyl-N 4 -(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)-N 4A solution of -((2-(trimethylsilyl)ethoxy)methyl)pyrimidine-2,4-diamine (60.0 mg, 82.5 μmol) in TFA (400 μL) and DCM (400 μL) was stirred at rt for 1 hour. Upon completion, MeCN (1 mL) was added to the reaction mixture and the volatiles were removed under reduced pressure. The crude residue was purified by preparative HPLC eluting with MeCN (30%-100%) in H2O (both containing 0.1% FA). The desired fractions were combined and lyophilized to provide compound 344 (15 mg, 36% yield) as a white solid. 1 H-NMR (400MHz, CDCl3): δ8.15 (s; 1H); 8.03 (s; 1H); 7.76-7.82 (m; 2H); 7.64 (t; J=7.70Hz; 1H); 7.56 (s; 1H); 5.80 (s ; 1H); 3.98 (s; 3H); 3.75-3.78 (m; 1H); 3.59 (s; 3H); 3.18 (s; 3H); 2.19 (s; 3H); 0.87-0.92 (s; 2H); 0.53-0.60 (m; 2H). UPLC-MS(+ESI):m / z=513.3[M+H] + .
[0863] Binding assay
[0864] To determine the affinity of the compounds described herein in the PLK4 NanoBRET target engagement assay, HEK293 T cells (ATCC Product No. CRL-3216) were first transfected with PLK4 NanoLuc fusion vector DNA and transfection vehicle DNA using Fugene HD transfection reagent in Opti-MEM phenol red-free buffer. After overnight incubation in a 37°C / 5% CO2 incubator, the transfected HEK293 T cells were trypsinized, counted, and resuspended in Opti-MEM phenol red-free buffer at a concentration of 200,000 cells / mL. Then 85uL of cells (17,000 cells / well) were plated in a white 96-well plate, to which 5uL of 20X K-5 tracer solution diluted in tracer dilution buffer was added. Finally, 10uL of 10X compound was added, and the plate was then incubated in a 37°C / 5% CO2 incubator for 2 hours. After incubation, 50uL of 3X solution of substrate / inhibitor mixture was added to the cells. The plate was then transferred to an Envision plate reader where acceptor emission (610 nm) and donor emission (450 nm) were measured.
[0865] IC of the compound 50 Determined as follows:
[0866] 1. Calculate the ratio between acceptor emission (610 nm) / donor emission (450 nm).
[0867] 2. This ratio is then multiplied by 1000 to get mBRET units (multiplication by 1000 is an arbitrary step to make the data easier to interpret; it has no effect on the dataset itself)
[0868] 3. The mBRET units were then used in Scigilian analysis software (https: / / analyze.sci gilian.io) to determine IC50 values using a 4-parameter fit analysis.
[0869] Exemplary prepared compounds and their activities are shown in Table 3 below. These compounds were prepared according to previously described methods A, B, C, D, E, F, G using intermediates described herein and commercially available reagents, or were readily prepared from commercially available reagents supported by literature precedent. m / z (M+H) + Columns indicate positive ion masses observed by UPLC-MS (+ESI).
[0870] Table 3
[0871]
[0872]
[0873]
[0874]
[0875]
[0876]
[0877]
[0878]
[0879]
[0880] Other embodiments Various modifications and variations of the described invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in conjunction with specific embodiments, it should be understood that the claimed invention should not be unduly limited to these specific embodiments. In fact, various modifications of the described modes for carrying out the invention that are apparent to those skilled in the art are intended to be within the scope of the invention.
[0881] Other embodiments are within the claims.
Claims
1. A compound of formula (I), or a pharmaceutically acceptable salt thereof, in n is 0, 1, 2, 3 or 4; m is 0, 1 or 2; L is an optionally substituted C 2-9 Heterocyclic group, optionally substituted C 2-9 Heteroaryl, optionally substituted C 6-10 Aryl or optionally substituted C 3-8 Cycloalkyl, wherein L is further optionally replaced by n occurrences of R 3 replace; R 1a is hydrogen, halogen, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Alkoxy, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl, or nitrile; R 1b is hydrogen; or R 1a and R 1b together with the atoms to which they are attached, are 3-5 membered cycloalkyl, cycloalkenyl, cycloalkynyl, heterocycloalkyl, aryl or heteroaryl; A is O or S, R 2A and R 2B None of them exist; or A is N, R 2A does not exist, and R 2B is hydrogen, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 6-10 Aryl C 1-6 Alkyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 6-10 Aryl, optionally substituted C 2-9 Heterocyclic group, optionally substituted C 1-9 Heteroaryl, optionally substituted C 1-9 Heteroaryl C 1-6 Alkyl, or optionally substituted C 1-6 Alkylsulfonyl, or R 2B and L together with the atoms to which they are attached combine to form an optionally substituted C 2-9 Heterocyclic or optionally substituted C 2-9 heteroaryl; or A is C, and R 2A and R 2B are each independently hydrogen, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 6-10 Aryl C 1-6 Alkyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 6-10 Aryl, optionally substituted C 2-9 Heterocyclic group, optionally substituted C 1-9 Heteroaryl, optionally substituted C 1-9 Heteroaryl C 1-6 Alkyl, or optionally substituted C 1-6 Alkylsulfonyl; Each R 3 are independently halogen, cyano, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 6-10 Aryl C 1-6 Alkyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 3-8 Cycloalkenyl, optionally substituted C 6-10 Aryl, optionally substituted C 2-9 Heterocyclic group, optionally substituted C 1-9 Heteroaryl, optionally substituted C 1-9 Heteroaryl C 1-6 Alkyl, -S(O) m R 3A 、-N(R 3B )2OR 3B ; R 3A is an optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 6-10 Aryl, optionally substituted C 2-9 Heterocyclic group, optionally substituted C 1-9 Heteroaryl, -OR 3B or -N(R 3B )2; Each R 3B are independently hydrogen, optionally substituted C 1-6 Alkyl, optionally substituted C 6-10 Aryl C 1-6 Alkyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 6-10 Aryl, optionally substituted C 2-9 Heterocyclic group, optionally substituted C 1-9 Heteroaryl, optionally substituted C 1-9 Heteroaryl C 1-6 Alkyl, or optionally substituted C 1-6 Alkylsulfonyl; or two R 3B The groups together with the atoms to which they are attached combine to form an optionally substituted C 2-9 Heterocyclic group; X is N, and R 4 does not exist; or X is C, and R 4 is hydrogen, halogen, cyano, optionally substituted amino, optionally substituted acyl, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 3-8 Cycloalkenyl, optionally substituted C 6-10 Aryl, optionally substituted C 2-9 Heterocyclic group, or optionally substituted C 1-9 heteroaryl; R 5 is an optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 3-8 Cycloalkenyl, optionally substituted C 6-10 Aryl, optionally substituted C 2-9 Heterocyclic group, optionally substituted C 1-9 Heteroaryl, -CONH2 or -ZR 5A ; Z is an optionally substituted amino group, an optionally substituted C 2-9 Heterocyclylene, optionally substituted C 2-9 Heteroarylene, optionally substituted C 6-10 Arylene, or optionally substituted C 3-8 Cycloalkylene; R 5A is hydrogen, halogen, cyano, optionally substituted C 1-6 Alkylsulfonyl, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl, optionally substituted C 3-8 Cycloalkenyl, optionally substituted C 6-10 Aryl, optionally substituted C 2-9 Heterocyclic group, or optionally substituted C 1-9 heteroaryl; R 6 is hydrogen, halogen, cyano, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 3-8 Cycloalkyl or -OR 6A ;and R 6A is hydrogen, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, or optionally substituted C 3-8 Cycloalkyl.
2. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound has formula (II):
3. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound has formula (III):
4. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound has formula (II-A):
5. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound has formula (III-A):
6. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound has formula (II-B):
7. The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein the compound has formula (III-B):
8. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 7, wherein R 2A and R 2B One of them is hydrogen.
9. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 7, wherein R 2A and R 2B One of which is an optionally substituted C 1-6 alkyl.
10. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 7, wherein R 2A and R 2B One of which is an optionally substituted C 1-6 Heteroalkyl.
11. The compound according to claim 9 or claim 10, or a pharmaceutically acceptable salt thereof, wherein R 2B for:
12. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound has formula (II-C):
13. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound has formula (III-C):
14. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound has formula (II-D):
15. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound has formula (III-D):
16. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 15, wherein R 1a and R 1b is independently optionally substituted C 1-6 Alkyl, halogen, optionally substituted C 1-6 alkoxy, optionally substituted alkynyl, or optionally substituted C 3-6 Cycloalkyl.
17. The compound according to claim 16 or a pharmaceutically acceptable salt thereof, wherein R 1a and R 1b are independently -CH3-Cl, -OMe, -CH2OMe, -CN, -CF2H, -CF3, -CHF2, cyclopropyl or cyclobutyl.
18. The compound of claim 15, wherein R 1a and R 1b Together with the atoms to which they are attached are cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclyl or heteroaryl.
19. The compound of claim 18, wherein R 1a and R 1b Together with the atoms they are attached to are:
20. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 19, wherein L is an optionally substituted C 6-10 Aryl.
21. The compound of claim 20 or a pharmaceutically acceptable salt thereof, wherein the optionally substituted C 6-10 Aryl is optionally substituted phenyl.
22. The compound or pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 19, wherein L is an optionally substituted C 2-9 Heteroaryl.
23. The compound of claim 22 or a pharmaceutically acceptable salt thereof, wherein L is an optionally substituted C5 heteroaryl.
24. The compound of claim 23, or a pharmaceutically acceptable salt thereof, wherein the optionally substituted C5 heteroaryl contains one N.
25. The compound of claim 24 or a pharmaceutically acceptable salt thereof, wherein -L-(R 3 ) n for:
26. A compound as described in any one of claims 1 to 25, or a pharmaceutically acceptable salt thereof, wherein at least one R 3 It is a halogen.
27. The compound of claim 26 or a pharmaceutically acceptable salt thereof, wherein at least one R 3 For F.
28. The compound of claim 26 or a pharmaceutically acceptable salt thereof, wherein at least one R 3 For Cl.
29. The compound of claim 26 or a pharmaceutically acceptable salt thereof, wherein at least one R 3 For Br.
30. A compound as described in any one of claims 1 to 25, or a pharmaceutically acceptable salt thereof, wherein at least one R 3 -S(O) m R 3A .
31. The compound of any one of claims 1 to 30, or a pharmaceutically acceptable salt thereof, wherein m is 1.
32. The compound of any one of claims 1 to 30, or a pharmaceutically acceptable salt thereof, wherein m is 2.
33. A compound as described in any one of claims 30 to 32, or a pharmaceutically acceptable salt thereof, wherein R 3A is an optionally substituted C 1-6 alkyl.
34. The compound of claim 33 or a pharmaceutically acceptable salt thereof, wherein R 3A It is -CH3.
35. A compound as described in any one of claims 30 to 32, or a pharmaceutically acceptable salt thereof, wherein R 3A is an optionally substituted C 3-8 Cycloalkyl.
36. The compound of claim 35 or a pharmaceutically acceptable salt thereof, wherein R 3A is an optionally substituted cyclopropyl group.
37. A compound as described in any one of claims 1 to 36, or a pharmaceutically acceptable salt thereof, wherein at least one R 3 is an optionally substituted C 2-9 Heteroaryl.
38. A compound as described in any one of claims 1 to 37, or a pharmaceutically acceptable salt thereof, wherein at least one R 3 -N(R 3B )2.
39. A compound as described in any one of claims 1 to 38, or a pharmaceutically acceptable salt thereof, wherein at least one R 3 For-OR 3B .
40. A compound as described in any one of claims 1 to 21 or a pharmaceutically acceptable salt thereof, wherein -L-(R 3 ) n for:
41. The compound of claim 40 or a pharmaceutically acceptable salt thereof, wherein -L-(R 3 ) n for:
42. A compound as described in any one of claims 1 to 21 or a pharmaceutically acceptable salt thereof, wherein -L-(R 3 ) n for:
43. A compound as described in any one of claims 1 to 21 or a pharmaceutically acceptable salt thereof, wherein -L-(R 3 ) n for:
44. A compound as described in any one of claims 1 to 19 or a pharmaceutically acceptable salt thereof, wherein -L-(R 3 ) n for:
45. A compound as described in any one of claims 1 to 21 or a pharmaceutically acceptable salt thereof, wherein -L-(R 3 ) n for:
46. A compound as described in any one of claims 1 to 19 and 22 to 25, or a pharmaceutically acceptable salt thereof, wherein -L-(R 3 ) n for:
47. A compound or a pharmaceutically acceptable salt thereof as described in any one of claims 1, 3, 5, 7 to 11, 13, 15 and 16 to 46, wherein R 4 It is a halogen.
48. The compound of claim 47 or a pharmaceutically acceptable salt thereof, wherein R 4 For F.
49. The compound of claim 47 or a pharmaceutically acceptable salt thereof, wherein R 4 For Cl.
50. A compound or a pharmaceutically acceptable salt thereof as described in any one of claims 1, 3, 5, 7 to 11, 13, 15 and 16 to 46, wherein R 4 It is cyano.
51. A compound or a pharmaceutically acceptable salt thereof as described in any one of claims 1, 3, 5, 7 to 11, 13, 15 and 16 to 46, wherein R 4 is an optionally substituted amino group.
52. The compound of claim 51 or a pharmaceutically acceptable salt thereof, wherein R 4 It is -NH2 or -N(CH3)2.
53. A compound or a pharmaceutically acceptable salt thereof as described in any one of claims 1, 3, 5, 7 to 11, 13, 15 and 16 to 46, wherein R 4 For hydrogen.
54. A compound or a pharmaceutically acceptable salt thereof as described in any one of claims 1, 3, 5, 7 to 11, 13, 15 and 16 to 46, wherein R 4 It is -CH3.
55. A compound as described in any one of claims 1 to 54, or a pharmaceutically acceptable salt thereof, wherein R 5 is an optionally substituted C 1-9 Heteroaryl.
56. The compound of claim 55 or a pharmaceutically acceptable salt thereof, wherein R 5 is an optionally substituted C3-C4 heteroaryl or an optionally substituted C4 heterocycle.
57. The compound of claim 56, or a pharmaceutically acceptable salt thereof, wherein the optionally substituted C3-C4 heteroaryl or optionally substituted C4 heterocycle contains 1 to 2 N atoms.
58. The compound of claim 57 or a pharmaceutically acceptable salt thereof, wherein R 5 for:
59. The compound of claim 58 or a pharmaceutically acceptable salt thereof, wherein R 5 for 60. The compound of claim 56 or a pharmaceutically acceptable salt thereof, wherein the optionally substituted C3 heteroaryl contains 1 N atom and 1 S atom or 1 O atom.
61. The compound of claim 60 or a pharmaceutically acceptable salt thereof, wherein R 5 for:
62. A compound as described in any one of claims 1 to 54, or a pharmaceutically acceptable salt thereof, wherein R 5 For-ZR 5A .
63. The compound of claim 62 or a pharmaceutically acceptable salt thereof, wherein Z is an optionally substituted amino group, and R 5A for 64. The compound of claim 63 or a pharmaceutically acceptable salt thereof, wherein Z is an optionally substituted C 2-9 Heteroarylene.
65. A compound as described in any one of claims 1 to 54, or a pharmaceutically acceptable salt thereof, wherein R 5 is an optionally substituted C 2-9 Heterocyclic group.
66. The compound of claim 65 or a pharmaceutically acceptable salt thereof, wherein R 5 for:
67. The compound of claim 65 or a pharmaceutically acceptable salt thereof, wherein R 5 for:
68. The compound of claim 64 or a pharmaceutically acceptable salt thereof, wherein R 5A for:
69. A compound as described in any one of claims 1 to 54, or a pharmaceutically acceptable salt thereof, wherein R 5 for:
70. A compound as described in any one of claims 1 to 69, or a pharmaceutically acceptable salt thereof, wherein R 6 is an optionally substituted C 1-6 alkyl.
71. The compound of claim 70 or a pharmaceutically acceptable salt thereof, wherein R 6 for:
72. A compound as described in any one of claims 1 to 69, or a pharmaceutically acceptable salt thereof, wherein R 6 For-OR 6A .
73. The compound of claim 72 or a pharmaceutically acceptable salt thereof, wherein R 6A It is -CH3.
74. A compound as described in any one of claims 1 to 69, or a pharmaceutically acceptable salt thereof, wherein R 6 is an optionally substituted C 3-8 Cycloalkyl.
75. The compound of claim 74 or a pharmaceutically acceptable salt thereof, wherein R 6 is an optionally substituted cyclopropyl group.
76. The compound of claim 75 or a pharmaceutically acceptable salt thereof, wherein R 6 for:
77. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound has formula (IV):
78. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound has Formula (V):
79. A compound selected from the group consisting of Compounds 1 to 365 and pharmaceutically acceptable salts thereof.
80. A pharmaceutical composition comprising a compound as claimed in any one of claims 1 to 79 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.
81. The pharmaceutical composition of claim 80, wherein the composition is isotopically enriched in deuterium.
82. A method of inhibiting PLK4 expression in a cell, the method comprising contacting the cell with a compound of any one of claims 1 to 79, or a pharmaceutically acceptable salt thereof.
83. The method of claim 82, wherein the cell overexpresses TRIM37 or has TRIM37 amplification.
84. The method of claim 82 or claim 83, wherein the cell is in a subject.
85. A method of treating a subject in need thereof, the method comprising administering to the subject a compound as described in any one of claims 1 to 79, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as described in claim 80 or claim 81.
86. The method of claim 85, wherein the subject suffers from a disease or disorder with symptoms of cellular hyperproliferation and is in need of treatment.
87. The method of claim 86, wherein the disease is cancer.
88. The method of claim 87, wherein the cancer is a cancer that overexpresses TRIM37 or a cancer that has TRIM37 amplification.
89. A method of treating cancer in a subject, the method comprising administering to the subject a therapeutically effective amount of a compound as described in any one of claims 1 to 79, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as described in claim 80 or claim 81, wherein the cancer has been previously identified as a cancer that overexpresses TRIM37 or a cancer that has TRIM37 amplification.
90. A method of treating cancer in a subject, the method comprising administering to the subject a therapeutically effective amount of a compound as described in any one of claims 1 to 79, or a pharmaceutical composition as described in claim 80 or claim 81, wherein the cancer is a cancer that overexpresses TRIM37 or a cancer with TRIM37 amplification.
91. The method of any one of claims 87 to 90, wherein the cancer is uterine cancer, ovarian cancer, breast cancer, gastric cancer, esophageal cancer, lung cancer, or endometrial cancer.
92. A method of inducing cell death in a cancer cell that overexpresses TRIM37 or a cancer that has TRIM37 amplification, the method comprising contacting the cell with an effective amount of a PLK4 inhibitor.
93. The method of claim 92, wherein the PLK4 inhibitor is a compound of any one of claims 1 to 75, or a pharmaceutically acceptable salt thereof.
94. The method of claim 92 or claim 93, wherein the cell is in a subject.
